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Alzheimer’s disease (AD) is a neurodegenerative disorder that is characterized clinically by 
progressive dementia and histopathologically by amyloid plaques and neurofibrillary tangles. The primary 
molecular culprit in AD is the amyloid-beta (Aβ) peptide, aggregates of which are the main components of 
the plaques. Numerous studies have implicated soluble Aβ oligomers as the predominant neurotoxic 
species, although the underlying mechanisms that lead to cognitive failure are not fully understood. In this 
thesis, I demonstrate that post-translational modification with the small ubiquitin-like modifier (SUMO) is 
required for normal synaptic and cognitive function but can be impaired by Aβ oligomers. I discovered that 
SUMOylation was significantly reduced in brain tissue from AD patients and a transgenic mouse model of 
AD. While neuronal activation normally induced upregulation of SUMOylation, this effect was impaired by 
Aβ and in the transgenic mice. Aβ is also a known potent disruptor of synaptic function. However, 
enhancing SUMOylation via transduction of its conjugating enzyme, Ubc9, rescued Aβ-induced deficits in 
synaptic plasticity and memory. I further demonstrate that inhibition of SUMOylation can directly cause 
such deficits, similar to Aβ. Overall, the data establish SUMO as a novel regulator of synaptic plasticity 
and cognition and point to SUMOylation impairments as an underlying factor in AD pathology. 
In addition to the pathological effects of Aβ, the normal physiological functions of this peptide, 
which is produced in the brain throughout life, remain unclear. A previous study in our lab demonstrated 
that physiologically-relevant (low picomolar) amounts of Aβ can enhance synaptic plasticity and memory. 
Astrocytes, as crucial glial support cells with roles in modulating synaptic transmission, are likely cellular 
candidates for participating in this type of physiological Aβ signaling. To test this hypothesis, primary 
cultures of murine astrocytes were exposed to exogenous picomolar Aβ peptides while undergoing 
calcium imaging. Upon addition of 200 pM Aβ peptides, the percentage of astrocytes exhibiting 
spontaneous oscillatory calcium transients increased significantly. The periodicities of these transients 
were analyzed, and it was found that both the frequency and amplitude of the transients were enhanced 
  
after Aβ exposure. These effects were dependent on calcium influx and α7 nicotinic acetylcholine 
receptors (α7-nAChRs), as the potentiation was blocked by a pharmacological α7 inhibitor and in cultures 
from an α7 knockout mouse strain. In addition to spontaneous signaling, evoked intercellular calcium 
waves were also analyzed. After picomolar Aβ exposure, no significant changes were found in several 
wave parameters, including spatial and temporal spread, propagation speed and maximum signal 
intensity. These results indicate that at physiologically-relevant concentrations, Aβ peptides enhance 
spontaneous astrocyte calcium signaling via astrocytic α7-nAChRs. Since astrocyte-mediated 
"gliotransmission" has been found to have multiple neuromodulatory roles, Aβ peptides may have a 
normal physiological function in regulating this type of neuron-glia signaling. 
These studies illustrate the diverse effects of Aβ peptides, which are dependent on the 
concentration and conformation state. Ultimately, knowledge of both normal Aβ physiology as well as Aβ 
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Chapter 1  
 
Amyloid-β: Pathology and Physiology 
 
 
1.1 Alzheimer’s Disease 
 Over one hundred years ago, in 1906, a German doctor named Alois Alzheimer presented a 
clinical case detailing the cognitive decline and various other neuropsychological symptoms of a 51 year 
old patient (Moller and Graeber, 1998). Upon post-mortem anatomical examination of the brains from this 
and subsequent patients suffering from similar symptoms, Alzheimer observed several key 
histopathological characteristics including general atrophy of the brain, degeneration of neurons, 
widespread “peculiar patches” and neuronal tangles that were “rolled up like coils or twisted like slings” 
(Alzheimer et al., 1991). 
 Today, the disease that carries that doctor’s name is the most common type of dementia 
worldwide, affecting more than 35 million people. Although a large amount of research in the past few 
decades have elucidated many pathological mechanisms involved in Alzheimer’s disease (AD), there is 
still much that is unknown including fundamental questions such as: what initiates the disease, are the 
underlying mechanisms qualitatively different from normal aging, and can the disease process be stopped 
or reversed? Unfortunately, the answers remain unclear, and there are currently no effective medications 
for altering AD progression. The development of new disease-modifying therapeutic strategies, capable of 
slowing down or even reversing the cognitive decline of AD, remains one of the top medical research 









Alzheimer’s disease is currently the 6th leading cause of death in the United States and is poised 
to become one of the major unmet medical needs in the upcoming decade. In the U.S., an estimated 5.4 
million people have AD in 2012; this number is expected to grow to 7.7 million by 2030 (Alzheimer's, 
2012). Advanced age is the primary risk factor, with 1 in 8 people over age 65 diagnosed with AD. Given 
the aging population structures worldwide, the global prevalence of AD is expected to greatly increase in 
the near future, a situation that will pose a severe socioeconomic burden if no effective medications are 
developed. In 2012 alone, the estimated total cost of medical care for AD patients was $200 billion in the 
U.S. The economic, societal and personal tolls of AD together form a tremendous impetus for advancing 




As Dr. Alzheimer observed, AD is a neurodegenerative disorder characterized by progressive 
dementia. On a histopathological level, AD is characterized by amyloid plaques and neurofibrillary tangles 
(NFTs) (Figure 1.1). The plaques contain insoluble extracellular deposits of amyloid-beta (Aβ) protein 
while NFTs are intracellular structures composed of aggregates of tau, a microtubule-binding protein 
(Holtzman et al., 2011). Another hallmark of AD is extensive neuronal degeneration and cell death – in 
the end-stages of the disease, there is widespread neuronal loss that is evident as gross cerebral atrophy 
in multiple regions, including the temporal, parietal and frontal lobes (Thompson et al., 2003). As is 
common with other neurodegenerative diseases, there is selective vulnerability of certain brain structures 
and cell types. In particular, the medial temporal lobe, including the hippocampus and entorhinal cortex, 







Figure 1.1.  Changes in Alzheimer’s disease brain 
(A)  Amyloid plaques and neurofibrillary tangles in the cerebral cortex of an AD patient. Adapted from 
(Blennow et al., 2006). 
(B)  Coronal sections from a normal brain (a) and Alzheimer’s disease brain (b), showing atrophy 




region even in very mild, early AD (Jack et al., 1997). On neurochemical and ultrastructural levels, 
numerous studies have found that neuronal deterioration is the most severe in the hippocampus (Arendt, 
2009). Cell death is prominent in this region; by disease end-stage, as much as 60-70% of the neurons 
are lost in parts of the hippocampus, with NFTs in many of the remaining cells (West et al., 1994). From 
the medial temporal lobe and fusiform gyrus, AD pathology spreads in a predictable pattern to other brain 
regions, including the posterior cingulate, precuneus, temporoparietal association neocortex and 





While most of the neurons lost in the cortical regions are glutamatergic, certain populations of 
subcortical projection neurons also exhibit selective vulnerability in AD. In particular, the noradrenergic 
neurons of the locus coeruleus and the cholinergic neurons of the basal forebrain become dysfunctional 
and undergo profound neurodegeneration relatively early in the disease (Holtzman et al., 2011). The 
initial observations of deficits in cholinergic neurotransmission led to the “cholinergic hypothesis” of AD, 
which resulted in several FDA-approved drugs that inhibit acetylcholinesterase, the enzyme that breaks 
down acetylcholine (ACh). However, as evidenced by the limited efficacy of this class of drugs, the 
cholinergic deficit is no longer viewed as an adequate explanation of AD etiology. 
It is currently unclear why certain brain regions and cell types are particularly vulnerable in 
neurodegenerative diseases such as AD. However, it is now known that the underlying pathological 
changes in these vulnerable cells, including deterioration at the synaptic level, can begin decades prior to 
the onset of symptoms (Gotz et al., 2009). Even in the earliest clinical stages of cognitive decline, known 
as mild cognitive impairment (MCI), neuropathological features are already substantial. At this MCI stage, 
there is significant neuron loss in the hippocampus and entorhinal cortex as well as widespread amyloid 
plaques in the neocortex (Morris and Price, 2001; Price et al., 2001). It has become apparent that due in 
part to cognitive reserves and network redundancies, there is already extensive and likely irreversible 
neuropathology at the time of first clinical AD presentation. These findings, compounded with the failures 
of several large clinical trials testing potential drugs, have led to a shift in focus towards earlier disease 
stages – by diagnosing and targeting preclinical pathology, possibly even prior to the onset of symptoms, 
there is a better chance for successful intervention that slows or averts synaptic dysfunction and 
dementia. 
While neurons predominantly undergo degeneration in AD, multiple other brain cell types are also 
involved in disease pathology. In particular, activation of glia cells in a process termed reactive gliosis is a 
pathological hallmark that is especially prominent near plaques (Mrak and Griffin, 2005). Both microglia 
and astrocytes become activated and proliferate in AD, although the net result of this activation is not well 
understood and may have dichotomous effects.  Microglia, as the resident innate immune cells of the 





microglia are often detected as components of cored plaques while astrocytic processes are found in the 
neuritic coronas of plaques. There is evidence that both cell types can participate in the clearance of Aβ 
deposits; in particular, microglia have the ability to phagocytose and degrade aggregated Aβ. However, 
these cells can also release inflammatory cytokines that exacerbate disease pathology (Maragakis and 
Rothstein, 2006; Streit, 2004). When neuroinflammation becomes a chronic state, as is the case in AD, 
glial activation may go from beneficial to detrimental and possibly pathogenic in and of itself.  
Some other cell types that are vulnerable to AD pathology include oligodendrocytes and 
pericytes. Oligodendrocytes, the myelinating glia cells of the CNS, become dysfunctional in AD, leading to 
demyelination and loss of white matter volume in the cortices (Kobayashi et al., 2002). This myelin 
breakdown disrupts axonal functioning and could further lead to neuronal damage. Pericytes are CNS 
cells that wrap around capillaries, functioning to regulate blood-brain barrier permeability, cerebral blood 
flow and clearance of toxins. While their role in AD is currently not well understood, there is evidence that 
these cells become abnormal early in the disease pathogenesis (Winkler et al., 2011). Neurovascular 
dysfunction is well-documented for neurodegenerative diseases and in some transgenic mouse models, 
and it is likely that pericyte pathology plays a role in this dysfunction. These multiple non-neuronal cell 
types appear to be involved in many aspects of AD pathophysiology, making these cells potential targets 
in drug discovery efforts. 
 
1.1.3 Amyloid-β 
Although amyloid plaques were observed histopathologically in AD brains since Alois Alzheimer’s 
early descriptions, the composition of the plaques remained unknown until the mid-1980s. There was a lot 
of interest in this question, since earlier studies had pointed to possible correlations between dementia 
severity and plaque counts (Blessed et al., 1968). In 1985, researchers were finally successful in purifying 
a 4 kDa, ~40 amino acid peptide that made up the bulk of the plaques (Masters et al., 1985). This small 
peptide was eventually named amyloid-beta (Aβ) and would become the primary molecular culprit 







Figure 1.2.  APP processing and production of Aβ 
Schematic diagrams depicting the proteolytic processing of APP and the various cleavage products. The 
non-amyloidogenic pathway involves α-secretase while the amyloidogenic pathway involves β-secretase 
and results in Aβ production. Adapted from (Haass et al., 2012). 
 
 
led to the identification and gene sequencing of the amyloid precursor protein (APP), from which Aβ is 
produced (Kang et al., 1987).  
APP is a type I transmembrane protein and one of three members of a family that also includes 
APLP1 and APLP2. All three include large extracellular domains that undergo proteolytic processing but 
only APP contains the sequence for Aβ (Thinakaran and Koo, 2008). APP can undergo a series of 
cleavages by secretase enzymes, one pathway of which results in the production of Aβ peptides (Figure 
1.2). APP contains α-, β- and γ-secretase cleavage sites. Processing at the α-secretase site releases a 
large portion of the ectodomain and precludes the formation of Aβ since the cleavage occurs within the 
Aβ sequence. Alternatively, APP can be cleaved at the β- secretase site, which together with an 
intramembrane γ-secretase cleavage, produces Aβ peptides.  
In neurons, the primary β-secretase is β-site APP cleaving enzyme 1 (BACE1), a transmembrane 





subunits: presenilin 1 or 2 (PS1/PS2), nicastrin, PEN-2 and APH-1. There are actually multiple γ-cleavage 
site possibilities, which result in the production of Aβ peptides with varying lengths (usually 38-43 amino 
acids). Approximately 90% of secreted Aβ is 40 amino acids long (Aβ40). However, there is also a smaller 
proportion of 42 residue-long Aβ peptides (Aβ42) that make up <10% of the total Aβ pool. In a series of 
studies, Aβ42 was found to have a much higher propensity for aggregation compared to the shorter 
peptides, leading to a focus on Aβ42 as the primary amyloidogenic species in AD (Burdick et al., 1992; 
Hilbich et al., 1991; Jarrett et al., 1993; Jarrett and Lansbury, 1993).  
A multitude of studies in the early 1990s provided further support for the amyloid hypothesis, as a 
number of mutations in the genes for APP or presenilin 1/2 were discovered in families with early onset 
AD (Chartier-Harlin et al., 1991; Goate et al., 1991; Mullan et al., 1992; Rogaev et al., 1995; Sherrington 
et al., 1995). All of these mutations were found to increase total Aβ production, enhance aggregate 
formation or increase the ratio of Aβ42:Aβ40, resulting in a higher proportion of aggregation-prone Aβ 
(Borchelt et al., 1996; Citron et al., 1992; Citron et al., 1997; Duff et al., 1996; Haass et al., 1995; 
Scheuner et al., 1996). So far, over 30 APP mutations and almost 200 PS1/PS2 mutations have been 
identified and linked with early-onset familial AD (FAD) (Cruts et al., 2012). Although FAD accounts for < 
5% of all AD cases, there is a very high degree of phenotypic similarity between FAD and sporadic late-
onset AD (LOAD), suggesting that mechanistic information obtained about FAD would also be directly 
relevant for LOAD (Selkoe, 2001).  
After decades of focus on Aβ as the primary pathogenic culprit, the amyloid hypothesis has been 
called into question after several recent high-profile failures of Aβ-targeted clinical trials (e.g. 
semagacestat, bapineuzumab, solanezumab). Previously, a multitude of basic research studies over the 
past few decades have indicated that high levels of Aβ, especially in aggregated forms, can kill neurons, 
disrupt synaptic function and impair memory. But is Aβ truly the primary neurotoxin in AD, and is lowering 
Aβ levels a valid therapeutic strategy? A recent study that examined the genomic sequences of an 
Icelandic population provides evidence that the amyloid hypothesis is still valid from a therapeutic 
standpoint (Jonsson et al., 2012). The researchers discovered the first APP mutation that is protective 





appears to be decreased BACE1 cleavage of the mutated APP, which results in significantly lower levels 
of Aβ peptides. The fact that this mutation also appears to protect against age-related cognitive decline is 
a striking finding which suggests that AD may ultimately be a form of accelerated brain aging, with shared 
common mechanisms. Overall, this study provides strong proof-of-principle support for the amyloid 
hypothesis and continuing anti-Aβ drug development efforts.  
 
1.1.4 Mouse Models 
Following upon the discoveries of the various FAD mutations, the creation of transgenic mouse 
models which express the mutated genes further emphasized the connection between Aβ and AD. These 
mouse models include ones which overexpress mutant human APP and/or presenilin 1 (Table 1.3). One 
of the more widely-used models is the Tg2576 mouse line, which has a transgene encoding human APP 
with two point mutations (K670N, M671L) that were originally identified in a Swedish family with FAD 
(Hsiao et al., 1996; Mullan et al., 1992). Transgenic mice such as the Tg2576 have demonstrated that 
overexpression of APP and/or Aβ is sufficient to recapitulate many important characteristics of AD. In the 
APP-overexpressing mice, there is amyloid plaque pathology, loss of synapses, impaired synaptic 
plasticity and learning and memory deficits. Co-expression of a mutant PS1 transgene accelerates the 
pathology to a significantly younger age. The caveat with these mice is that there is minimal widespread 
neurodegeneration, a defining characteristic of AD. However, a triple transgenic mouse model that 
expresses mutant tau along with the APP and PS1 transgenes has been reported exhibit significant 
neurodegeneration along with neurofibrillary tangles (Oddo et al., 2003). 
In AD research efforts, transgenic mouse models have been valuable tools in elucidating disease 
mechanisms as well as testing possible therapeutic strategies. Although their applicability for AD drug 
discovery has been called into question, due in part to a lack of successful translatability to humans in 
multiple cases, there is no doubt that transgenic mouse models are essential tools for accessing and 















Table 1.3.  Commonly-used animal models for Alzheimer’s disease research  
Partial list of commonly-used transgenic and non-transgenic models.  
Previously published in adapted form in (Shineman et al., 2011). 
 
 
1.1.5 Synaptic Dysfunction  
Ultimately, Alzheimer’s disease (AD) is a disorder of cognitive dysfunction and by extension, 
synaptic failure. It was first posited in 1975 that the degeneration of dendritic arbors seen in AD may be of 
clinical significance in addition to neuronal loss (Scheibel et al., 1975). Since then, it has been confirmed 
that synapse loss is indeed a major structural correlate of dementia and likely underlies the cognitive 
impairments of AD (Terry et al., 1991). Synaptic deterioration is an early event that occurs well before the 
formation of amyloid plaques and neuron death (Selkoe, 2002). This degeneration is evident both on an 
ultrastructural level as abnormal spine morphology and decreased spine densities as well on a 
neurochemical level as decreased levels of synaptic proteins. Of all brain regions, the hippocampus is the 
most severely affected by synaptic loss, which matches the pattern of NFT pathology, another strong 
correlate of cognitive dysfunction (Arendt, 2009). Even at the MCI stage, there is already substantial 
synapse loss which worsens with disease progression (Masliah et al., 1994). Even at the mild AD stage, 
there is a loss of approximately half of the synapses in the CA1 area of the hippocampus (Scheff et al., 
2007; Scheff et al., 2006).  
Soluble oligomers of Aβ have been implicated as the primary cytotoxic species in AD, and 
indeed, these aggregates have been shown to have many detrimental effects at the synapse. Several 
studies have demonstrated that Aβ oligomers appear to preferentially bind to or cluster at synapses, with 
one study observing that >90% of Aβ oligomer binding in neurons occurs at dendritic spines at sites 
positive for PSD-95, a marker for post-synaptic compartments (Lacor et al., 2004). On a structural level, 
Aβ oligomers have been shown to cause changes in spine morphology and decreases in spine density 
(Lacor et al., 2007; Selkoe, 2008). However, the identity of the Aβ binding partner(s) that mediate such 
effects remains unclear and controversial. Several neurotransmitter receptors have been implicated in 





signaling pathway(s) may be, the downstream effects of Aβ oligomers on synaptic physiology are well-
studied. The numerous detrimental effects observed in these studies include internalization of glutamate 
receptors, altered neurotransmitter release and uptake and deficits in synaptic plasticity (Li et al., 2009). 
The latter effect has been particularly well-documented by studies demonstrating the inhibition of long 
term potentiation (LTP) and facilitation of long term depression (LTD) by Aβ (Li et al., 2009; Selkoe, 2008; 
Shankar et al., 2008; Walsh et al., 2002). The functional consequences of this Aβ-induced synaptic 
dysfunction is evident in the learning and memory deficits of various rodent AD models, including acute 
intracerebral Aβ injections and transgenic mice overexpressing amyloid precursor protein (APP). In a 
particularly compelling study, passive immunization with an Aβ antibody rapidly reversed memory 
impairments in a transgenic APP mouse model without affecting the overall Aβ burden in the brain 
(Dodart et al., 2002), Although the translatability of this finding into humans remains to be fully 
determined, this study does emphasize the acute toxicity of soluble Aβ species on synaptic functioning as 
well as the value of therapeutic approaches that may prevent such damage. 
 
1.1.6 Amyloid-β Oligomers 
 While Aβ is initially produced as a single monomeric peptide from the secretase cleavages of 
APP, Aβ peptides, and especially Aβ42, have the propensity to aggregate into oligomeric species. A 
tremendous amount of research now indicates that these soluble Aβ oligomers are the primary molecular 
culprits involved in AD pathogenesis (Benilova et al., 2012; Selkoe, 2008). These aggregates can be 
formed from synthetic Aβ as well as natural Aβ secreted by cultured cells. In addition, soluble Aβ 
oligomers can be directly extracted from Alzheimer’s patient brains and cerebrospinal fluid (CSF); these 
natural human Aβ oligomers have been found to have potent neurotoxic and inhibitory effects on synaptic 
plasticity and cognition (Jin et al., 2011; Li et al., 2009; Shankar et al., 2008). In contrast to amyloid 
plaques, which do not correlate well with cognitive decline, soluble Aβ species are significantly correlated 





 While it is generally agreed upon that high concentrations (> nM) of Aβ oligomers are neurotoxic, 
the exact definition of what these oligomers encompass currently is not well-defined in the field. Multiple 
Aβ oligomer assemblies have been described and characterized in previous studies; and many more 
studies have not clearly defined the preparation techniques and/or aggregation states of the Aβ used in 
the experiments (Benilova et al., 2012). Since the numerous Aβ species of varying lengths, modifications, 
conformations, and aggregation states very likely possess different biological activities and toxicities, the 
ill-defined and non-standardized Aβ preparations in the literature have resulted in an unfortunate lack of 
comparability between studies. The following is a brief overview of the types of the Aβ oligomers that 
have been previously described. 
 The smallest Aβ multimer assembly that has been described to exert synaptotoxic effects are 
dimers. In AD patients, Aβ dimers and trimers are the predominant species in soluble cortical extracts (as 
analyzed by LDS-PAGE) (Shankar et al., 2008). However, dimers alone were determined to be the 
primary neurotoxic species, fully sufficient for disrupting synaptic plasticity and memory when applied to 
rodent hippocampal slices or in vivo. In a related study, Aβ dimers, but not monomers, in human CSF 
were shown to impair long term potentiation (Klyubin et al., 2008). Thus, Aβ dimers appear to be the 
minimal multimer state for neurotoxicity, although it cannot be ruled out that such dimers represent, at 
least in part, breakdown components of larger endogenous oligomer complexes and are therefore an 
observational artifact. Supporting this notion, another study using AD patient brain extracts found larger 
Aβ aggregate species, termed amylospheroids (ASPD) (Noguchi et al., 2009). These ASPDs are high 
mass (>100 kDa), 10-15 nm spherical oligomers which were shown to induce neurodegeneration in 
cultured neurons.   
 Studies with mouse models of AD have generated additional insights as well as unclear results. 
In one particular FAD APP-overexpressing model (J20), no significant correlation was detected between 
soluble Aβ oligomers and cognitive dysfunction (Shankar et al., 2009). However, in another high-profile 
study that used the Tg2576 APP-overexpressing model, a specific 56 kDa dodecameric species was 
correlated with memory loss (Lesne et al., 2006). Furthermore, this oligomer species, termed Aβ*56, 





oligomer has garnered attention and investigation in multiple rodent studies, Aβ*56 was not detected in 
the studies mentioned above using human brain extracts or CSF (Klyubin et al., 2008; Shankar et al., 
2008). However, as previously alluded to, larger assemblies such as Aβ*56 could potentially be detected 
as smaller oligomers (e.g. dimers), dependent on the extraction and detection techniques. According to a 
description of currently unpublished data, Aβ*56 has been detected in brain extracts from a large cohort 
of AD patients, with peak levels found in the preclinical stage of the disease (Larson and Lesne, 2012). 
 While these naturally-occurring oligomeric species have validated the central importance of 
soluble Aβ aggregates in AD pathology, a large proportion of studies have utilized Aβ prepared in vitro 
from synthetic peptides. Different types of aggregates can result from these in vitro preparations, 
dependent on multiple parameters such as concentration, temperature, buffer constituents, pH, etc. The 
exact biological relevance of the resultant aggregate species to the actual pathology in vivo remains to 
determined. In general, however, synthetic Aβ oligomers have produced qualitatively similar synaptotoxic 
effects, albeit with multi-fold lower potency compared to naturally-derived oligomers (Benilova et al., 
2012). This may indicate that there is a biologically active conformation or perhaps as-yet unidentified 
modifications/co-factors that endow endogenous Aβ oligomers with enhanced toxicity. 
 One of the main oligomeric categories formed by synthetic Aβ has been termed Aβ-derived 
diffusible ligands (ADDLs). These include globular structures (“globulomers”) which may be composed of 
~3-24 Aβ monomers (Benilova et al., 2012; Larson and Lesne, 2012). In numerous experiments, ADDL 
preparations have been shown to have detrimental effects on many aspects of neuronal physiology 
including synaptic plasticity, cognitive performance, tau pathology, mitochondrial dysfunction, calcium 
dysregulation and membrane perturbations. Significantly, tools and antibodies developed for ADDLs have 
also been shown to detect endogenous Aβ oligomers, indicating some level of shared conformation and 
structure (Larson and Lesne, 2012). Although clearly there are significant differences between synthetic 
ADDL preparations and endogenous oligomers, given the differences in potency, there are enough 
shared structural and toxicity similarities that ADDLs can be considered an experimentally-valid approach 





 Ultimately, however, “the one” type of Aβ assembly that mediates AD pathology may not really 
exist. Instead, it is likely that there is a dynamic equilibrium of a heterogeneous mixture of Aβ species 
and/or conformations in the living brain, changes in which may underlie the etiology of the disease. And 
from this mixture of soluble Aβ species arises the numerous binding interactions and downstream effects 
that have thus far been discovered using various natural and synthetic Aβ preparations.  
 
1.1.7 Receptors for Amyloid-β Oligomers 
 Among the numerous cell surface proteins which been proposed to serve as receptors for Aβ 
oligomers, a few of the most prominent include metabotropic glutamate receptor 5 (mGluR5) (Renner et 
al., 2010), the receptor for advanced glycation end products (RAGE) (Sturchler et al., 2008; Yan et al., 
1996), the α7 nicotinic acetylcholine receptor (α7-nAChR) (Dougherty et al., 2003; Wang et al., 2000a), 
receptor tyrosine kinase EphB2 (Cisse et al., 2011a) and the cellular prion protein (PrPC) (Lauren et al., 
2009). To summarize briefly, each of these proposed cell surface proteins have been shown to interact 
with and/or exhibit direct binding affinity for Aβ oligomers, which in turn mediates pathogenic downstream 
signaling events (Larson and Lesne, 2012). Of particular interest for this thesis, the neurotransmitter 
receptor α7-nAChR has been proposed to serve as an Aβ receptor in multiple studies; a review of this 
topic can be found in section 5.2. 
 One of the more controversial proposed receptors for Aβ is the cellular prion protein (PrPC). PrPC 
is a cell surface glycoprotein that is highly expressed in the central nervous system (Biasini et al., 2012). 
PrPC is localized mostly to lipid rafts at the cell membrane, with a small fraction undergoing clathrin-
dependent endocytosis. PrPC is best-characterized for its involvement in prion diseases. The scrapie 
prion protein (PrPSc) is the infectious conformer characterized by higher β-sheet content. As the 
predominant feature of prion-type infectivity, PrPSc has the ability to convert normal PrPC to the infectious 
conformation, thus spreading via self-perpetuating templating. On the other hand, the normal 
physiological functions of PrPC remain unclear. Some studies have suggested that PrPC may be involved 





 In the past few years, PrPC has also been identified as a potential cell surface binding receptor for 
Aβ peptides. In the original study from 2009, PrPC was identified in a cell-based screening for Aβ-binding 
proteins (Lauren et al., 2009). The binding affinity was much stronger for Aβ42 oligomers compared to 
freshly-prepared (predominantly monomeric) Aβ42, with a dissociation constant estimated to be in the low 
to sub-nanomolar range. While in wild-type hippocampal slices, Aβ42 oligomers normally inhibit long-term 
potentiation, slices from PrPC null mice were resistant to this effect. In a subsequent study from the same 
lab, crossing PrPC null mice with a mouse model of AD (APP/PS1 double mutant) led to neuroprotection 
and rescued spatial memory performance (Gimbel et al., 2010). These effects were not attributable to 
changes in Aβ levels or plaque burden, although a few previous studies have found significantly altered 
Aβ levels and plaque counts from PrPC inhibition or overexpression (Parkin et al., 2007; Schwarze-Eicker 
et al., 2005).  
 Currently, the issue of whether PrPC is a bona fide Aβ receptor that mediates Aβ synaptotoxicity 
remains unclear and controversial. Some studies have confirmed that PrPC is essential for mediating Aβ-
dependent toxicity and can be targeted with passive immunotherapy for therapeutic benefit in vivo (Barry 
et al., 2011; Bate and Williams, 2011; Chung et al., 2010; Freir et al., 2011). In contrast, others have not 
been able to replicate the initial observations with PrPC null mice, using either exogenous Aβ oligomers or 
crosses with transgenic AD mouse models (Balducci et al., 2010; Calella et al., 2010; Cisse et al., 2011b; 
Kessels et al., 2010). These conflicts in the results may reflect, at least in part, differences in the synthetic 
Aβ oligomer preparations and mouse lines; this would indicate that PrPC can serve as a Aβ binding 
partner with only certain aggregate states and/or conformations and likely is just one of many Aβ 
signaling pathways in vivo. Future studies are required to resolve the question of PrPC and Aβ-mediated 
synaptotoxicity. 
 Given the slew of various Aβ-induced neurotoxic effects that have been and continue to be 
discovered, an alternative hypothesis is that Aβ oligomers exert their actions through a generic toxicity, 
rather than defined signaling receptors and pathways. Instead of specific receptors for Aβ oligomers 
(which themselves remain ill-defined), the multitude of pathological Aβ effects may also be explained by a 





such aggregates to bind and alter membranes and other molecules. Supporting such a hypothesis, 
general cell stressors, such as excess glutamate, hydrogen peroxide, and serum deprivation, have been 
shown to lead to pathological tau alterations very similar to those induced by Aβ oligomers (Zempel et al., 
2010). Thus, while certain receptors and proteins may be particularly susceptible to interactions with 
abnormal Aβ oligomers, ultimately it may be a generic toxicity of the aggregates which lead to 
neurodegeneration in AD as well as other misfolding-related diseases.  
 
1.1.8 Current Therapeutic Options 
All currently available FDA-approved drugs for AD involve modulation of neurotransmission. 
Donepezil (Aricept; Eisai, Pfizer), galantamine (Razadyne; Ortho-McNeil-Janssen), rivastigmine (Exelon; 
Novartis) and tacrine (Cognex; Sciele Pharma) are all inhibitors of acetylcholinesterase (AChE), an 
enzyme that breaks down acetylcholine. These drugs were born out of the “cholinergic hypothesis” of AD, 
which was based on early observations of extensive neurodegeneration of cholinergic projection neurons 
in the basal forebrain (Davies and Maloney, 1976; Whitehouse et al., 1982). Acetylcholine was already 
well-established as an important modulator of cognitive processes. Combined with several neurochemical 
deficits observed in AD, including reductions in choline acetyltransferase, choline uptake, and ACh 
release, the cholinergic hypothesis was created to attribute the cognitive dysfunction of the disease to 
deficits in cholinergic neurotransmission (Bartus et al., 1982). This idea took a firm hold of the field and 
resulted in the first AD drugs, which remain the primary pharmacological options today. Unfortunately, 
data from the nearly two decades of experience with these drugs indicate that efficacy is limited, with only 
mild improvements in cognition but no lasting effect on disease progression (Hansen et al., 2007). In 
addition, only 25-50% of AD patients respond to treatment with these drugs (Giacobini, 2000); the 
underlying reasons for this clinical variability remain unclear but may be due to individual stage of 
cholinergic degeneration. Given the lack of better treatment options, donepezil is currently the most 





 The second most widely prescribed AD drug is memantine (Namenda; Forest), which is the only 
approved drug that is not an AChE inhibitor. Memantine works as an uncompetitive voltage-dependent 
antagonist of NMDAR, an ionotropic glutamate receptor that is involved in synaptic plasticity and memory. 
Since there is evidence of abnormal hyperexcitability in AD, memantine is proposed to work by 
decreasing glutamate excitotoxicity (Reisberg et al., 2003). There is also evidence that it binds 
preferentially to extrasynaptic NMDARs, which may have a pathological role in triggering Aβ production 
(Bordji et al., 2010; Hardingham and Bading, 2010). Memantine is currently approved for moderate to 
severe AD. However, like the AChE inhibitor drugs, efficacy in improving cognition is limited, without 
significant disease-modifying effects.  
 Given the minimal efficacy of current AD drugs, which are neurotransmitter-based, recent drug 
discovery efforts have been focused on Aβ, a target that will more likely to yield a disease-modifying 
treatment. However, there is still development of a variety of nootropic therapeutic strategies that target 
synaptic plasticity and cognition, with multiple compounds in clinical testing. Most of these strategies 
focus on various neurotransmitter systems, including acetylcholine, monoamines, glutamate and GABA. 
However, there are also multiple novel targets under development that could lead to cognition 
enhancement via non-transmitter mechanisms; these include calcium channels, phosphodiesterases and 
histone acetylation enzymes (Lane et al., 2012). 
Prior to neuron death, in the asymptomatic preclinical stages, synaptic abnormalities are likely 
reversible events that can be targeted pharmacologically. This further emphasizes the need for early 
diagnosis and intervention, when AD pathology is the most amendable to modification. Although current 
neurotransmitter-based drugs are limited symptomatic treatments, the possibility that a synaptic plasticity-
targeted compound could be disease-modifying is not excluded since synaptic activity is crucial for 
neuronal viability. Depending on what future research uncovers about AD etiology, hitting the right 
synaptic targets may have significant downstream effects in preventing neurodegeneration. In addition, 
even with the discovery of disease-modifying treatments, drugs that acutely target synaptic plasticity 





on cognition may not be immediate. A combination therapy in such cases would be ideal, involving both 
acute cognition enhancement/maintenance as well as chronic modification of disease pathways.  
 
1.1.9 Next Steps  
Over the past decade, Aβ has been the primary target of modern AD drug development efforts, 
given the large amount of research supporting its primary causative role in the disease (Walsh and 
Selkoe, 2007). However, multiple large setbacks have recently cast significant doubt on anti-Aβ 
strategies. In 2012, highly-anticipated phase 3 clinical trials testing two Aβ antibodies in mild-to-moderate 
AD failed to meet primary efficacy endpoints – bapineuzumab (Pfizer, Johnson & Johnson) and 
solanezumab (Eli Lilly). Both are humanized monoclonal antibodies that target Aβ. However, while 
bapineuzumab has high affinity for fibrillar Aβ, the form that is found in amyloid plaques, solanezumab is 
able to bind soluble Aβ oligomers, which are likely the primary neurotoxic species (Seubert et al., 2008). 
Recent analyses of clinical data for solanezumab actually do indicate that in a subpopulation of patients 
with milder forms of AD, drug treatment did significantly slow the rate of cognitive decline. In what seems 
like a constant stream of failures, including the phase 3 trials of dimebon (Pfizer) and semagacestat (Eli 
Lilly) in 2010, the efficacy of solanezumab, even if limited, is seen as a spark of hope.  
It supports a growing general consensus in the field that therapeutic intervention needs to occur 
well before the onset of neurological symptoms. Several recent studies have indicated that the 
pathological processes underlying AD, including brain atrophy and hypometabolism, can start years and 
even decades before a diagnosis. By the time a patient experiences significant cognitive problems and is 
diagnosed with AD, approximately half of the neurons in the hippocampal formation are already lost – the 
neurodegeneration is severe and irreversible at this point so drug interventions would have little chance of 
improving or even slowing the chronic pathology. The thought now is that AD diagnosis needs to occur 
much earlier, before the onset of symptoms, when there is a much higher likelihood of modifying disease 
mechanisms. Of course, in order to do so, there also needs to be accurate and sensitive biomarker 





biomarkers, with several promising candidates. Neuroimaging biomarkers that have demonstrated 
efficacy in tracking AD progression include PET amyloid imaging with Pittsburgh Compound-B (PIB) and 
florbetapir F18 (Amyvid), fluorodeoxyglucose (FDG)-PET to measure brain glucose utilization, and MRI to 
assess changes in brain structure volumes. Cerebrospinal fluid (CSF) biomarkers, including Aβ and 
phospho-tau levels, have also demonstrated high utility as AD diagnostic parameters. 
Three new clinical trials are being planned that will test the early intervention/prevention 
hypothesis as well as the utility of new biomarker tools in populations that have a much higher or certain 
probability of AD. The Dominantly Inherited Alzheimer's Network (DIAN) study will test three treatments in 
patients with familial AD mutations in APP, PS1 or PS2. The Alzheimer's Prevention Initiative (API) will 
test crenezumab (Genentech), an Aβ antibody, in an extended Columbian family carrying a PS1 mutation 
that guarantees early onset AD. The Anti-Amyloid Treatment of Asymptomatic Alzheimer's (A4) trial will 
test treatments in cognitively normal patients over the age of 70 who have positive amyloid PET scans, 
indicating significant Aβ deposits in the brain. The results from these studies, which will not be completed 
for years, will provide highly valuable insights and possible validation of the Aβ hypothesis. 
In the meantime, basic research in the AD field will continue working out the pathological 
mechanisms underlying disease etiology. However, as a prerequisite for developing the most effective 
therapeutics, we need to better understand both the pathology and normal physiology of the molecular 
and cellular events involved in AD. 
 
1.2 Amyloid-β: Physiological Roles? 
Although amyloid-β (Aβ) peptides have been extensively characterized as the primary neurotoxic 
molecules in Alzheimer’s disease, the fact remains that Aβ is produced and secreted by neurons 
throughout life. Aβ peptides are constantly present in the central nervous system, in the absence of any 
pathology (Shoji and Kanai, 2001). In the AD field, a large amount of research has focused on very high 
concentrations and/or aggregated assemblies of Aβ, and usually Aβ42, which is the more aggregation-





physiological function(s), which occur with much lower concentrations and includes the majority peptide 
Aβ40, remains a very important question that is highly relevant to the AD field. Can we truly understand 
Aβ’s involvement in AD pathogenesis if we do not understand its normal roles and signaling pathways? 
Such physiological functions very likely underlie parts of AD pathology, when normal Aβ-related signaling 
becomes dysfunctional and possibly pathogenic. Therefore, research on the physiological role(s) of Aβ 
will complement AD research and enlighten drug discovery efforts. 
 
1.2.1 APP Trafficking and Processing 
 I will now expand on the previous introduction of amyloid precursor protein (APP) and discuss its 
processing and trafficking. APP, together with APLP1 and APLP2, are large type I transmembrane 
proteins with large ectodomains and shorter cytoplasmic C-terminal regions (Thinakaran and Koo, 2008). 
APP is expressed widely in both adult and fetal tissues, with highest expression levels in the brain and 
kidneys. There are multiple isoforms of APP, which are generated from alterative splicing of exons 7, 8 
and 15. In the brain, the predominant isoform is APP695, which is expressed in neurons (Turner et al., 
2003). Glial cells can express other isoforms, APP751 and APP770, which contain the Kunitz Protease 
Inhibitor (KPI) domain.  
After translation, APP is transported from the endoplasmic reticulum to the cell surface plasma 
membrane. In neuronal cells, APP undergoes anterograde trafficking along axons, which is likely 
mediated by binding to the kinesin-1 motor protein (Kamal et al., 2000; Koo et al., 1990). During transport, 
APP can be post-translationally modified by N- and O-glycosylation, phosphorylation and tyrosine 
sulfation. In non-neuronal (cultured) cells, under basal conditions, most of the APP population does not 
remain at the cell surface and is instead found in the Golgi and trans-Golgi network (TGN). This is due to 
a YENPTY internalization motif that leads to endocytosis, by which some APP molecules are trafficked 
through the recycling endosomal pathway back to the cell surface and another subpopulation is targeted 





At the cell surface, APP can be proteolytically processed by α-secretases. Multiple zinc 
metalloproteinases, including ADAM9, ADAM10, ADAM17, MDC-9, and the aspartyl protease BACE2 can 
function as APP α-secretases, cleaving APP at a site located within the Aβ sequence (between Lys16 
and Leu17) (Kojro and Fahrenholz, 2005). Since this precludes Aβ formation, it is known as the non-
amyloidogenic pathway (Figure 1.2). The large sAPPα ectodomain is shed extracellularly, where is has 
been found to have multiple signaling functions in modulating synaptic activity, neurite outgrowth, 
synaptogenesis, neuronal proliferation and cell survival (Caille et al., 2004; Mattson, 1997). 
Alternatively, APP can be cleaved by the β-secretase BACE1, which is localized mostly to the 
late Gogli/TGN and endosomes. Subsequent intramembrane proteolysis by the γ-secretase complex, 
which can be found in the ER, Golgi, TGN, endosome and plasma membrane, results in Aβ formation and 
release into the lumen. The Aβ peptides generated in the recycling compartments can then be secreted 
into the extracellular space. As previously discussed, the predominant Aβ peptide in the brain is Aβ40, 
although a small proportion also includes Aβ peptides of other lengths including Aβ42, which has been the 
focus of AD research efforts due to its higher propensity for aggregation. 
The full array of mechanisms regulating APP processing are not yet understood, although some 
types of regulation are known. The YENPTY endocytosis motif is important in Aβ production, as 
demonstrated by mutations in this motif that decrease Aβ levels (Perez et al., 1999). Many adaptor 
proteins are known to bind to this motif, including JNK-interacting proteins (Miller et al., 2006) and 
members of the Fe65 and munc-18 interacting protein (Mint; also known as X11) families. Supporting 
their role in Aβ regulation, overexpression of Fe65, Mint1, or Mint2 in a transgenic AD mouse model 
reduces Aβ production and decreased plaques in the brain. These adapter proteins can be regulated by 
phosphorylation, as in the case of Fe65 where phosphorylation causes a conformational change that 






1.2.2 Physiological Functions of Amyloid-β 
APP has been found to have many functions, some specific for neurons (Mattson, 1997; 
Thinakaran and Koo, 2008). Multiple functional domains are found in the various isoforms of APP 
including: metal binding, growth factor-like, protease inhibitor (KPI), and extracellular matrix binding. The 
best-known and most consistently observed biological function for APP is trophic support. In early 
studies, it was observed that APP knockdown reduced cell growth (Saitoh et al., 1989; Selkoe, 1994) 
while in neurons, APP was found to stimulate neurite outgrowth (Qiu et al., 1995). Eventually, a number 
of APP functions were attributed to the soluble ectodomains released from APP processing. In particular, 
sAPPα has been found to be involved in modulating synaptic plasticity, synaptic density and cognitive 
functioning (Ishida et al., 1997; Mattson et al., 1993; Ring et al., 2007; Taylor et al., 2008; Turner et al., 
2003).  
 In contrast, the physiological role(s) of Aβ peptides are not as well-understood, despite the fact 
that Aβ has been known to be a normal cell metabolic product since the early 1990s (Haass et al., 1992). 
Due to the prominent involvement in AD, the study of Aβ has been dominated by its pathological roles. As 
discussed above, it is apparent that APP and at least one of its cleavage products are involved in 
neuronal physiology. Could the “amyloidogenic” pathway and Aβ peptides also play a role in normal 
neuronal and synaptic functioning? The overall role of APP cleavage products in synaptic plasticity and 
memory is supported by in vivo data. Mouse models have been made in which APP or its secretase 
cleavage enzymes (e.g. presenilin, BACE1) are knocked out. These mice demonstrate impaired synaptic 
plasticity and cognitive deficits to varying degrees (Dawson et al., 1999; Laird et al., 2005; Yu et al., 
2001). However, these effects cannot be attributed to only Aβ since full length APP and its other cleavage 
products or the other functions of the secretase enzymes cannot be ruled out for causing the defects. 
Conversely, a transgenic mouse model which overexpresses wild-type human APP (Tg5469) exhibits 
enhanced hippocampal synaptic plasticity and memory, increases that were found to depend on the 
activity of BACE1 (Ma et al., 2007). However, besides Aβ peptides, BACE1 processing also leads to other 
cleavage products (e.g. sAPPβ) and thus precludes definitive support for the involvement of Aβ peptides 





organotypic hippocampal slices found that APP overexpression depresses excitatory synaptic 
transmission (Kamenetz et al., 2003). However, as an overall caveat, these results and others from 
studies with genetically altered animals or cells are difficult to interpret since expression levels and protein 
dosages cannot be controlled and do not accurately reflect normal physiological processes. 
Exogenously applying Aβ peptides is another experimental approach which enables more direct 
study of Aβ’s effects as well as control of dosage and timing. Using this approach, the earliest support for 
a normal biological function of an Aβ peptide was in 1989, when it was discovered that exogenously-
applied Aβ28 enhanced the survival of primary hippocampal neuron cultures (Whitson et al., 1989). In a 
subsequent study, the neurotrophic effect of Aβ40 on cultured neurons was found to be dependent on 
concentration – trophic properties were observed at low concentrations (half-maximal ~60 pM) while toxic 
effects were observed at high concentrations (half-maximal ~100 nM) (Yankner et al., 1990). These early 
results correlate well with our current knowledge of normal physiological Aβ levels – in adult wild-type 
mice, the concentration of interstitial Aβ peptides in the hippocampus has been found to be in the low 
picomolar range (Cirrito et al., 2003). In another study, Aβ peptides, especially Aβ40, were found to be 
critical for neuronal viability in vitro (Plant et al., 2003). Again, this effect was observed with very low 
concentrations, starting from 10 pM.  
While these studies provided evidence for the trophic properties of Aβ at low, physiologically-
relevant concentrations, little was known about Aβ’s potential involvement in modulating synaptic 
plasticity. Our lab was the first to directly address this issue by acutely administering picomolar amounts 
of Aβ and assessing the effects on long-term synaptic plasticity and memory. We discovered that 
applying a low picomolar amount of Aβ42 (200 pM) to wild-type hippocampal slices led to an enhancement 
of synaptic plasticity, as measured by significantly increased long term potentiation (Puzzo et al., 2008). 
In addition, direct in vivo infusion of 200 pM Aβ42 peptides to the hippocampus improved learning and 
memory performance in adult mice. In the converse situation, reducing endogenous rodent Aβ levels with 
anti-Aβ antibodies or siRNA inhibited both synaptic plasticity and memory (Puzzo et al., 2011).  
Another approach to studying the physiological roles of Aβ peptides is blocking their normal 





include members of the M13 zinc-dependent metallopeptidase family: neprilysin, insulin-degrading 
enzyme (IDE), and endothelin-converting enzymes 1 and 2 (Iwata et al., 2005). Neprilysin is the most 
efficient and also appears to be the predominant and rate-limiting Aβ-degrading enzyme in the brain, at 
least in the membrane fraction (Iwata et al., 2001; Shirotani et al., 2001; Takaki et al., 2000). When 
neprilysin was pharmacologically blocked by thiorphan in hippocampal cultures and slices, leading to an 
elevation of Aβ levels, synaptic release probability and overall spontaneous activity was increased 
(Abramov et al., 2009). This presynaptic enhancement was found to depend on synaptic activation 
history, in that less enhancement was observed after high firing rates. These findings along with the data 
from our lab provide strong evidence that Aβ peptides are normally involved in modulating synaptic 
activity. 
Additional evidence comes from studies on the activity-dependent regulation of APP processing 
and Aβ release. In neurons, as previously mentioned, APP is transported to presynaptic terminals. In 
addition, APP may also serve as a kinesin-1 membrane receptor that is also involved in transporting β-
secretase and presenilin-1, a γ-secretase component, to the synapses (Kamal et al., 2001). Proteolytic 
processing of APP may occur in the axons, in the co-transported membrane compartments, or in the 
synapses, as later discovered. It was observed early on that APP cleavage products can be released by 
electrical depolarization or LTP induction in hippocampal slices (Fazeli et al., 1994; Nitsch et al., 1993; 
Turner et al., 2003). A subsequent study in organotypic slices specifically demonstrated that Aβ secretion 
can be regulated by synaptic activity (Kamenetz et al., 2003).  
More recently, in vivo experiments have provided valuable insight in discovering that Aβ peptides 
are released during neurotransmission in an endocytosis-dependent manner (Cirrito et al., 2008; Cirrito et 
al., 2005). These studies utilized a microdialysis technique which enabled direct access and 
measurement of Aβ dynamics inside the living brain. Using this technique in awake behaving mice, a 
direct positive correlation was found between interstitial Aβ concentrations and levels of synaptic activity 
in the hippocampus. In addition, the activity-regulated effects on Aβ levels were found to involve APP 
processing, not degradation, and were directly linked to synaptic vesicle exocytosis as well as clathrin-





potential depolarization at the terminal leads to endocytosis of cell surface APP that is then proteolytically 
processed in endosomes, with the resulting Aβ peptides released extracellularly (Figure 1.4).  
Microdialysis has also been used in human patients to demonstrate that Aβ levels positively 
correlate with overall neurological health and functioning (Brody et al., 2008). This study also found the 
concentration of interstitial Aβ peptides in the patients to be in the picomolar range, in agreement with the 
previous murine data. Together, these studies reveal a normal physiological synaptic regulation of Aβ 
release that fits with the finding that these peptides have a neuromodulatory role. However, the actual 





Figure 1.4.  APP processing and Aβ release at the synapse 
Schematic diagram of a model for the synaptic activity-dependent release of Aβ.  
(A) Activity-mediated depolarization of the presynaptic terminal leads to calcium influx. 
(B) Membrane localized APP is internalized via clathrin mediated endocytosis. 
(C) Proteolytic processing of APP within the endosomes produces APP cleavage products. 
(D) Aβ peptides are released from the terminal into the extracellular space. 











2.1 Post-translational Modifications  
 Post-translational modifications (PTMs), which include the covalent attachment of a chemical 
moiety to a pre-existing protein, are ubiquitously involved in the modulation of most proteins in 
eukaryotes. From stable modifications to highly dynamic reversible modifications, PTMs serve as 
essential regulatory elements in cellular signaling networks (Mann and Jensen, 2003). By changing or 
creating surfaces on the target protein, multiple functional properties can be altered by PTMs, including: 
localization, protein-protein interactions, activity state, stability and turnover rates. Mechanistically, these 
are accomplished by altering, inducing or blocking interactions with downstream effectors.  
 There are many types of PTMs involving a large variety of chemical groups (Table 2.1). Among 
the most common and well-studied PTMs is phosphorylation, which is the covalent attachment of a 
phosphate group to a serine, threonine or tyrosine amino acid. In the neurosciences, phosphorylation has 
been particularly well-studied as an essential regulator of neuronal function including learning and 
memory and the underlying cellular correlate, synaptic plasticity (Routtenberg and Rekart, 2005; 
Soderling and Derkach, 2000).  
Expanding on the role of phosphorylation in the brain, early studies of synaptic plasticity 
demonstrated increases in kinase activity and overall protein phosphorylation following various types of 
neuronal stimulation (Akers et al., 1986; Klann et al., 1991, 1992; Rosenblum et al., 1996; Rostas et al., 
1996; Siciliano et al., 1994; Sweatt and Kandel, 1989; Woodrow et al., 1992). A large amount of 





including those involving the kinases PKC, CaMKII and MAPK (Lovinger et al., 1986; Malenka et al., 
1986; Routtenberg and Rekart, 2005; Sweatt, 2001). The necessity of protein phosphorylation in synaptic 
plasticity was demonstrated by various studies that observed impaired long term potentiation and memory 
when phosphorylation was inhibited (Blum et al., 1999; Lovinger et al., 1987; Malenka et al., 1989; 
Malinow et al., 1988; Schafe et al., 1999). The key involvement of phosphorylation in synaptic plasticity 
underscores the importance and necessity of PTMs for regulating neural processing. 
More recently, multiple other types of PTMs have also been found to participate in synaptic 
plasticity, including ubiquitination, acetylation, methylation and palmitoylation (Borrelli et al., 2008; 
DiAntonio and Hicke, 2004; Fukata and Fukata, 2010; Sharma, 2010). Adding to that list, a relatively 
newly-discovered PTM has been gaining traction and has come to be recognized as an important 







Location Function Notes 
phosphorylation phosphate 80 Ser, Thr, Tyr activity modulation, interactions, 
cell signaling 
acetylation acetyl  42 Lys, N-term. stability, protein-DNA interactions 
(histones) 
methylation methyl 14 Lys genomic regulation 
glycosylation carbohydrate > 800 N-linked (Asn); 
O-linked (Tyr, 
Ser, Lys) 
excreted proteins, cell-cell 
recognition and signaling 
palmitoylation fatty acid 238 Cys membrane tethering, localization, 
targeting, interactions 
sulfation sulfate 80 Tyr interactions 
nitration nitrate 45 Tyr oxidative damage 
ubiquitination ubiquitin 8 kDa Lys stability, interactions 
neddylation Nedd8 9 kDa Lys interactions,  
SUMOylation SUMO 11 kDa Lys localization, interactions, activity 








2.2 Small Ubiquitin Like Modifier  
 Over a decade ago, a novel gene named Smt3 was identified in a genetic screen using 
Saccharomyces cerevisiae (Meluh and Koshland, 1995). The following year, in 1996, the protein product 
of that gene was found as a covalent attachment to RanGAP1, a Ran GTPase-activating protein (Matunis 
et al., 1996). This study and a subsequent paper, which coined the term SUMO to describe the small 
ubiquitin-like modifier, were the first to describe this new post-translational modification and its functional 
effect on the localization of the RanGAP1 target protein (Mahajan et al., 1997). Following upon these 
early discoveries, many subsequent studies over the past decade have elucidated the enzymatic 
pathways and biochemical functions of SUMO conjugation, a process termed SUMOylation.  
Although its name implies high similarity to ubiquitin, SUMO shares only ~18% sequence 
homology with ubiquitin. The overall folded structure of SUMO, especially at the C-terminal, is indeed 
similar to that of ubiquitin (Figure 2.2); however, the distribution of surface charges on the two PTM 
proteins are very different (Bayer et al., 1998). SUMO genes are highly conserved across all eukaryotes. 
In some organisms, including C. elegans, D. melanogaster and S. cerevisiae, there is one SUMO gene 
(Geiss-Friedlander and Melchior, 2007; Johnson, 2004). In vertebrates, there are four known SUMO 
paralogs: SUMO1-4. SUMO4 mRNA transcripts are only found in the lymph nodes, kidneys and spleen 
and, functionally, SUMO4 has been associated with type I diabetes (Guo et al., 2004). However, it is 
currently unclear if modification with SUMO4 can occur in vivo due to a unique proline residue (P90) that 
likely inhibits maturation and conjugation (Owerbach et al., 2005). 
Since SUMO2 and SUMO3 share ~95% sequence homology (with only a 3 amino acid 
difference) and have not been differentiated functionally, the two are often collectively referred to as 
SUMO2/3 and have been assumed to be functionally identical (Johnson, 2004). SUMO1 shares ~50% 








Figure 2.2.  Small ubiquitin-like modifier (SUMO) 
Diagrams of the NMR structures of human ubiquitin, SUMO1 and SUMO2. SUMO3 is structurally identical 
to SUMO2. Adapted from (Martin et al., 2007b). 
 
 
that inside cells, there is generally a large pool of unconjugated SUMO2/3; however, very little free 
SUMO1 is present, with most existing in the SUMO1 conjugates (Saitoh and Hinchey, 2000). The second 
main difference is that the N-terminal of SUMO2/3 proteins contain the SUMOylation consensus site, 
which allows for the formation of poly-SUMO chains (Tatham et al., 2001). The function of poly-SUMO 
chains versus mono-SUMO conjugation remains unclear; in yeast, preventing SUMO chain formationdoes 
not appear to cause significant effects (Bylebyl et al., 2003; Takahashi et al., 2003). In addition to these 
differences, there is data to suggest that SUMO1 conjugation serves functionally distinct roles from 
SUMO2/3, with differing target subsets (Rosas-Acosta et al., 2005; Saitoh and Hinchey, 2000; Vertegaal 
et al., 2006). However, there also appears to be significant redundancy in paralog-specific SUMOylation, 
as SUMO1 knockout mice have been reported to be fully viable, with compensation by SUMO2/3 
(Evdokimov et al., 2008; Zhang et al., 2008). However, this issue is currently unresolved since another 






2.2.1 SUMO Conjugation Cycle 
In the process of SUMOylation, a SUMO protein is covalently attached to a lysine residue on the 
target protein (Figure 2.3) (Johnson, 2004). A consensus site has been identified (ΨKxE) which consists 
of the target lysine flanked by an aliphatic branched amino acid on one side (Ψ) and another residue plus 
glutamic acid on the other side (x = any a.a., E = glutamic acid). This consensus site has also been found 
in an extended form that includes regulation by a downstream negative charge (Yang et al., 2006). One 
example of this is the phosphorylation-dependent SUMOylation motif (PDSM; ΨKxExxpSP) which 
includes a phosphorylated serine plus proline residues after the core consensus site. The neighboring 
phosphorylation enhances SUMOylation, possibly by increasing Ubc9-substrate interactions 
(Hietakangas et al., 2003; Mohideen et al., 2009; Yang et al., 2006). Examples of this type of SUMO 
regulation have been found for multiple proteins including heat shock factor-1, Smad nuclear interacting 
protein-1 and MEF2 (Hietakangas et al., 2006). Although many identified SUMOylated proteins have 
consensus sites, roughly one third do not; many instances of non-consensus lysine conjugation by SUMO 
have been observed in a variety of proteins. The mechanisms underlying  this type of SUMO acceptor 
site recognition remain unknown. 
 
 
Figure 2.3.  Cycle of SUMOylation and de-SUMOylation 





SUMO is initially expressed as a precursor protein, with a C-terminal sequence that requires 
cleavage in a maturation process to reveal a di-glycine (G-G) motif. SUMO-specific proteases (SENPs) 
are responsible for this endopeptidase (C-terminal hydrolase) activity, although it is currently unknown if 
this process is constitutive or regulated. After maturation, a heterodimeric E1 activating enzyme 
composed of AOS1 and UBA2 (also known as SAE1 and SAE2) forms a thioester intermediate complex 
with SUMO in an ATP-dependent process (Desterro et al., 1999; Gong et al., 1999; Johnson et al., 1997; 
Okuma et al., 1999). In the next step, the SUMO is transferred to the E2 conjugation enzyme, Ubc9, 
which results in a thioester bond between the C-terminal carboxyl group of SUMO and a catalytic cysteine 
in Ubc9 (Johnson and Blobel, 1997; Lee et al., 1998; Saitoh et al., 1998). In the last step, Ubc9 forms an 
isopeptide bond between the C-terminal glycine of the SUMO and a lysine residue on the substrate. 
Interestingly, Ubc9 is the sole conjugating enzyme for all SUMOs, a situation unlike many other PTMs 
such as ubiquitin and phosphorylation. It is also important to note that Ubc9 is highly specific for SUMO 
and does not conjugate other proteins such as ubiquitin (Desterro et al., 1997). 
Although the E1 activating enzyme and Ubc9 are together sufficient for SUMOylation, there is 
also another class of SUMO E3 ligases which can facilitate the conjugation process (Geiss-Friedlander 
and Melchior, 2007). For example,  one group of E3 ligases, characterized by a SP-RING motif, can bind 
Ubc9 and the target substrate as well as interact with SUMO; through these interactions, the E3 ligase 
may function in target specificity as well as coordinating the individual pieces for optimal conjugation. A 
sub-family of this E3 group includes the PIAS proteins, which have been among the more widely-studied 
E3 ligases in the brain. Other proteins which have been described as E3 ligases in vertebrates include 
the nuclear pore protein RanBP2 and Polycomb group (PcG) proteins (Geiss-Friedlander and Melchior, 
2007). Since SUMOylation involves just one E1 activating and one E2 conjugating enzymes, a situation 
unlike other common PTMs, it has been suggested that the many SUMO E3 ligases serve as the 
necessary regulatory elements dictating specificity. This hypothesis along with a fuller understanding of 
the general regulation of SUMOylation remain to be worked out – at this relatively early stage of SUMO 
research, it is almost certain that the full array of SUMO enzymes and regulatory elements have yet to be 





A characteristic that SUMO does share with some of the other PTMs, especially those involved in 
cell signaling, is the highly dynamic and reversible nature of the modification. Actually, for most SUMO 
targets, only a small percentage of the overall population is SUMOylated at any given time, likely 
reflecting highly labile conjugation and de-conjugation cycling. The SUMO-specific proteases (SENPs) 
that are involved in SUMO maturation also possess isopeptidase activity and are responsible for 
removing SUMO conjugation. Unlike the situation with the sole conjugating enzyme, there are multiple 
SENPs involved in SUMO deconjugation. The SENPs represent a single gene family, with two 
homologues in yeast (Ulp1, Ulp2) and seven known homologues in humans (SENP1-3, 5-8) (Geiss-
Friedlander and Melchior, 2007; Mikolajczyk et al., 2007). The activities and specificities of the various 
SENPs differ on many levels. Broadly speaking, SENP1 is the most efficient endopeptidase while SENP2 
and SENP5-7 are more active isopeptidases (Mikolajczyk et al., 2007). And while SENP1, and to a lesser 
extent SENP2, have deconjugating activity for both SUMO1 and SUMO2/3, the remaining SENPs appear 
to be much more specific for SUMO2/3 (Mukhopadhyay and Dasso, 2007). There also appears to be 
specificity in monomeric versus polymeric deconjugation; for example, SENP6 appears to have high 
specific activity for poly-SUMO2/3 chains (Mukhopadhyay et al., 2006). After a SUMO has been 
deconjugated, it becomes free to cycle back and participate in another SUMOylation reaction. However, 
the regulation of the turnover and stability of the SUMO proteins is unclear and remains to be elucidated. 
 
2.2.2 Molecular Consequences of SUMOylation 
 Upon modification by SUMO, a target protein can be altered in multiple, non-exclusive ways. As 
previously discussed for PTMs in general, conjugation can alter, induce or block binding sites for 
downstream effectors. SUMO modifications contribute to the protein’s surface topology and can also 
directly induce an intra-molecular conformational change, both of which can affect the target protein’s 
activity and interactions with other molecules. Notably, one type of downstream signaling is mediated by 
SUMO-interaction motifs (SIMs) in effector proteins. These motifs are hydrophobic sequences, flanked by 





al., 2000; Song et al., 2004). The binding affinity between a SUMO and a SIM is in the high µM range, 
due to a relatively small binding interface (Hecker et al., 2006; Song et al., 2005). However, the overall 
interaction could be highly specific if the downstream target or complex contains more than one SIM. 
SIMs have been found in multiple proteins so far, including PML and the transcriptional repressor Daxx . 
Notably, SIMs can be utilized in either non-SUMOylated effectors or in SUMOylated targets, in which the 
motifs may function in SUMO paralog specificity. For example, the ubiquitin specific protease 25 (USP25) 
has a SIM that preferentially recruits SUMO2/3 over SUMO1, leading to paralog-specific conjugation 
(Meulmeester et al., 2008). SIMs are also found in the SUMOylating enzymes themselves, including 
UBA2 and PIAS E3 ligases and likely contribute to enzyme function (Geiss-Friedlander and Melchior, 
2007).  
 
2.2.3 Cross-talk Interactions With Other PTMs 
 Another important aspect of SUMOylation is the potential co-regulation and crosstalk with other 
PTMs. As previously discussed with the phosphorylation-dependent SUMOylation motif, the various 
modifications of a single target protein can exhibit a significant level of interaction. Conjugation with one 
type of PTM can affect conjugation of another PTM at a different residue. In the case of phosphorylation, 
both positive and negative phosphorylation-regulated SUMOylation have been observed (Wilkinson and 
Henley, 2010). There is also significant cross-talk with ubiquitin, another protein-group PTM. Both 
ubiquitin and SUMO attach to lysine residues so there is the potential for competitive antagonism 
between the two modifications. On the other hand, there is also evidence that ubiquitin and SUMO can 
act in concert, sequentially and/or synergistically. For example, when the tumor suppressor p53 is 
ubiquitinated, it recruits the SUMO E3 ligase PIASy, which then enhances SUMOylation at another lysine 
(Carter et al., 2007). Another example demonstrates multi-step PTM synergy: In the case of the NF-κB 
essential modulator (NEMO), SUMOylation results in accumulation in the nucleus, where NEMO can be 





originally SUMOylated, allowing NEMO to be exported from the nucleus for forming part of an active 
kinase (Wilkinson and Henley, 2010).  
Along the same vein, acetylation has also been demonstrated to interact with SUMOylation, again 
either at the same lysine residue or other residues in the same protein. Among the proteins that have 
lysines which can be modified by either SUMOylation or acetylation are the transcription factors MEF2A 
and Sp3, transcriptional co-activator p300 and the tumor suppressor HIC1 (Bouras et al., 2005; 
Sapetschnig et al., 2002; Shalizi et al., 2006; Stankovic-Valentin et al., 2007). In some SUMOylated 
proteins, a defined motif is present which may target either acetylation or SUMOylation to the same 
residue. This “SUMO-acetyl switch” can be regulated by yet another PTM, as in the case of MEF2A; 
phosphorylation adjacent to the motif flips the switch to SUMO conjugation, and vice-versa, providing a 
phosphorylation-dependent SUMO-acetyl switch that controls the activity of the transcription factor 
(Shalizi et al., 2006).  
 Beyond co-regulated PTM interactions within the same protein, there is another level of cross-
regulation via direct and oftentimes reciprocal modification of PTM enzymes. In the case of 
phosphorylation, several kinases and phosphatases are known to be SUMOylated, including the focal 
adhesion kinase, glycogen synthase kinase 3β, extracellular signal-regulated kinase 5, and protein 
tyrosine phosphatase 1B (Dadke et al., 2007; Eun Jeoung et al., 2008; Kadare et al., 2003; Woo et al., 
2008). At the same time, some SUMO enzymes can be regulated by phosphorylation, including Ubc9 and 
several SUMO E3 ligases (Su et al., 2012; Wilkinson and Henley, 2010). An example of this type of 
reciprocal regulation can be seen in an autoregulatory feedback loop involving the Pc2 SUMO E3 ligase 
and the homeodomain interacting protein kinase 2 (HIPK2) – upon DNA damage, HIPK2 phosphorylates 
Pc2, which then activates the ligase to SUMOylate HIPK2 and results in transcriptional silencing (Roscic 
et al., 2006).  
There is similar cross-talk regulation of PTM pathways in ubiquitination and acetylation as well. 
SUMOylation can occur with the ubiquitin E2 enzyme, E2-25K, which results in inhibition of its 
conjugation activity (Pichler et al., 2005). And in turn, SUMO enzymes can be regulated by ubiquitination. 





E3, RanBP2, which results in enhanced proteasomal degradation (Um et al., 2006).  Interestingly, parkin 
can also interact non-covalently with SUMO1, an interaction that increases its ubiquitin ligase activity (Um 
and Chung, 2006). This may result in a modulatory feedback loop with implications for PD. A similar 
situation exists for regulatory interactions with acetylation, and in particular, histone acetylation. There are 
several reports that some histone deacetylases (HDACs) can be SUMOylated and/or function as SUMO 
E3 ligases. SUMOylation of HDAC1 and HDAC4 increases their deacetylase activities, which in turn 
correlates with increased transcriptional repression (Cheng et al., 2004; David et al., 2002; Kirsh et al., 
2002). In addition, HDAC4 has also been reported to have SUMO E3 ligase functionality; HDAC4 was 
found to increase SUMOylation of MEF2 transcription factors independent of its deacetylase activity  
(Gregoire and Yang, 2005).  
 The various types of cross-talk interactions discussed above highlight the complex and intricate 
regulatory mechanisms that involve SUMO. Combined with the other PTM types, there is the potential for 
a highly dynamic layer of regulatory information coded in the modifications at multiple sites within a 
protein and multiple components of a signaling network. 
 
2.2.4 Nuclear functions of SUMOylation 
Various studies involving deletion/knockout of SUMO or its enzymatic machinery indicate that 
SUMOylation is essential for viability and normal cell functioning in multiple organisms including C. 
elegans, S. cerevisiae and mice (Geiss-Friedlander and Melchior, 2007). Mutant or knockout mice for 
SENP1 or Ubc9 experience early embryonic lethality (Nacerddine et al., 2005; Yamaguchi et al., 2005). In 
the Ubc9 knockout, detailed analyses indicate severe defects in nuclear structure and genomic function, 
ranging from problems with chromosome condensation and segregation to altered nuclear and sub-
nuclear morphology. Even prior to these studies, since the original discovery of SUMOylation with the 
nuclear transport protein RanGAP1, SUMOylation has been best-characterized for its genomic and 
nuclear functions. Processes found to depend on SUMO include DNA repair, transcription, nuclear body 





 Transcription is one major function which appears to be heavily regulated by SUMO modification. 
Indeed, transcription factors make up the largest class of SUMOylated proteins. A generalized trend was 
observed in the early days of SUMO research – it appeared that SUMO modification induced either 
activation of transcriptional repressors or inhibition of transcription activators/co-activators (Bies et al., 
2002; Gill, 2005; Girdwood et al., 2003; Hirano et al., 2003; Kim et al., 2002; Poukka et al., 2000; Ross et 
al., 2002; Sapetschnig et al., 2002; Ungureanu et al., 2003; Yang et al., 2003a). Thus, it initially seemed 
that SUMOylation generally repressed transcription. However, recent findings from this rapidly-growing 
field indicate that SUMOylation can also increase transcription and that regulation by SUMO is not so 
easily simplified (Choi et al., 2011; Sehat et al., 2010). Currently, a large number of transcription factors 
and co-factors have been characterized as SUMOylated proteins (at least using in vitro systems) (Zhao, 
2007). Among the factors that have some neuron-specific functions during development and/or normal 
physiology: AR, BMAL1, C/EBP, c-Jun, CBP, CREB, Dnmt3a, Elk-1, GATA-1, Huntingtin, IRF-1, Kap1, 
Lef1-1, MBD1, MEF2, Msx1, p53, p63, p73, p300, PPARγ, RXRα, Sam68, Smad4, Sox2, Sox3, Sox6, 
Sox10, Sp1, Sp3, SREBPs, SRF. SUMOylation can also affect transcription via regulation of PML 
nuclear bodies (NBs), the large subnuclear structures that are involved in a variety of essential nuclear 
functions. The primary component of these structures is PML protein, which has been found to be 
SUMOylated at multiple sites (Kamitani et al., 1998; Muller et al., 1998). PML SUMOylation is required for 
the normal formation and morphology of the PML NBs. When PML SUMOylation is inhibited, the 
recruitment of other NB-associated proteins such as transcription factors is greatly disrupted, leading to 
large effects on transcriptional activity (Best et al., 2002; Kamitani et al., 1998). Among the other nuclear 
processes that have been found to require SUMOylation are: chromosome organization, DNA repair and 
nuclear transport. In all of these processes, the SUMOylation of certain proteins is essential for normal 
functioning (Johnson, 2004; Zhao, 2007). Due to this obvious core functionality of SUMOylation in 







2.3 SUMO in Cancer 
 SUMOylation has been implicated in multiple cancers and the tumorigenesis process 
(Bettermann et al., 2012; Sarge and Park-Sarge, 2012). In general, it appears that aberrant SUMOylation 
is associated with faulty genomic regulation and cancer cell growth. In diverse cancers including 
adenocarcinoma, melanoma, ovarian cancer, colon cancer, prostate cancer and multiple myeloma, 
expression levels of the SUMO E2 conjugating enzyme, Ubc9, were observed to be elevated (Driscoll et 
al., 2010; McDoniels-Silvers et al., 2002; Mo et al., 2005; Moschos et al., 2010; Moschos et al., 2007). 
Intriguingly, in some of the cancers, patient survival outcomes were correlated with the degree of Ubc9 
upregulation – higher Ubc9 expression was associated with increased patient mortality and enhanced 
resistance to chemotherapeutics. As expected given SUMO’s role in transcriptional regulation, the 
underlying mechanisms likely involve the dysregulated expression of oncogenic proteins, such as bcl-2 
(Mo et al., 2005). In experiments testing Ubc9’s involvement, the expression of a dominant negative 
Ubc9, in which a catalytic cysteine is replaced by a serine (C93S), reduced cancer cell growth and 
increased apoptosis after radiation treatment (Driscoll et al., 2010; Mo et al., 2005). Besides Ubc9, 
increased levels of other SUMO enzymes, including the E1 activating enzyme and E3 ligases, have also 
been found in a large variety of cancers (Driscoll et al., 2010; Wang and Banerjee, 2004). It is currently 
unknown why levels of SUMO enzymes are increased. Genetic variation may play a part, as breast 
cancer has been associated with certain single nucleotide polymorphisms in the genes for Ubc9 and 
PIAS3, an E3 ligase (Dunnebier et al., 2009a, b). 
While these data seem to suggest that abnormally increased SUMOylation is to blame, there is 
also evidence that decreased SUMOylation is also associated with cancer. In studies of prostate and 
thyroid cancers, levels of the SUMO protease, SENP1, are increased (Cheng et al., 2006; Jacques et al., 
2005). In the case of prostate cancer, deSUMOylation by SENP1 affects the activity of the androgen 
receptor and c-Jun transcription factors. Besides these examples, multiple other cancer-related 
transcription factors have been identified as SUMO targets, including p53, Mdm2, pRB, p63 and p73 
(Sarge and Park-Sarge, 2012).  In some cases, mutations in the SUMO targets which affect conjugation 





proposed oncogene, mutations that alter a SUMO consensus site decrease SUMOylation and is 
associated with a significantly increased risk of melanoma and renal cell carcinoma (Bertolotto et al., 
2011). 
 The data from the cancer field demonstrate the complex regulatory functions of SUMO 
conjugation, especially as pertains to transcription, and highlight the difficulty and inapplicability of trying 
to oversimplify the consequences of SUMOylation – as one PTM mechanism in the cell-wide signaling 
network, the impact of altered SUMOylation on a phenotypic output is hard to predict and cannot be 
considered in isolation. Overall, however, the multitude of studies suggest that targeting SUMOylation 
could be a therapeutic strategy for future cancer drug development.  
  
2.4 SUMOylation in the Brain  
 Although a large amount of SUMO research has been focused on its genomic functions, 
SUMOylation is not confined to just the nucleus. Neither the SUMO proteins nor the SUMO enzymes are 
restricted to the nuclear compartment and can be found throughout the cell. In a new wave of SUMO 
research, many extra-nuclear proteins have recently been described as SUMOylated targets. As 
previously discussed, SUMOylation of these cytoplasmic or membrane-bound proteins can affect many 
functional parameters including localization, protein-protein interactions and stability. 
 In particular, SUMOylation in the central nervous system has garnered increasing attention. Along 
the lines of phosphorylation, SUMOylation has the potential to impact a large array of neuronal functions, 
particularly at the synapses. In the adult brain, SUMO1 and SUMO2/3 are expressed abundantly (Lee et 
al., 2011; Zhang et al., 2008). In addition, the SUMO conjugating enzyme, Ubc9, is expressed throughout 
the cerebral cortex and hippocampus, with high levels in pyramidal neurons and dentate granule cells 
(Golebiowski et al., 2003; Watanabe et al., 2008). In primary neuron cultures, Ubc9, AOS1, PIAS3, 
SENP1 and SENP6 have all been detected throughout the cytoplasm and at the synapses (Loriol et al., 





Multiple proteins with neuron-specific roles have been found to be SUMOylated, including 
transcription factors, kinases and neurotransmitter receptors (Wilkinson et al., 2010). In terms of neuronal 
functioning, SUMOylation has been shown to be involved in a variety of processes such as kainate-
mediated basal synaptic transmission and homeostatic synaptic scaling (Craig et al., 2012; Martin et al., 
2007a). Here, I will review examples of SUMOylation of neuronal proteins and the functional 
consequences of the modification. 
 
2.4.1 Transcriptional Regulation 
 In the rodent brain, the SUMO enzymes and overall SUMOylation are developmentally-regulated 
throughout embryogenesis and early postnatal development (Loriol et al., 2012b; Watanabe et al., 2008). 
SUMO1 and SUMO2/3 conjugation levels, Ubc9, SENP1 and SENP6 were shown to exhibit significant 
changes in protein levels with different stages of brain development. Although it has not been directly 
determined, the SUMOylated substrates likely include transcription factors necessary for precursor 
proliferation and neuronal differentiation. For example, the tumor suppressor protein p53, which is known 
to be SUMOylated, functions also in neuronal and oligodendrocyte differentiation (Eizenberg et al., 1996).  
 A more specific and detailed example can be seen with photoreceptor development in the retina. 
For the correct specification of rods versus cones, Pias3-dependent SUMOylation of the appropriate 
transcription factors is required (Onishi et al., 2010; Onishi et al., 2009). In the case of rod 
photoreceptors, SUMOylation of the Nr2e3 transcription factor leads to repression of cone-specific gene 
expression. For cone photoreceptor development, Pias3-dependent SUMOylation is involved in the 
specification of medium wavelength-sensitive cones through transcriptional control of cone opsin 
expression. Thus, Pias3-dependent SUMOylation is required in both cases, which illustrates the complex 
role of SUMO in the positive and negative regulation of neuronal differentiation.  
 Synapse formation is another process in which SUMOylation has been found to be essential. The 
myocyte enhancer factor 2 (MEF2) transcription factors are involved in the formation of dendritic claws in 





transcriptional regulation that results in restricted synapse number (Flavell et al., 2006). MEF2A, one of 
the MEF2 family members, was found to have a phosphorylation-regulated SUMO-acetyl switch (as 
discussed previously). When neuronal activity activates the phosphatase calcineurin, MEF2A is 
dephosphorylated, a state that leads to the replacement of a SUMO modification with an acetyl 
modification (Shalizi et al., 2006). Acetylation activates MEF2A transcriptional activity, leading to an 
inhibition of dendritic claw differentiation. The SUMOylation of MEF2A was later found to be dependent 
on the PIASx SUMO E3 ligase (Shalizi et al., 2007). 
 These examples illustrate the potential of SUMOylation in regulating transcription in neuron-
specific processes. This topic is still in its early days so I expect that the upcoming years will bring a much 
more complete understanding of SUMO involvement in neuronal transcriptional regulation, both in 
developmental processes and normal physiology.  
 
2.4.2 Kinases 
 As previously discussed, SUMOylation can have many types of co-regulatory and cross-
regulatory interactions with other PTMs. Several examples of SUMO-regulated phosphorylation, via 
modification of kinases and phosphatases, have been discovered. Although very few have been directly 
investigated in neuronal cells, I will include a few examples that likely have functional impact in the brain.  
 Glycogen synthase kinase 3β (GSK3β) is a constitutively active serine/threonine kinase that is 
involved in many biological functions, including its well-characterized role in energy metabolism. In the 
brain, as a downstream effector of multiple signaling pathways, GSK3β has been found to participate in 
neural development, neuroinflammation and synaptic plasticity (Salcedo-Tello et al., 2011). GSK3β has 
also been implicated in multiple neurological diseases including schizophrenia, bipolar disorder and 
Alzheimer’s disease (Bhat et al., 2004). As one of the primary kinases responsible for phosphorylating 
tau, GSK3β has been the focus of many studies on tau hyperphosphorylation in neurodegeneration 
(Hanger et al., 2009). Therefore, as a regulator of long term synaptic plasticity and a potential therapeutic 





Furthering that goal, GSK3β has been reported to be SUMOylated at a non-consensus site lysine (Eun 
Jeoung et al., 2008). SUMOylation alters GSK3β localization to the nucleus and also decreases its kinase 
activity. Since GSK3β inhibition appears to be critical for long term potentiation (Hooper et al., 2007; 
Peineau et al., 2007), neuronal activity-regulated SUMOylation of GSK3β may be involved in synaptic 
plasticity. Future research will determine if this speculation is valid. 
 Related to GSK3β signaling, a known interaction partner, Axin, has also been found to be 
SUMOylated. Axin forms a complex with GSK3β and β-catenin that participates in the negative regulation 
of Wnt signaling (Ikeda et al., 1998). In the brain, Axin is involved in neuronal differentiation, neuronal 
polarization and axon formation (Fang et al., 2011; Lyu et al., 2003). Axin has also been found to 
negatively regulate the ability of GSK3β to phosphorylate tau (Stoothoff et al., 2002). The SUMOylation of 
Axin may play a role in regulating these functions. Axin has been found to be heavily SUMOylated in its 
C-terminal region (Rui et al., 2002). Inhibition of this SUMOylation prevented the Axin-mediated activation 
of the c-Jun N-terminal kinase (JNK), which has multiple downstream effects on nuclear and 
mitochondrial proteins; Wnt pathway signaling, however, was not affected. This demonstrates that 
SUMOylation can alter multiple components of a signaling cascade with high specificity for individual 
pathways.  
Protein tyrosine phosphatase 1B (PTP1B) is another example of a SUMOylated phosphorylation 
enzyme, the SUMO modification of which likely has a functional impact in neurons. PTP1B is highly 
expressed in the brain and belongs to a family of tyrosine phosphatases with many diverse roles. 
Regarding neuron-specific functions, PTP1B has been shown to be involved in regulating body adiposity 
and energy expenditure via its functions in hypothalamic neurons (Bence et al., 2006; Tsou et al., 2012; 
Xue et al., 2009). PTP1B has also been implicated in retinal degenerative diseases (Basavarajappa et al., 
2012). Although not directly demonstrated in neurons, PIAS1-mediated SUMOylation of PTP1B in 
response to insulin signaling has been discovered in fibroblasts (Dadke et al., 2007). SUMO modification 
was found to have a negative regulatory effect on PTP1B, reducing its catalytic activity. Phosphatases 
are critical components in many neuronal signaling networks and, as demonstrated with PTP1B, may 





 The calcium/calmodulin-dependent serine protein kinase (CASK) is one of the few examples of a 
SUMOylated kinase/synaptic scaffolding protein that has been detected in modified form in neurons and 
brain tissue (Chao et al., 2008). CASK is a member of the membrane-associated guanylate kinase 
(MAGUK) family, which is involved in synapse formation. CASK was discovered to be SUMOylated by 
SUMO1 at a consensus motif lysine. This modification reduces the interaction between CASK and protein 
4.1, which inhibits spine morphogenesis in vitro. These data indicate that SUMO is involved in regulating 
dendritic spine morphology, an important role given that > 90% of excitatory synapses form onto these 
structures (Nimchinsky et al., 2002).  
  
2.4.3 Axonal Transport 
 Intracellular transport is an essential process in all eukaryotic cells. However, neurons in 
particular, with their highly polarized morphology, depend on axonal transport  for shuttling a variety of 
molecules to the synaptic terminals (De Vos et al., 2008). For example, synaptic plasticity is well-
established to depend on local protein synthesis, a process that requires the transport and targeting of 
mRNAs. This transport in turn depends on RNA binding proteins that participate in packaging the nucleic 
acids and interacting with the cytoskeletal network and motor proteins. The direction of fast axonal 
transport depends on the motor proteins dynein, which mediates retrograde transport, and kinesin, which 
mediates anterograde transport. In neurodegenerative diseases, axonal transport can become 
dysregulated early on and exacerbate neuronal pathology.  
In dorsal root ganglion sensory neurons, the RNA-binding protein La was discovered to be 
SUMOylated at a single lysine (van Niekerk et al., 2007). SUMOylation regulates the binding of La to 
either dynein or kinesin and therefore controls the direction of the transport – SUMOylated La binds only 
dynein while non-SUMOylated La binds only kinesin. SUMOylation functions here as a regulatory switch 






2.4.4 Synaptic Function 
 Cell surface receptors are likely targets of SUMOylation, which may function analogously to other 
PTMs, such as phosphorylation, in regulating parameters such as trafficking and activity. As the first-
discovered example of a directly SUMOylated neurotransmitter receptor, the GluR6 subunit of the kainate 
receptor was shown to be modified by SUMO-1 in a consensus site lysine (K886) in cultured hippocampal 
neurons (Martin et al., 2007a). SUMO conjugation regulates the endocytosis of the kainate receptor in 
response to stimulation. While there is normally a low level of SUMOylation under basal conditions, 
kainate rapidly increases GluR6 SUMOylation, which leads to endocytosis of the receptor. The functional 
effects were observed in hippocampal slices, where kainate-mediated basal transmission (measured in 
postsynaptic currents) was reduced by SUMOylation and enhanced by deSUMOylation. This study was 
among the first to demonstrate a role for SUMO in synaptic function. A subsequent study investigated this 
process under ischemia-related pathology and found that SUMOylation of the GluR6 subunit activates the 
MLK3-JNK3 pathway, which contributes to ischemic neuronal cell death (Zhu et al., 2012). GluR6 
SUMOylation provides an example of the normal regulatory function of SUMO as well as the dysregulated 
function under pathological conditions.  
 Another example of a SUMOylated neurotransmitter receptor is the cannabinoid receptor type 1 
(CB1). Cannabinoid receptors constitute a class of widely-expressed G protein-coupled receptors 
(GPCRs) in the brain and are involved in modulating neurotransmission. The CB1 cannabinoid receptor 
has been found to be SUMOylated by SUMO1 in primary cortical neurons (Gowran et al., 2009). ∆9-
tetrahydrocannabinol (∆9-THC), which is the primary psychoactive compound in cannabis, was found to 
decrease SUMOylation of CB1 and p53, a known SUMO substrate. It was proposed that ∆9-THC may 
exert neuroprotective effects by regulating p53 SUMOylation, which affects its stability and activity. 
 Receptor trafficking can also be regulated by SUMO indirectly (versus direct conjugation). 
Recently, SUMOylation was found to be involved in homeostatic synaptic scaling induced by activity 
silencing (Craig et al., 2012). Tetrodotoxin, an inhibitor of voltage gated sodium channels, increases the 
cell surface expression of AMPA receptors in cultured neurons after prolonged exposure (1 µM for 24 





SUMO protease. While the AMPA receptor was not found to be directly SUMOylated, the immediate early 
gene product Arc is SUMOylated by SUMO1, a modification that is required for synaptic scaling. These 
findings demonstrated that SUMOylation of Arc is involved in AMPA receptor trafficking in neurons.  
 Presynaptic function may also involve SUMOylation. In a study of synaptosomes prepared from 
cortical and hippocampal tissue, increasing SUMO1 levels decreased KCl-induced glutamate release 
while in contrast, decreasing SUMOylation with SENP1 enhanced glutamate release (Feligioni et al., 
2009). However, with kainate stimulation, the opposite was observed (SUMO1 increased and SENP1 
decreased glutamate release). Thus, SUMOylation may have presynaptic regulatory functions that are 
stimulus-dependent.  
In the same synaptosome study, stimulation with AMPA or high KCl caused redistribution of Ubc9 
into the presynaptic compartment along with a general increase in SUMOylation by SUMO1. Similarly, in 
transfected SHSY5Y cells, which are a neuroblastoma-derived cell line, stimulation with high KCl (50 mM) 
for an hour led to an increase in SUMO conjugation by all SUMO paralogs (SUMO1-3) (Lu et al., 2009). 
Although this type of activity-dependent SUMO regulation has not been demonstrated in neurons/brain 
tissue (prior to my thesis project), these studies do indicate that SUMOylation is likely involved in multiple 
signaling pathways involved in synaptic activity.  
 
2.4.5 Channels and Transporters 
 Through the regulation of channels and transporters, non-synaptic neuronal functioning can also 
be modulated by SUMOylation. The following are examples discovered in non-neuronal cells but which, 
although not directly demonstrated, may function in the brain. 
 Glucose transporters are membrane proteins that influence neuronal functioning and have been 
shown to be SUMOylated. Levels of GLUT1 and GLUT4 glucose transporters, which are highly 
expressed throughout the brain, were found to be regulated by Ubc9 expression in adipocyte and muscle 
cell lines (Giorgino et al., 2000). Overexpression of Ubc9 led to reduced GLUT1 levels but greatly 





GLUT1 carries out basal transport, the effect of increased SUMOylation was an enhancement of insulin 
responsiveness. These findings raise the possibility that glutamate transport in neurons is similarly 
regulated by SUMO. 
 Potassium channels, which influence the resting membrane potential of excitable cells, have also 
been found to be SUMOylation targets. One such channel, K2P1, is a plasma membrane leak channel 
that is strongly expressed in the brain (Orias et al., 1997). However, although it is expressed, the channel 
appeared to be functionally inactive and electrically silent. In a study using Xenopus laevis oocytes and 
COS-7 cells, it was observed that K2P1 colocalized with Ubc9 at the plasma membrane and is basally 
SUMOylated (Rajan et al., 2005). Normally inactive, the K2P1 channels were able to conduct ionic 
currents when the SUMO protease SENP1 was introduced intracellularly. The authors concluded that the 
SUMO modification normally blocks K2P1 channel activity, and deSUMOylation removes the block and 
activates the channel. However, this issue is not resolved since subsequent studies did not confirm K2P1 
as a SUMO substrate and were not able to activate channel activity by altering its SUMOylation state 
(Feliciangeli et al., 2007; Feliciangeli et al., 2010). Future research will determine if K2P1 is actually 
SUMOylated and what the consequences of the modification are. 
 Another potassium channel, Kv1.5, has also been reported to be a SUMO substrate (Benson et 
al., 2007). Kv1.5 is a voltage-gated potassium channel that has been best-studied for its role in action 
potential repolarization in atrial myocytes. This channel was found to be SUMOylated by all SUMO 
paralogs in vivo. Inhibition of SUMOylation, via mutation or expression of the SENP2 SUMO protease, led 
to a hyperpolarizing shift (~ 15 mV) in the voltage dependence of steady-state inactivation. With this 
channel, and likely many others, SUMOylation presents a way to dynamically regulate electrical 
excitability, a mechanism which may be involved in modulating neuronal membrane properties. 
  
2.5 SUMOylation in Neurological Diseases 
 Given the wide variety of neuronal proteins which are SUMOylated or likely to be SUMOylated, it 





diseases (Sarge and Park-Sarge, 2011; Wilkinson et al., 2010). Here I will review some of the examples 
and the specific SUMOylated proteins involved. 
 
2.5.1 Cell Stress 
 Neurological diseases, including neurodegeneration, involve pathological processes that strongly 
induce cellular stress, whether caused by aberrant protein aggregation, disrupted transport, mitochondrial 
dysfunction, blood-brain barrier dysfunction and/or any of a multitude of possible pathological factors. 
Since SUMOylation is generally involved in cell stress responses, I will first go through a brief review of 
this involvement. The findings from previous studies, although largely in non-neuronal cell lines, are 
relevant for evaluating SUMO’s roles in normal and diseased brain functioning.  
It was observed relatively early on that environmental cell stressors, including hypoxia, heat, 
radiation, ethanol, oxidative stress and osmotic shock, can induce changes in global SUMOylation 
(Tempe et al., 2008). These effects have been observed with various cell cultures, including mammalian 
cell lines and S. cerevisiae, and involve SUMO2/3 and SUMO1 conjugation (Bossis and Melchior, 2006; 
Saitoh and Hinchey, 2000; Sramko et al., 2006; Zhou et al., 2004). In general, the SUMOylation changes 
are in a upward direction, with increased levels of SUMO conjugates.  
In terms of mechanisms, the SUMOylation changes are generally caused by effects on the 
conjugation machinery and/or target protein phosphorylation. The specific pathways involved are 
dependent on the stimulus type, intensity and duration. In COS-7 cells, heat stress, metabolic stress 
(ethanol), and osmotic stress (high NaCl) greatly increased PIAS3-mediated SUMOylation of the c-Myb 
transcription factor, which repressed its activity (Sramko et al., 2006). In addition, this effect was found to 
be partially influenced by a phosphorylation dependent sumoylation motif (PDSM). Heat shock, which 
involves heating cells to 42-43 C for 30 minutes to 1 hour, can induce strong SUMOylation of heat shock 
factor 1 (HSF1), which leads to increased DNA binding (Hong et al., 2001). In contrast to c-Myb, 
SUMOylation increases HSF1-mediated transcriptional activity in response to stress. The HSF1 





required for the stress-induced SUMOylation (Hietakangas et al., 2003). Although some of the SUMO 
substrates in these stress-related responses are known, including the above-discussed examples, the 
mechanisms that lead to the SUMOylation changes are not yet elucidated.  
 In the case of oxidative stress, the upstream changes that affect SUMOylation are better 
understood. Oxidative stress, which is experimentally induced by H2O2 exposure, can inhibit overall 
SUMOylation via the formation of a disulfide bond between the catalytic cysteines of the SUMO E1 and 
E2 enzymes (Bossis and Melchior, 2006). With much higher amounts of H2O2 (100 mM), which likely 
never occur in vivo, the opposite occurs, and there is a general increase in SUMOylation; this is likely due 
to inactivation of SENPs that occurs at this concentration (Xu et al., 2008). Downstream of the SUMO 
enzymes, the substrates for oxidative stress-mediated SUMOylation changes involve transcription factors, 
including ERM and NEMO (Tempe et al., 2008). 
 Hypoxic stress has been shown to upregulate SUMOylation as well. In vivo, hypoxia can occur 
pathologically, with ischemia and in tumors, as well as physiologically, with normal embryogenesis where 
hypoxia induces vascular development (Ulrich, 2007). The main molecular regulator of oxygen-related 
transcription is the hypoxia-inducible factor 1 (HIF1), which has been shown to be increasingly 
SUMOylated by SUMO1 with hypoxic stress (Carbia-Nagashima et al., 2007; Shao et al., 2004). This 
effect is mediated by a hypoxia-induced SUMO E3 ligase, the RWD-containing sumoylation enhancer 
(RSUME), which enhances HIF1 SUMOylation by increasing interaction between Ubc9 and SUMO1 
(Carbia-Nagashima et al., 2007). However, the consequences of HIF1 SUMOylation remain unclear – two 
studies indicate that  SUMO modification stabilizes HIF1 and increases its transcriptional activity while 
two other studies  found that HIF1 SUMOylation leads to its degradation (Bae et al., 2004; Berta et al., 
2007; Carbia-Nagashima et al., 2007; Cheng et al., 2007). Hypoxia in the adult brain and heart has also 
been correlated with increased levels of SUMO1 mRNA and protein (Comerford et al., 2003; Shao et al., 
2004), which support the importance of SUMO regulation in hypoxia responses. 
 Another transcriptional regulator involved in hypoxia has also been observed to be SUMOylated – 
the cyclic AMP-response element-binding protein (CREB) (Comerford et al., 2003). CREB is a 





including its particularly well-studied role in neural plasticity and memory. In hypoxia, CREB has been 
found to undergo phosphorylation-dependent degradation, as part of the regulation of inflammation-
related genes with cAMP response element motifs (Taylor et al., 1999). With prolonged hypoxia (> 24 
hours) in mammalian cell lines, CREB was found to be modified by SUMO1 at two lysine residues (K285, 
K304), which stabilized the protein and increased transcriptional activity (Comerford et al., 2003). 
Mutation of the acceptor lysines disrupted the nuclear localization of CREB. The authors concluded that 
CREB SUMOylation may therefore play a role in the resolution of hypoxia-induced inflammation. Because 
of CREB’s well-known role in synaptic plasticity, it is tempting to speculate that SUMOylation of CREB 
may also occur in the brain with physiological processes. We have investigated this possibility in the lab 
with no conclusive results so far (see Chapter 4). 
 
2.5.2 Ischemia  
 After the demonstration of SUMO involvement in hypoxia and general cell stress responses, 
ischemia was a logical next step in investigating the role of SUMOylation in a neuropathological process. 
In vitro, in primary hippocampal neurons, oxygen and glucose deprivation (OGD) have been shown to 
increase SUMOylation by both SUMO1 and SUMO2/3 (Cimarosti et al., 2011). Although Ubc9 levels were 
not affected by OGD, the SUMO protease SENP1 was found to increase up to 24 hours afterwards. 
Directly overexpressing SENP1 increased OGD-induced neuronal cell death, so apparently conflicting 
SUMOylation changes occur with OGD.  Another study with primary cortical neurons supports the 
neuroprotective effect of SUMOylation; knockdown of SUMO2/3 expression increased vulnerability to 
OGD-induced cell death (Datwyler et al., 2011). In the SHSY5Y neuroblastoma cell line, a similar effect 
was observed in that Ubc9 overexpression increased tolerance to OGD while a Ubc9 dominant-negative 
decreased tolerance (Lee et al., 2007b). Since SUMOylation was also observed to be greatly increased 
with hibernation torpor in squirrels, the authors posited that SUMOylation is involved in cytoprotection. 
Recently, a possible mechanism was discovered by the same group. In hibernating squirrels, multiple 





miRNAs were able to regulate expression of the SUMO1-3 proteins and the SUMO enzymes, including 
E1, Ubc9, and multiple SENPs (Lee et al., 2012). Inhibiting these miRNAs led to increases in PTM 
modifications and conferred protection against OGD-induced cell death. 
Several reports have confirmed the ischemia-induced SUMOylation in vivo with animal models. In 
rats, focal cerebral ischemia caused by transient middle cerebral artery occlusion (MCAO) elevated 
SUMOylation by SUMO1 and SUMO2/3 in the infarcted region at 6 and 24 hour time-points (Cimarosti et 
al., 2008). Interestingly, outside of the infarct, including in the hippocampal region, only SUMO2/3 
changes were observed; this indicates that secondary processes to the ischemia, including stroke-
induced hyperexcitability/plasticity , may involve SUMO2/3 modification (Fujioka et al., 2004; Johansson, 
2000). Ischemia-related SUMOylation has also been observed in global cerebral ischemia and spinal cord 
ischemia (Wang et al., 2012; Yang et al., 2008a, b). Further demonstrating that SUMO-targeted 
therapeutics may be a viable option for stroke treatment, global Ubc9 transgenic mice, exhibiting modest 
overexpression in the brain, have recently been shown to be more resistant to focal ischemia compared 
to wild-type mice (Lee et al., 2011).  
  
2.5.3 Polyglutamine Disorders 
Polyglutamine diseases are dominantly-inherited genetic disorders caused by abnormal 
expansion of polyglutamine (polyQ) tracts in a protein. The polyQ expansions, also known as CAG 
repeats for the glutamine codon, disrupt normal protein folding and lead to aggregation, which eventually 
causes neuronal dysfunction and cell death. Huntington’s disease (HD) is a well-known polyQ 
neurodegenerative disease that results from polyQ expansion in the huntingtin protein (Htt). Htt can be 
SUMOylated by SUMO1 and ubiquitinated in its N-terminal region at the same lysine residues (Steffan et 
al., 2004). In a Drosophila model of HD, SUMOylation of Htt was found to exacerbate neurodegeneration 
while ubiquitination ameliorates it. Since SUMOylation of Htt reduces its aggregation propensity, the 
increased pathology may arise from an increased level of soluble cytotoxic Htt. Recently, an underlying 





characterizes HD. A guanine nucleotide-binding protein, Rhes, was discovered to function as a SUMO E3 
ligase that induces SUMOylation of mutant Htt. Intriguingly, Rhes is highly localized to the striatum, which 
is the brain region that undergoes dramatic degeneration in HD. SUMOylation therefore is tightly involved 
with HD pathogenesis. 
Another polyQ disease, spinal and bulbar muscular atrophy (SBMA), also implicates SUMO. 
SBMA is caused by a polyQ expansion in the androgen receptor (AR) transcription factor, which has been 
found to be SUMOylated and ubiquitinated (Poukka et al., 2000). SUMOylation of AR, which is dependent 
on the PIAS1 and PIASxα E3 ligases, represses its transcriptional activity (Nishida and Yasuda, 2002). 
SUMOylation (and ubiquitination) of AR also appear to counter pathology, as inhibition of either PTM led 
to exacerbated degeneration in a Drosophila model (Chan et al., 2002). In HeLa cell line cultures, 
increasing SUMOylation decreased formation of polyQ AR aggregates, which had protective effects on 
cell viability (Mukherjee et al., 2009). These results demonstrate SUMO regulation can have 
unpredictable consequences on pathology, dependent on the substrate protein – while in both HD and 
SBMA, the solubility of the disease protein is increased by SUMOylation, that effect increases toxicity in 
HD but is protective in SBMA.  
Spinocerebellar ataxias (SCAs) are another neurodegenerative polyQ disease, one in which 
SUMOylation of the disease protein has varying effects on aggregation . Type I SCA results from a polyQ 
expansion in a ataxin-1, a RNA-binding protein that has at least five SUMOylate-able lysines (Riley et al., 
2005). SUMOylation of ataxin-1 enhances its aggregation, a process that is increased by oxidative stress 
only in mutant polyQ ataxin-1 (Ryu et al., 2010). In type 7 SCA, a polyQ expansion in ataxin-7 is to blame. 
Ataxin-7 has been recently found to be SUMOylated by SUMO1 and SUMO2, modifications which reduce 
the aggregation and toxicity of the protein (Janer et al., 2010). This is in contrast to ataxin-1 and again 
highlights the unpredictable complexity of SUMO regulation. Any future SUMO-targeted drug discovery 
efforts for neurodegenerative diseases will need to be tailored for the specific SUMOylation effects 
involved in the pathology. 
Dentatorubral-pallidoluysian atrophy (DRPLA) is the final polyQ disease which has been found to 





intranuclear inclusions. Increasing levels of SUMO1 increased this pathology in transfected PC12 cells 
while a non-conjugatable SUMO1 actually reduced inclusions (Terashima et al., 2002). The mechanisms 
are unclear but it appears that SUMO does have a role in DRPLA. 
 
2.5.4 Parkinson’s Disease and Synucleinopathies 
 Parkinson’s disease (PD) is a neurodegenerative movement disorder characterized by the 
selective loss of dopaminergic projection neurons in the substantia nigra of the midbrain. Similar to other 
neurodegenerative diseases, there are abnormal aggregates of misfolded protein. In PD as well as other 
synucleinopathies, aggregates of α-synuclein form inclusions known as Lewy bodies inside neurons. 
When examined by immunostaining, Lewy bodies from patients with Dementia with Lewy Bodies (DLB) or 
multiple system atrophy (MSA), both synucleinopathies, exhibit positive SUMO1 signals (Pountney et al., 
2005). α-synuclein has been reported to be SUMOylated in HEK293 cell cultures (Dorval and Fraser, 
2006), although it is unclear if this occurs in neurons.  
 DJ-1 is another PD-related protein that has been found to be directly SUMOylated in cell line 
cultures (Shinbo et al., 2006). DJ-1 is a protein with currently unknown function but which appears to be 
neuroprotective against cell stress (Canet-Aviles et al., 2004). SUMOylation of DJ-1 is increased after UV 
irradiation. However, when SUMOylation of DJ-1 was inhibited via a mutation, the protective effects were 
abrogated and protein insolubility was increased (Shinbo et al., 2006). 
 Parkin, an ubiquitin E3 ligase, is associated with an early onset familial form of PD. As previously 
discussed, Parkin can ubiquitinate RanBP2, a SUMO E3 ligase, thereby controlling its stability (Um et al., 
2006). In addition, Parkin can also interact non-covalently with SUMO in cell line cultures, an interaction 
that increases its E3 ligase activity (Um and Chung, 2006). Thus, there is a negative SUMO regulatory 
loop involving Parkin-mediated ubiquitination. These findings indicate that disease pathogenesis may be 






2.5.5 Amyotrophic Lateral Sclerosis 
 Amyotrophic lateral sclerosis (ALS; also known as Lou Gehrig's disease) is a motor neuron 
disease characterized by muscle atrophy and eventual paralysis (Rothstein, 2009). Mutations in the 
copper-zinc superoxide dismutase 1 (SOD1), an antioxidant protein, have been associated with ~20% of 
familial ALS. This protein has also been shown to be a SUMO substrate – several studies with yeast and 
cell line cultures have found that SOD1 can be SUMOylated, potentially at multiple lysines (Fei et al., 
2006; Zhou et al., 2004). In HEK293 cells, SUMOylation of SOD1 enhances its stability and propensity for 
aggregation, which may contribute to its pathogenicity.   
 Another protein implicated in ALS is the glutamate transporter EAAT2, which is found 
predominantly in astrocytes. These glia cells have been gaining attention as likely central players in ALS 
pathogenesis (Di Giorgio et al., 2007; Hedlund and Isacson, 2008; Marchetto et al., 2008; Nagai et al., 
2007; Papadeas et al., 2011; Yamanaka et al., 2008). The EAAT2 transporter in astrocytes is responsible 
for the majority of glutamate uptake in the nervous system. Therefore, any disturbances in this process 
could lead to excitotoxicity and enhance neurodegeneration. In ALS-related pathology, EAAT2 levels are 
reduced, in part due to caspase-mediated cleavage (Boston-Howes et al., 2006). This results in the 
accumulation of a C-terminal fragment of EAAT2, which has been found to be a SUMO substrate in an 
ALS mouse model (Gibb et al., 2007). The SUMOylated fragment accumulates in nuclear PML bodies 
and appears to be sufficient for causing toxicity in neighboring motor neurons in vitro (Foran et al., 2011). 
Interestingly, mutant SOD1 has been found to inactivate EAAT2 via oxidative reactions (Trotti et al., 
1999). Therefore, SUMOylation is likely involved in multiple aspects of ALS pathology, which if validated, 
would indicate that SUMO may be a potential therapeutic target for ALS. 
 
2.5.6 Alzheimer’s Disease and Tauopathies 
 Alzheimer’s disease, as previously reviewed, involves the aberrant aggregation of amyloid-β (Aβ) 
and tau proteins, both of which have neurotoxic properties in the oligomerized forms. Interestingly, 





including Parkinson’s disease, frontotemporal dementia and chronic traumatic encephalopathy. In the 
HEK293 mammalian cell line, overexpressed tau has been found to be SUMOylated, primarily at one 
consensus site (K340) and predominantly by SUMO1 (Dorval and Fraser, 2006). Inhibition of the 
proteasomal system with MG132 decreased SUMO1-tau conjugates while increasing ubiquitinated tau, 
indicating that the two PTMs may be competing for the same lysine residue. Furthermore, tau 
SUMOylation also has a phosphorylation dependence, since inhibition of phosphatases by okadaic acid 
increased SUMO1-tau levels. Finally, increasing levels of free tau with the microtubule de-polymerizer, 
colchicine, also significantly increased tau SUMOylation. It appears that free soluble tau is the preferred 
target subset, with possible cross-talk interactions with ubiquitin and phosphorylation. Supporting these 
findings is another study which demonstrated SUMO1 immunoreactivity in phospho-tau aggregates in 
aged Tg2576 APP transgenic mice (Takahashi et al., 2008). Interestingly, this co-localization was not 
observed in the JNPL3 tau transgenic mice, which overexpress human four-repeat tau with a pathogenic 
mutation (P301L).  
 Amyloid precursor protein (APP) has also been reported as a SUMOylation substrate by one 
study which detected SUMO-APP conjugates in transfected HeLa cells and purported SUMO-APP in 
mouse brain tissue (Zhang and Sarge, 2008). In the HeLa cultures, both SUMO1 and SUMO2/3 were 
found to modify APP at consensus motif lysine residues (K595, K587), which also are adjacent the β-
secretase cleavage site (between residues Met596 and Asp597). Intriguingly, a mutation at K595 (to 
asparagine) is one of the Swedish mutations associated with familial early-onset AD. It is tempting to 
speculate that the pathogenicity of the mutant APP may involve altered SUMOylation (Sarge and Park-
Sarge, 2012).  
 As for the effects of SUMOylation on APP processing, the previously-discussed study found that 
APP SUMOylation by either SUMO1 or SUMO2/3 decreased levels of Aβ aggregates in transfected HeLa 
cells (Zhang and Sarge, 2008). Un-SUMOylatable mutant APP was associated with increased Aβ 
aggregate levels while increasing SUMOylation with Ubc9 transfection decreased Aβ aggregates. In 
addition, this study observed that Ubc9 is found in the ER lumenal compartment of the secretory pathway, 





conclusive currently, as two other studies reported conflicting data. One of those studies, performed in 
HEK293 cells, found that SUMO3 overexpression increased APP levels and production of Aβ40 and Aβ42 
peptides (Dorval et al., 2007). However, these effects were independent of actual PTM since mutant 
SUMO3s defective in conjugation or chain formation gave similar effects. It was also observed that 
expression of BACE, the APP β-secretase, was specifically increased by SUMO3 overexpression, which 
together with higher APP expression could explain the increased Aβ levels. On the other hand, knocking 
down SUMO1 or SUMO2/3 expression did not affect either APP or Aβ levels.  
 In the other conflicting study, performed with HEK293 and SK-N-MC neuroblastoma cell lines, 
overexpression of SUMO3 reduced total Aβ levels while a dominant negative mutant SUMO3 had the 
opposite effect (Li et al., 2003). In addition, another SUMO3 mutant, in which the internal SUMOylation 
consensus site was abolished, was also observed to increase Aβ production; this was concluded to mean 
that polySUMO chains are involved in APP processing. This group also specifically looked for SUMO-
APP conjugates and did not find any. However, they did preliminary immunohistochemistry with brain 
sections from AD and Down’s syndrome patients and observed that the pattern of SUMO3 staining 
appears to be altered, with a more limited somal distribution compared to somal and nuclear staining in 
controls.  
 Very recently, a new study has been published on this topic. This one found that overexpression 
of any of the SUMO paralogs increased APP expression and Aβ40 levels in the H4 neuroglioma cell line, 
independent of SUMO conjugation and dependent on BACE1 (Yun et al., 2012). The Aβ effects were 
likely due to upregulation of  BACE1 levels caused by SUMO overexpression, which is in agreement with 
one of the above previous studies by Dorval et al. In addition, treatment with Aβ40 for 48 hours was found 
to increase SUMO1 conjugation in a dose-dependent manner (0.5 – 10 µM). 
 Overall, the topic of SUMOylation in APP processing is murky with no solid conclusions. It is still 
uncertain if and how SUMO modification affects Aβ production and if APP is really SUMOylated in vivo 
(the immunoprecipitation western blots from Zhang and Sarge, 2008, are without appropriate controls and 





neurons and in the brain, since the above studies were performed mostly in immortalized cell lines 
manipulated with transient transfections. 
 Besides the possible upstream effects on APP processing by SUMO, Aβ may directly impact 
SUMOylation in downstream signaling pathways. With high concentrations of soluble oligomeric 
assemblies, Aβ is well-established as a neurotoxin with many deleterious effects on synaptic function. 
Given SUMO’s currently known (and expanding) role in synaptic signaling, it is likely that Aβ-induced 
pathology could alter neuronal SUMO regulation. However SUMO is found to be involved in AD, it is 
highly probable that multiple SUMO substrates are affected, given the widespread roles of SUMOylation 
in basic cell and neuron-specific functioning.  
 Thus far, the only study to investigate this possibility in an AD mouse model, using 9-month old 
Tg2576 mice, did not find changes in global SUMO1 or SUMO2/3 conjugation levels (McMillan et al., 
2011). However, it was observed that some individual SUMO2/3 conjugate bands were altered. 
Specifically, a two high molecular weight SUMO2/3 conjugates (~130, 150 kDa) were significantly 
decreased in Tg2576 cortical tissue (but not hippocampal or cerebellar tissue). A caveat must be noted 
for this particular study however, since most of the high molecular weight region (> 75 kDa) was not 
successfully blotted in the displayed western blot figures; since it is this high molecular weight region of 
SUMO conjugates that are most labile to regulatory changes, observed in many previous studies, it is 
probable that the authors missed these conjugates in their analyses (Johnson and Gupta, 2001; Saitoh 
and Hinchey, 2000; Tatham et al., 2008). The study also looked at Ubc9 and SENP1 levels in the 
different brain regions and found no significant differences. 
 The issue of SUMOylation in Alzheimer’s disease presents an open field, one with many 
unanswered questions that could have significant clinical implications. There is currently an increasing 
focus on and discovery of neuronal and synaptic SUMO substrates – and AD, as a disease of synaptic 
failure, most likely impacts many aspects of the PTM-based regulation of such proteins. Phosphorylation, 
ubiquitination and acetylation are PTMs currently known to be affected in AD pathology and are 





also a central PTM, the manipulation of which could become a future therapeutic strategy for AD as well 


































Chapter 3  
 




3.1 Astrocytes: Tripartite Synapse   
In my thesis, I propose that astrocytes, a type of glia cell, are likely cellular participants in the 
physiological signaling mechanisms of Aβ peptides in the brain. Astrocytes are the most numerous cell 
type in the CNS, compromising half of the volume of adult mammalian brains, and can be found 
throughout gray and white matter. In terms of cytoarchitecture, these stellate glial cells are organized in 
non-overlapping domains which form networks characterized by inter-astrocyte gap junction coupling as 
well as paracrine signaling. Astrocytes participate in many ways to support brain functioning and 
homeostasis, with crucial roles including ion and pH homeostatic maintenance, metabolic and antioxidant 
support, cerebrovascular bridging (functional hyperemia), and immune surveillance (Bains and Oliet, 
2007; Haydon, 2001). These are some of the astrocyte’s traditionally-accepted roles, which can influence 
the functioning and excitability of neurons in multiple ways.  
However, research over the past two decades have established that astrocytes can also actively 
participate in synaptic transmission (Agulhon et al., 2008; Auld and Robitaille, 2003; Haydon and 
Carmignoto, 2006; Perea et al., 2009). Morphologically, the numerous processes of an astrocyte 
intimately surround and ensheathe synapses, providing the ideal physical substrate for a “tripartite 
synapse” (Figure 3.1) (Haydon and Carmignoto, 2006). At such synapses, astrocytic modulation can 







Figure 3.1.  Tripartite synapse 
(A)  Electron micrograph of a tripartite synapse in the dentate gyrus of the hippocampus. Arrowheads 
indicate presynaptic vesicles. Arrows indicate synaptic-like vesicles in an astrocytic process, which is 
closely apposed to synaptic structures. Adapted from (Volterra and Meldolesi, 2005). 
(B)  Schematic diagram illustrating astrocyte involvement in the modulation of synaptic transmission at a 
tripartite synapse. Neurotransmitter (Nt) release is detected by astrocytes, which respond with calcium 
elevations. Astrocytes can actively respond via release of gliotransmitters (Gt), which may affect pre- or 
post-synaptic compartments. Adapted from (Perea et al., 2009). 
 
 
facilitative or depressive modulation. As for cellular machinery, astrocytes possess almost the full 
neuronal repertoire of receptors and channels as well as vesicles capable of SNARE-dependent 
exocytosis. Glutamate, ATP, and D-serine are a few of the astrocyte’s “gliotransmitters” that have been 
found to target and affect neurotransmission. Although astrocytes are not electrically excitable, they do 
respond robustly to various forms of stimulation with intracellular Ca2+ elevations and oscillations. These 
signals can be encoded with spatial and temporal specificity and can result in gliotransmitter release. In 
addition, the gap junction-connected astrocytic networks (“syncytiums”) may provide a non-synaptic 





and Oliet, 2007; Haydon, 2001; Haydon and Carmignoto, 2006). All of the above characteristics place 
astrocytes in a prime position to both sense and respond to the synaptic microenvironment and act as key 
integrating units in neural circuits.   
 
3.1.1 Calcium Signaling 
The “astrocyte revolution” began in the early 1990s when it was observed that primary astrocytes 
in culture have a form of excitability based on intracellular calcium elevations (Charles et al., 1991; 
Cornell-Bell et al., 1990). Before then, not much attention was paid to these glia cells, which were viewed 
as passive, non-excitable support cells. However, many subsequent studies in cultures, brain slices, and 
in vivo have now established that astrocytes are excitable in response to many stimuli, including 
neurotransmitters. Astrocyte calcium elevations can be either intrinsically spontaneous or induced by 
neurotransmitters released during synaptic transmission, such as glutamate (Aguado et al., 2002; Nett et 
al., 2002; Parri et al., 2001; Perea and Araque, 2005). Both types are dependent on release of calcium 
from intracellular stores and can be blocked by calcium store inhibitors such as thapsigargin and 
cyclopiazonic acid. Regarding astrocytic neurotransmitter receptors, many are metabotropic G-protein 
coupled receptors (GPCRs) of the Gq type (Agulhon et al., 2008). Upon transmitter binding, the G proteins 
stimulate phospholipase C and formation of the secondary messenger, inositol 1,4,5-trisphosphate (IP3), 
which then increase intracellular calcium levels via IP3 receptor-gated stores in the endoplasmic reticulum 
(Agulhon et al., 2008; Perea et al., 2009).  IP3 receptor type 2 appears to be the predominant subtype in 
hippocampal astrocytes (Petravicz et al., 2008). Astrocyte neurotransmitter receptors can also be 
ionotropic, in which case calcium-induced calcium release (CICR) from ryanodine receptor-gated stores 
underlies the elevations. This has been specifically demonstrated for nicotinic acetylcholine receptors on 
hippocampal astrocytes (Sharma and Vijayaraghavan, 2001).  
In contrast to neurotransmitter-induced calcium signaling, spontaneous intrinsic astrocyte calcium 
transients and oscillations also appear to depend on voltage-gated calcium channels (VGCCs). While 
neuronally-evoked astrocyte calcium events are not affected by VGCC inhibitors, extracellular calcium 





(Aguado et al., 2002; Parri et al., 2001). L-type calcium channels appear to be the majority subtype, with 
additional minor involvement of N and P/Q-type channels (Parri et al., 2001).  
Astrocytic calcium signaling can take the form of transients in localized microdomains along the 
processes, cell-wide cytoplasmic elevations/oscillations or intercellular calcium waves (Perea et al., 
2009). Similar to neuronal excitation, spatially restricted calcium transients, some induced by local 
synaptic activity, can remain localized or propagate to other regions of the cell, leading to whole-cell 
responses. Recently, the involvement of astrocyte calcium signaling in local basal synaptic transmission 
was observed for the first time using high resolution two-photon microscopy in acute hippocampal slices 
(Di Castro et al., 2011; Panatier et al., 2011). Astrocyte calcium elevations in functionally distinct 
microdomains along processes were found to be triggered by both spontaneous and action potential-
dependent synaptic activity. There were two categories of elevations, highly confined focal transients 
caused by spontaneous activity and expanded events spanning along a process, caused by action 
potentials.  
Furthermore, the communication with neurons is bidirectional – altering the calcium responses in 
astrocytes also affected basal synaptic transmission at nearby synapses. In the mouse hippocampal CA1 
region, a single astrocyte can contact an estimated 140,000 synapses from many neurons (Bushong et 
al., 2002). Therefore, astrocyte calcium signaling, whether localized or propagated, can have a huge 
potential impact on neural network dynamics.   
Another type of astrocyte calcium signaling are intercellular calcium waves (Scemes et al., 1998). 
These can be evoked in primary cultures and brain slices with pharmacological, mechanical and electrical 
stimulation. Mechanistically, intercellular waves can spread from one astrocyte to neighboring astrocytes 
via direct gap junction coupling as well as paracrine ATP signaling (Finkbeiner, 1992; Guthrie et al., 1999; 
Venance et al., 1997). However, the physiological relevance of intercellular calcium waves remains 
unclear since they have not been observed to occur normally in vivo (Dani et al., 1992; Hirase et al., 
2004; Schummers et al., 2008; Wang et al., 2006).  
With recent technological advances, in vivo calcium imaging has added valuable supporting 





that astrocytes in vivo do exhibit spontaneous and neurotransmitter-induced transients (Bekar et al., 
2008; Dombeck et al., 2007; Hirase et al., 2004; Nimmerjahn et al., 2004; Schummers et al., 2008; 
Takata and Hirase, 2008). Importantly, astrocyte calcium signaling has also been found to be triggered by 
normal physiological stimuli – for example, stimulation of whiskers leads to astrocyte calcium elevations in 
the barrel cortex (Wang et al., 2006), and visual stimuli can elicit fine-tuned astrocyte calcium responses 
in the visual cortex, organized in spatial receptive fields (Schummers et al., 2008).  
 
3.1.2 Gliotransmission 
Communication between neurons and astrocyte neighbors is bidirectional, via the release of 
synaptically active gliotransmitters that can modulate synaptic transmission (Figure 3.1). Astrocytes at 
tripartite synapses can both listen to and sense transmission as well as actively respond with their own 
chemical messages. Activated astrocytes, whether spontaneously or by synaptic activity, have been 
found to be capable of calcium-regulated, SNARE-dependent exocytosis and can release multiple 
neuromodulatory molecules including glutamate, ATP/adenosine, D-serine, TNFα and GABA (Agulhon et 
al., 2008; Perea et al., 2009). Gliotransmission is supported by ultrastructural studies, which observed 
small vesicles in astrocytic processes that resembled those in synapses and were in close apposition to 
presynaptic and postsynaptic structures (Bezzi et al., 2004; Jourdain et al., 2007). Other release 
mechanisms have also been described for astrocytes, including lysosome exocytosis, connexin 
hemichannels, P2X7 receptor pores, glutamate transporter reversal and activation of volume-regulated 
channels (Perea et al., 2009). 
Glutamate was the first gliotransmitter to be identified (Araque et al., 1998a). Numerous studies in 
cultures and brain slices have confirmed this finding and expanded on the roles of astrocytic glutamate in 
neuronal physiology. One of the earliest described functions is the triggering of slow inward currents 
(SICs) via postsynaptic and extrasynaptic NMDA receptors; this can occur in multiple neurons within an 
astrocyte’s domain, leading to synchronization and regulation of neuronal excitability (Angulo et al., 2004; 
Araque et al., 1998a; Fellin et al., 2004; Shigetomi et al., 2008). Astrocytic glutamate has also been 





or extrasynaptic NMDA receptors (Jourdain et al., 2007; Perea and Araque, 2007). This type of regulation 
has been found to regulate neurotransmitter release, which affects the frequency of spontaneous and 
evoked synaptic currents. In addition to these excitatory transmission effects, astrocyte glutamate can 
also modulate inhibitory synaptic transmission by interneurons through the activation of presynaptic 
kainate receptors or group II/III mGluRs (Liu et al., 2004a; Liu et al., 2004b). These data illustrate how a 
single astrocytic gliotransmitter can have multiple regulatory functions, dependent on location and 
receptor.  
Besides glutamate, ATP is another relatively well-studied gliotransmitter. When released, from 
either neurons or glia, ATP is rapidly broken down to the inhibitory transmitter adenosine by multiple 
ectonucleotidases. Adenosine can then act upon purinergic receptors, which can be found pre- or post-
synaptically. In the previously discussed study that discovered localized astrocyte regulation of basal 
synaptic transmission, the signaling pathway was found to involve mGluR5 receptors on astrocytes and 
release of ATP/adenosine which activated presynaptic A2A receptors (Panatier et al., 2011). 
Heterosynaptic depression in the hippocampus has also been found to involve astrocyte ATP release 
(Serrano et al., 2006; Zhang et al., 2003). In an interneuron-mediated example, GABA release is detected 
by an astrocyte, which then mediates heterosynaptic depression through release of ATP at other 
synapses (Serrano et al., 2006). Astrocytes may also underlie the tonic presence of extracellular 
adenosine in the hippocampus via SNARE-dependent ATP release (Pascual et al., 2005).  It has been 
proposed that this tonic suppression of synaptic transmission may serve to enhance the dynamic range of 
synaptic plasticity.  
In summary, current data strongly support a role for astrocytes in the sensing and active 
modulation of synaptic transmission. Capable of both highly localized as well as propagated signaling, 
astrocytes are well-positioned to serve as regulators and integrators in neural circuits. 
 
3.1.3 Astrocytes in Synaptic Plasticity and Memory 
 Given their well-studied roles in synaptic physiology, it should be no surprise that astrocytes can 





slower and longer time scales compared to fast neurotransmission, these glial cells are well-situated to 
exert long-term effects on a large number of synapses. Gliotransmission is the main mechanism whereby 
astrocytes modulate synaptic plasticity. In transgenic mice in which SNARE-dependent release is 
specifically inhibited in astrocytes, long-term potentiation (LTP) was significantly decreased compared to 
wild-type mice (Pascual et al., 2005). However, basal transmission was enhanced in the transgenic mice, 
and along with other data, it was concluded that the LTP effect was due to a lack of tonic inhibition by 
astrocyte ATP release.  
Astrocytes can also play a more active role in synaptic plasticity through regulated and localized 
gliotransmitter release. One particular gliotransmitter molecule that is critical for plasticity regulation is D-
serine, an amino acid that is the endogenous ligand of the glycine co-agonist binding site of NMDA 
receptors. It was initially observed that D-serine is localized to astrocytic processes and can be released 
in astrocyte cultures by stimulation with glutamate (Schell et al., 1995). The requirement of astrocyte-
released D-serine in LTP has now been demonstrated in cultures and acute hippocampal slices 
(Henneberger et al., 2010; Yang et al., 2003b). In the Schaffer collateral synapses of the CA1 
hippocampal region, a widely-studied common site for the induction of LTP, inhibition of astrocyte calcium 
signaling or exocytosis in a single cell prevented LTP in nearby synapses; this effect was rescued by the 
exogenous application of D-serine or glycine, indicating that astrocyte-released D-serine is critical for long 
term synaptic plasticity (Henneberger et al., 2010). Astrocytes have also been shown to directly contribute 
to a form of single-cell LTP, also in CA1 synapses (Perea and Araque, 2007). Astrocyte calcium elevation 
temporally coincident with postsynaptic depolarization induced a long-term potentiation of 
neurotransmitter release. This potentiation was found to be calcium and SNARE-dependent in astrocytes, 
and overall mGluR-mediated but NMDAR-independent. These data indicate that the traditional view of 
Hebbian plasticity may need to be expanded to include astrocytes as active participants in information 
transfer and storage in the brain.  
On the other side of the plasticity coin, astrocyte involvement has also been found to be essential 
for long-term depression (LTD) in the hippocampus. Specifically, cannabinoid-mediated in vivo LTD of 





signaling (Han et al., 2012). Cannabinoid-mediated impairments of spatial working memory were also 
dependent on astrocyte CB1Rs. Although neurons can express this receptor, the cannabinoid-mediated 
effects on LTD and memory only seemed to involve astrocytic CB1Rs. Mechanistically, the effects were 
mediated by NMDARs and AMPAR endocytosis, which led to the working model: 1) cannabinoids 
stimulate astrocyte CB1Rs, 2) astrocyte activation (and downstream calcium signaling) leads to glutamate 
gliotransmitter release, 3) stimulation of neuronal NMDARs causes AMPAR endocytosis, 4) LTD 
expression and memory impairments. This study provides an example of how astrocyte gliotransmission 
can also modulate synaptic function in an overall inhibitory direction. 
Beyond active gliotransmission, astrocytes can contribute to synaptic plasticity and cognitive 
processes via metabolic support. Recently, it was discovered that astrocytic glycogen breakdown and 
release of lactate to neurons is required for LTP maintenance and long-term memory formation (Suzuki et 
al., 2011). This metabolic coupling is essential for high-energy neural processes since glycogenolysis 
cannot occur in neurons. Lactate uptake by neurons was found to be critical for inducing the molecular 
correlates of long-term plasticity, including phospho-CREB, Arc and phospho-cofilin. Thus, astrocytes are 
active players in synaptic plasticity with multiple roles including both localized “tripartite” gliotransmission 
as well as dynamic metabolic support.   
 
3.1.4 Controversial Issues 
 Although the majority of data in this field support a role for astrocytes in synaptic transmission 
and plasticity, I would like to note that there have also been conflicting and controversial findings that 
have raised questions. In particular, a relatively high-profile study in 2007 found that selectively elevating 
calcium levels in astrocytes did not affect excitatory synaptic activity or neuronal slow inward currents 
(SICs) (Fiacco et al., 2007). This study utilized a novel transgenic mouse line in which a Gq–coupled 
GPCR (MrgA1) was expressed only in astrocytes and could only be activated by an agonist with no 
known endogenous binding in the brain. Widespread global calcium elevations could be evoked in 
astrocytes with the agonist but no effects were observed on neuronal mEPSCs or SICs. These were 





study, directly uncaging IP3 inside astrocytes was found to enhance AMPA EPSCs (Fiacco and McCarthy, 
2004).  
However, there are multiple potential explanations for the discrepancies. One factor is inherent to 
transgenic animals – the expression levels and/or spatiotemporal distribution of the transgenic receptor 
may not be appropriate for evoking physiologically-accurate calcium signals. In addition, the widespread 
whole-cell activations of a large number of astrocytes at the same time may also blunt or alter calcium 
signaling-related consequences on neurons. Related to that is a more significant issue – the non-
endogenous receptor is likely uncoupled from the regulatory signaling networks and downstream 
signaling pathways that are normally involved in astrocyte calcium signaling. These factors may at least 
partly explain the negative results in that particular study. In the years since then, a number of other 
studies, some with more advanced higher-resolution techniques, have continued to validate the 
involvement of astrocyte calcium signaling and gliotransmission in synaptic activity modulation (Di Castro 
et al., 2011; Henneberger et al., 2010; Min and Nevian, 2012; Panatier et al., 2011; Santello et al., 2011).  
 
3.2 Astrocytes: Alzhiemer’s Disease 
 In Alzheimer’s disease (AD), many cell types besides neurons undergo drastic changes and 
become dysfunctional. Glial cells, including astrocytes and microglia, are well-documented for their 
involvement in multiple neurological diseases including AD. In a process termed reactive gliosis, which 
can involve astrocytes (astrogliosis) and microglia (microgliosis), the glial cells undergo large 
morphological and functional changes. Such gliosis is observed with a number of pathologies including 
trauma, stroke, tumors and neurodegeneration (Pekny and Nilsson, 2005). In AD, reactive gliosis is a 
well-established pathological hallmark. Since astrocytes provide essential support and regulation of 
neuronal physiology, any disruption of their normal functioning can have potentially large pathological 
consequences. For example, astrocytes are responsible for the majority (> 80%) of glutamate reuptake in 
the brain (Anderson and Swanson, 2000; Maragakis and Rothstein, 2006). Therefore, pathologies that 
involve disrupted or altered glutamate transporter expression/function in astrocytes can result in 





observed in a number of diseases including AD, Huntington’s disease, amyotrophic lateral sclerosis and 
tauopathies (Sofroniew and Vinters, 2010). In addition, astrocytes provide essential metabolic molecules 
to support neurons. For example, astrocytes are the major reservoirs of antioxidants in the brain and can 
shuttle essential antioxidant molecules, such as glutathione, to neurons (Dringen, 2000). Astrocytes are 
also energy reserves, with astrocyte-specific stores of glycogen which can be broken down to lactate as 
an energy source; the transport and shuttling of lactate to neurons has been shown to be essential for 
long-term synaptic plasticity and memory (Suzuki et al., 2011). It follows that any disruption of such 
essential processes in AD or other neurological diseases may significantly contribute to the pathology. 
 In AD specifically, astrocytes are prominent players in the well-established inflammatory 
reactions. Histopathologically, large numbers of reactive astrocytes are found intimately associated with 
amyloid plaques (Figure 3.2). The reactive astrogliosis is characterized by morphological changes 
involving cell hypertrophy and strong upregulation of intermediate cytoskeletal filaments, especially glial 
fibrillary acidic protein (GFAP) (Pekny and Nilsson, 2005). The presence of astrocytes surrounding 
plaques may be attributed to chemoattractant molecules or even Aβ itself. There are data suggesting that 
astrocyte migration is partly mediated by the chemokine, monocyte chemoattractant protein-1 (MCP-1), 
but astrocytes can also directly detect, phagocytose and degrade Aβ peptides (Nagele et al., 2003; 
Nielsen et al., 2009; Wyss-Coray et al., 2003). Intriguingly, the ability of astrocytes to degrade Aβ appears 
to depend on apolipoprotein E (Apoe), which raises the possibility that Apoe polymorphisms, known to 
influence risk of sporadic late-onset AD, may impact pathology by affecting astrocytic Aβ degradation 
(Koistinaho et al., 2004).  
Overall, a likely hypothesis at this point is that reactive astrogliosis, at least initially, may 
constitute a protective response. This view has been strongly bolstered by a recently-published study in 
which attenuated astrogliosis actually accelerated pathology in the APP/PS1 transgenic mouse model; a 
double deletion of GFAP and another intermediate filament protein required for astrocyte activation, 
vimentin, prevented astrogliosis but exacerbated amyloid plaque load and neuritic dystrophy without 








Figure 3.2.  Reactive astrogliosis in Alzheimer’s disease 
(A) Immunohistochemistry of cerebral cortex tissue from an AD patient. An amyloid plaque is 
circumferentially surrounded by reactive astrocytic processes. GFAP (brown), hematoxylin nuclear 
counterstain (blue). Scale bar 10 µm. Adapted from (Sofroniew and Vinters, 2010). 
(B) Immunofluorescence of reactive astrogliosis in a mouse model of AD (3xTg-AD). An amyloid plaque is 
surrounded by reactive astrocytes, the most closely associated of which exhibits intracellular Aβ 
accumulation (arrows). GFAP (green), Aβ (red). Scale bar 20 µm. Adapted from (Rodriguez et al., 2009). 
 
 
 Reactive astrogliosis also appears to be an early event that may even precede plaque formation. 
In the transgenic APP[V717I] mouse model, focal astrocyte activation and increased inflammation 
markers are detected at 3 months of age, well before the onset of plaque deposition (Heneka et al., 
2005). These findings indicate that astrocytes can detect and respond to Aβ early in disease 
pathogenesis. With progressive neurodegeneration, the reactive astrogliosis progresses in intensity. In 
human AD brains, the amount of astrogliosis is positively correlated with Braak staging of neurofibrillary 
tangles (Simpson et al., 2008). In addition, as mentioned above, levels of astrocyte glutamate 
transporters are also decreased with disease progression. Thus, although reactive activation of 
astrocytes may be a protective response initially, eventual loss-of-function or gain-of-(toxic) function in  
astrocytes likely further contributes to the pathology.  
This point is also illustrated by astrocyte interactions with microglia, the resident innate immune 
cells of the brain. Microglia can also sense and respond to Aβ and are potent secretors of cytokine and 





damaged/dead cells and toxic molecules. Relatively early on, microglia were observed to be activated by 
Aβ42 and have phagocytic capacity for Aβ aggregates (Rogers et al., 2002; Weldon et al., 1998). 
However, the Aβ-induced responses also lead to pro-inflammatory changes, including upregulation of 
inducible nitric oxide synthase (iNOS) and expression of cytokines, including TNFα, IL-1 and TGFβ. 
These inflammatory molecules have been shown to either inhibit normal astrocyte functions or stimulate 
the astrocytes to further release inflammatory and/or neurotoxic molecules, such as excess glutamate 
(Bezzi et al., 2001; Meme et al., 2006; Minagar et al., 2002). On the other hand, astrocytes can also 
regulate microglia functions, including microglial phagocytosis of plaques and cytokine production (DeWitt 
et al., 1998; Farina et al., 2007; Minagar et al., 2002). These bidirectional regulatory interactions provide 
the setup that can turn into a positive inflammatory feedback cycle under pathological conditions such as 
AD. 
Although astrocytes do express APP, their ability to secrete Aβ peptides in vivo is uncertain. 
Astrocytes have been found to express mostly the longer isoforms of APP, including APP751 and 
APP770 (Gray and Patel, 1993; Rohan de Silva et al., 1997). However, APP processing in both 
astrocytes and microglia favors internal localizations, with minimal secretion of cleavage products (Haass 
et al., 1991). The ability of these cells to even produce Aβ peptides is controversial since they do not 
appear to normally express the β-secretase BACE under resting conditions. However, a few studies have 
observed that reactive astrocytes can express BACE1 and produce Aβ peptides after trauma or in aged 
APP transgenic mice (Blasko et al., 2004; Rossner et al., 2001; Rossner et al., 2005). Cultured astrocytes 
may also be able to express the APP processing enzymes and secrete Aβ under certain conditions 
(Grolla et al., 2012). In addition, immunohistology with AD brain tissue indicates that reactive astrocytes, 
especially in the vicinity of plaques, can express BACE1 (Leuba et al., 2005). Therefore, under 
pathological conditions, astrocytes may become a contributing source of Aβ peptides. 
 
3.2.1 Pathological Amyloid-β Signaling 
 Amyloid-β peptides have been shown to have many effects on astrocyte functioning. As partially 





and chemokine production, mitochondrial dysfunction, reactive oxygen species formation, metabolic 
dysfunction and decreased glutamate uptake (Abramov et al., 2004a; Allaman et al., 2010; Hu et al., 
1998; Johnstone et al., 1999; Matos et al., 2008; Pike et al., 1994; Smits et al., 2002; White et al., 2005).  
Aβ-induced abnormalities in astrocyte calcium signaling likely underlie at least some of these 
effects. Several studies have demonstrated that exogenous Aβ exposure at high concentrations can 
disrupt intracellular calcium dynamics in primary astrocyte cultures (Abramov et al., 2003, 2004b; Chow et 
al., 2010; Grolla et al., 2012; Haughey and Mattson, 2003). In one study, 5 µM of Aβ40 acutely applied to 
primary cortical astrocyte cultures led to abnormal calcium transients and spontaneous intercellular waves 
(Chow et al., 2010). Calcium waves were also investigated in another imaging study which used a 
mechanical stimulus to trigger the waves (Haughey and Mattson, 2003). Exposure to 5 µM of Aβ42 altered 
evoked-wave parameters, including amplitude, velocity and distance travelled. Given the importance of 
astrocytes in normal synaptic transmission, such Aβ-induced disruptions in astrocyte calcium signaling 
may contribute to the synaptic deficits that are well-characterized in AD. Abnormal astrocyte calcium 
signaling can also more directly damage nearby neurons, as observed by one study in which Aβ-induced 
aberrant calcium signaling in astrocytes led to depletion of glutathione, which enhanced the vulnerability 
of nearby neurons to cell death (Abramov et al., 2003).  
 Besides Aβ, other AD-related factors may also contribute to abnormal astrocyte calcium 
signaling. For example, mutations in presenilin-1 (PS1) are linked to familial early-onset AD. When 
primary astrocyte cultures were transfected with a mutant PS1 (L286V), calcium oscillations were 
sensitized to stimulation by glutamate and ATP, indicating that PS1 may be involved in regulating 
astrocyte calcium dynamics (Johnston et al., 2006). These studies in primary cultures provided interesting 
evidence of aberrant astrocyte calcium signaling involvement in AD; however, do these observed effects 
translate to the situation in vivo?  
A study using multi-photon fluorescence lifetime imaging microscopy in a transgenic mouse 
model of AD affirmed that these effects do occur in the living brain (Kuchibhotla et al., 2009). In APP/PS1 
mice, which  express both mutant APP and mutant PS1, multiple astrocyte calcium aberrations were 





synchrony of astrocyte calcium events was enhanced. In the analysis of the spontaneous calcium 
transients, the percentage of actively oscillating astrocytes and the amplitude of the events were higher in 
the APP/PS1 mice with plaques. These effects were not due to neuronal activity changes, since blocking 
activity with tetrodotoxin did not affect the proportion of oscillating astrocytes. In addition, confirming 
previous in vivo imaging data, intercellular calcium waves were not observed in wild-type mice (Hirase et 
al., 2004). However, such astrocyte waves did occur spontaneously in the APP/PS1 mice and tended to 
originate near amyloid plaques. Thus, AD-type pathology can lead to abnormal astrocyte calcium 
signaling in vivo. 
 Very recently, the pathological involvement of such activated astrocytes in AD pathogenesis was 
additionally confirmed in the APP/PS1 mouse model. Using viral vectors to reduce inflammatory immune 
signaling specifically in astrocytes, both astrogliosis and microgliosis were reduced and amyloid-related 
pathology was ameliorated (Furman et al., 2012). More importantly, measures of both synaptic and 
cognitive function were significantly improved. These findings validate a central role for astrocytes in AD 














Chapter 4  
 
SUMOylation in Alzheimer’s Disease  
 
 
4.1 Summary  
Alzheimer’s disease (AD) disrupts many signaling pathways regulated by posttranslational modifications. 
Here we demonstrate that conjugation with the small ubiquitin-like modifier (SUMO) is required for normal 
synaptic and cognitive function but is impaired by amyloid-beta (Aβ), a neurotoxic molecule implicated in 
AD. We found that SUMOylation was significantly reduced in brain tissue from AD patients and a 
transgenic mouse model of AD. While neuronal activation normally induced upregulation of SUMOylation, 
this effect was impaired by Aβ and in the transgenic mice. Aβ is also a known potent disruptor of synaptic 
function. However, enhancing SUMOylation via transduction of its conjugating enzyme, Ubc9, rescued 
Aβ-induced deficits in synaptic plasticity and memory. We further demonstrate that inhibition of 
SUMOylation can directly cause such deficits, similar to Aβ. Overall, our data establish SUMO as a novel 
regulator of synaptic plasticity and cognition and point to SUMOylation impairments as an underlying 











Posttranslational modifications (PTMs) are ubiquitously involved in cell signaling cascades. Such 
modifications allow for the rapid and highly dynamic modulation of a cell’s signaling networks and its 
responses to the environment. In the nervous system, regulation by PTMs is of critical necessity for 
complex neuronal processing and is a well-established mechanism required for learning and memory as 
well as the underlying cellular correlate, long-term synaptic plasticity (DiAntonio and Hicke, 2004; Fukata 
and Fukata, 2010; Routtenberg and Rekart, 2005; Soderling and Derkach, 2000). 
The regulation of PTMs can become disrupted and dysfunctional under disease conditions. In 
AD, as well as many other neurodegenerative diseases, abnormal phosphorylation and ubiquitination are 
pathological hallmarks (Lee et al., 2001; Ross and Poirier, 2004). Aberrant PTM regulation can occur cell-
wide as well as in the localized microenvironments of synapses. For example, one of the mechanisms by 
which Aβ, the primary molecular culprit in AD, impairs synaptic transmission is through the dysregulation 
of neurotransmitter receptor phosphorylation (Hsieh et al., 2006; Snyder et al., 2005). The disruption of 
normal PTM-based signaling at the synapse is a general pathological mechanism that likely contributes to 
cognitive dysfunction in diseases such as AD.  
Recently, another PTM, involving the small ubiquitin-like modifier (SUMO), has been described 
for multiple neuronal proteins (Martin et al., 2007b). SUMOylation involves the covalent attachment of an 
11 kDa SUMO protein to a lysine residue on the target. There are four known SUMO paralogs in 
vertebrates: SUMO1-4. Since SUMO2 and SUMO3 share ~95% sequence homology and have not been 
differentiated functionally , they are collectively referred to as SUMO2/3 (Geiss-Friedlander and Melchior, 
2007; Johnson, 2004). SUMO1 and SUMO2/3 are expressed abundantly in the adult brain (Lee et al., 
2011; Zhang et al., 2008). In addition, the sole E2-type conjugating enzyme for all SUMO isoforms, Ubc9, 
is expressed throughout the cerebral cortex and hippocampus, with high levels in dentate granule cells 
and pyramidal neurons (Watanabe et al., 2008). Modification by SUMO can alter multiple functional 
properties of the target protein including localization, activity and protein-protein interactions (Geiss-





Since its discovery over a decade ago, SUMOylation has been best-characterized for its roles in 
nuclear and genomic maintenance (Johnson, 2004). Recently, the involvement of SUMOylation in 
extranuclear neuronal functioning and neurological diseases has come into focus. Multiple proteins with 
neuron-specific roles are now known to be SUMOylated, including transcription factors and 
neurotransmitter receptors (Wilkinson et al., 2010). However, while SUMOylation was shown to be 
involved in a specific type of basal synaptic transmission (Martin et al., 2007a), the role of SUMOylation in 
synaptic plasticity as well as learning and memory is unknown. Furthermore, given its role in synaptic 
function, the potential involvement of SUMOylation in the cognitive impairment that characterizes AD 
constitutes an unanswered question with significant clinical implications.  
To address these issues, we asked two main questions. First, is SUMOylation impacted by Aβ-
related pathology and can such changes be countered to improve synaptic and cognitive functioning? 
And second, is SUMOylation involved in normal learning and memory – does impaired SUMOylation 
directly cause cognitive deficits?  By examining global SUMO conjugation as an assay for changes in its 
regulation, we found that SUMOylation is impaired by Aβ and in AD. Strikingly, acute enhancement of 
SUMOylation ameliorated Aβ-induced deficits in both long-term synaptic plasticity as well as learning and 
memory. Furthermore, we discovered that SUMOylation inhibition is sufficient to cause synaptic and 
memory deficits, suggesting that the SUMOylation impairment observed in AD could be an underlying 















Table 4.3.1.  Brain bank sample characteristics 
Frozen post-mortem hippocampal formation tissue samples. Diagnosis of either control / usual aging or 
Alzheimer’s disease (AD). Scores include Braak neurofibrillary tangles (NFT), Consortium to Establish a 
Registry for Alzheimer's Disease (CERAD) Neuropsychological Battery, National Institute of Aging – 





4.3.1 SUMOylation is decreased in Alzheimer’s disease and APP transgenic mice 
To investigate whether SUMOylation is altered in Alzheimer’s disease, we analyzed post-mortem 
tissue samples from the hippocampal formation of six confirmed AD patients along with six non-demented 
controls (Table 4.3.1). When blotted and probed with an anti-SUMO2/3 antibody, the AD samples 
exhibited significantly less labeling intensity compared to controls (Figure 4.3.2A). This decrease was 
significant in the high molecular weight SUMO conjugates (> 75 kD), where the AD samples had about 







Figure 4.3.2.  High molecular weight SUMOylation is reduced in Alzheimer’s disease and APP 
transgenic mice 
(A) SUMOylation is decreased in AD. Representative SUMO2/3 western blot with post-mortem 
hippocampal formation tissue from AD and control patients. Starred bracket indicates the analyzed high 
molecular weight region exhibiting the most significant reduction of SUMO conjugates. Control and AD n 
= 6 each; *p = 0.015. 
(B) SUMOylation is decreased in APP mice. Representative SUMO2/3 western blots with hippocampi 
from Tg2576 APP transgenic and wild-type littermate mice. 1-2 mo. n = 6 each WT and APP, 7-8 mo. n = 
3 each, 13-14 mo. n = 4 each; 24-26 mo. n = 3 each. ANOVA p = 0.0005; *p < 0.05 vs. 1-2 mo. group. 






We also examined hippocampal tissue from Tg2576 transgenic mice, which overexpress the 
amyloid precursor protein (APP) and are a widely-used model of AD (Hsiao et al., 1996). In aged APP 
mice, similar to the AD patients, there was a significant decrease in SUMOylation compared to wild-type 
littermate controls (Figure 4.3.2B). This decrease was observed starting around 7-8 months of age; this is 
before the onset of widespread amyloid plaque deposition but does correlate with the presence of spatial 
memory deficits as well as detergent-insoluble Aβ aggregates (Westerman et al., 2002). The decreased 
SUMOylation was apparent at all of the older ages examined, up to two years of age. At that point, the 
overall ratio of SUMOylation compared to wild-type controls is actually increased from younger ages; 
however, this is due mostly to an apparent age-related decrease in SUMOylation in the wild-type mice 
(Figure 4.3.3E). The decreased SUMOylation was again most evident in the high molecular weight area. 
This is consistent with previous studies that have found a similar effect, wherein various manipulations 
cause SUMOylation changes that are primarily observed in the high molecular weight region (Johnson 
and Gupta, 2001; Saitoh and Hinchey, 2000; Tatham et al., 2008). Since SUMO2/3 can form polymeric 
SUMO chain modifications (Tatham et al., 2001), this region may include various poly-SUMOylated 
conjugates which are especially liable to changes in SUMO regulation. 
The downregulation of SUMOylation primarily involves SUMO2/3, as seen in both AD and 
Tg2576 hippocampi. We detected minimal alteration of SUMO1 conjugates in either the AD brain 
samples or the APP samples of varying ages (Figures 4.3.3A, B). In addition, we did not detect changes 











Figure 4.3.3.  SUMO1 conjugation and Ubc9 levels in Alzheimer’s disease and APP transgenic 
mice  
(A) Representative SUMO1 western blot with post-mortem hippocampal formation tissue from AD and 
control patients, showing high molecular conjugates. Control and AD n= 6 each; no significant difference. 
(B) Representative SUMO1 western blots with hippocampi from Tg2576 APP transgenic and wild-type 
littermate mice. 1-2 mo. n = 6 each WT and APP, 7-8 mo. n = 3 each, 13-14 mo. n = 4 each; no 
significant differences. 
(C) Representative Ubc9 western blot with AD and control tissue. No significant difference. 
(D) Representative Ubc9 western blot with Tg2576 APP and wild-type littermate hippocampi. No 
significant differences. 
(E) High-molecular weight SUMO2/3 conjugation is decreased in aged wild-type mice. 1-2 mo. n = 3, 7-8 
mo. n = 3, 13-14 mo. n = 4; 24-26 mo. n = 3; no significant difference. Relates to Figure 1B.  
Data presented as means ± SEM. 
 
 
4.3.2 Depolarization increases SUMOylation in hippocampal slices 
 In order to determine how Aβ may impact neuronal SUMOylation, we first investigated how an 
activating stimulation normally affects SUMOylation in situ. With acute hippocampal slices, we used a two 
minute incubation in elevated KCl (50 mM) buffer to briefly depolarize and activate neurons. This type of 
high-potassium protocol results in a type of long-term potentiation in slices that shares several 
characteristics with tetanus-induced LTP (Baron et al., 1996; Fleck et al., 1992). Slices were collected 
immediately after the stimulation or following various incubation times in regular ACSF buffer. 
Immediately after the stimulation, minimal changes were observed in overall SUMOylation compared to 
non-stimulated control slices (Figure 4.3.4A). However, by 5 minutes post-stimulation, there was a 40-
50% increase in SUMOylation, especially in the high molecular weight region (~150 – 350 kD). This 
increase is again specific for SUMO2/3; no changes were observed in SUMO1 conjugation (Figure 
4.3.5A). The increased SUMOylation by SUMO2/3 persisted at the 10 minute time point but reversed by 
30 minutes post-depolarization. These data indicate that hippocampal SUMOylation in situ can be 












Figure 4.3.4.  Depolarization-induced SUMOylation is impaired by Aβ 
(A) Hippocampal slices were stimulated with high KCl and subsequently incubated for varying amounts of 
time in regular ACSF buffer. Representative western blots show high molecular weight SUMO2/3 
conjugation. Quantification of blots indicated increase in SUMOylation at the 5 minute post-depolarization 
time point. 0 min n = 3 each non-stimulated and stimulated, 3 min n = 3 each, 5 min n = 3 each, 10 min n 
= 4 each, 30 min n = 3 each. 
(B) The depolarization-induced increase in SUMOylation at the 5 minute time point was impaired in APP 
mice compared to WT littermate controls. WT n = 6, APP n = 5; *p = 0.012. 
(C) Exposure to Aβ42 oligomers impaired the depolarization-induced SUMOylation at the 5 minute time 
point. Vehicle and Aβ-treated n = 6 each; **p = 0.01. 




 Further analyzing the SUMOylation increase at the 5 minute time point, we wanted to determine 
whether the upregulation resulted from the depolarization itself or from any evoked firing activity 
(Lopantsev et al., 2009; Ludvig et al., 1996). Tetrodotoxin (TTX), an inhibitor of voltage-gated sodium 
channels, was used to block action potentials one hour before and during the stimulation and recovery 
times. When slices were treated with TTX (1 µM), stimulation no longer resulted in increased 
SUMOylation (Figure 4.3.5C). Thus, the high KCl-induced SUMOylation appears to be dependent on 
neuronal activity. In addition, it has been previously reported that a long TTX incubation (24 hrs) in 
neuronal cultures leads to an increase in SUMOylation (Craig et al., 2012); with our 1 hour TTX protocol 
in acute slices, we did not observe any changes in basal non-stimulated global SUMOylation levels 
(Figure 4.3.5D).  
 Demonstrating that activity-induced SUMOylation is not limited to high-potassium stimulation, we 
also found that SUMOylation increases occur with a tetanizing stimulus that is commonly used to induce 
LTP. In acute hippocampal slices,  theta-burst stimulation resulted in significantly enhanced SUMOylation 
in area CA1, starting from 10 minutes post-tetanus and lasting at least one hour (Figure 4.3.5E). While 
the time course of the elevated SUMOylation differs from that of high-KCl stimulation, likely reflecting 
differences in stimulation strength and coverage (whole slice vs. CA1), both sets of experiments support 













Figure 4.3.5.  Characteristics of activation-induced SUMOylation 
(A) SUMO1 conjugation is not significantly affected by high-KCl depolarization. Representative western 
blots show increase in SUMO2/3 high molecular weight conjugation that does not occur with SUMO1. 
SUMO1 n = 8, SUMO2/3 n = 14; ***p = 0.001. 
(B) Ubc9 levels are not significantly affected by high KCl depolarization or Aβ42 treatment (200 nM, 20 
minutes).  
(C) Tetrodotoxin (TTX) blocks the depolarization-induced increase in SUMOylation. Representative 
SUMO2/3 western blot. Vehicle n = 3, TTX n = 3; *p=0.03. 
(D) TTX does not significantly affect basal high molecular weight SUMO2/3 conjugation. Quantified from 
western blots. 
(E) Theta-burst stimulation (TBS) induces SUMOylation increase in area CA1 of acute hippocampal 
slices, at 10 minutes and 60 minutes post-tetanus. Representative SUMO2/3 western blots. n = 5 slices 
per time point. (Elena Dale performed the experiments in panel E.) 
Data presented as means ± SEM. 
 
 
4.3.3 Depolarization-regulated SUMOylation is impaired by Aβ 
 We next wanted to determine whether activity-induced SUMOylation is altered by Aβ. We first 
examined hippocampal slices from APP mice. Using the high-potassium stimulation and 5 minute 
incubation time point, which induced the highest SUMOylation increase, we found that the APP slices 
were completely deficient in depolarization-induced SUMOylation (Figure 4.3.4B). In contrast, slices from 
wild-type littermate controls exhibited a significant increase in high molecular weight SUMO conjugates. 
 Although APP-overexpressing mice are useful models of amyloid pathology, there are also many 
other products of APP processing besides Aβ. To pinpoint whether or not Aβ is responsible for the 
impairment in SUMOylation, we also carried out the high-KCl stimulation experiments with wild-type slices 
exposed to Aβ oligomers, which are thought to be the primary neurotoxins in AD. A 20-minute incubation 
with Aβ42 oligomers (200 nM) prior to stimulation completely blocked the SUMOylation increase (Figure 
4.3.4C). These experiments provide strong evidence that high levels of Aβ can impair neuronal 
SUMOylation. 
  
4.3.4 Enhancing SUMOylation rescues Aβ-induced deficits in long-term synaptic plasticity 
 We next asked whether this Aβ-induced SUMOylation impairment can be rescued and, in doing 





conjugating enzyme, Ubc9. Although we did not find Ubc9 levels to be affected in APP hippocampi or by 
acute Aβ exposure (Figures 4.3.3D, 4.3.5B), Ubc9 is the only SUMO conjugating enzyme and therefore 
presents a way to globally manipulate SUMOylation. To allow direct, temporally-specific delivery of Ubc9 
into cells, the enzyme was recombinantly fused to the TAT protein transduction domain, which has been 
previously used to successfully deliver a variety of active proteins (Gong et al., 2006; Gump and Dowdy, 
2007). We purified recombinant TAT-Ubc9 and observed that this enzyme had active SUMOylating 
function and could transduce neurons in slices as well as in culture (Figure 4.3.6A-E).  
 Using the high-potassium stimulation protocol, incubation of Aβ-treated hippocampal slices for 1 
hour with TAT-Ubc9 (100 nM) fully rescued the previously-observed SUMOylation impairment (Figure 
4.3.7A). Depolarization-induced SUMOylation was restored to normal levels comparable to the control 
groups. Notably, TAT-Ubc9 treatment alone did not alter levels of basal non-stimulated SUMOylation 
(Figure 4.3.7A). With stimulation, there was a trend towards increased activity-dependent conjugation 
although it did not reach significance. Under this transduction protocol, it appears that the delivered TAT-
Ubc9 is supplemental and can be recruited to participate in stimulation-induced SUMOylation. 
High concentration Aβ exposure has been well-documented as a potent inhibitor of synaptic 
function and plasticity. We therefore wanted to see if treatment with TAT-Ubc9 affects Aβ-induced deficits 
in long-term potentiation (LTP). Aβ42-treated slices (200 nM, 20 min) normally exhibit significantly reduced 
LTP. However, by perfusing with TAT-Ubc9 (50 nM) for 1 hour prior to LTP induction, we were able to 
restore LTP in slices also perfused with Aβ (Figure 4.3.7B).  
 We then administered TAT-Ubc9 to hippocampal slices from 1 year-old Tg2576 APP mice to test 
if supplementing SUMOylation can improve synaptic plasticity caused by chronic Aβ pathology. At this 
age, LTP was significantly impaired in the APP mice. Consistent with our previous Aβ results above, 
perfusion with TAT-Ubc9 (50 nM) for 1 hour prior to LTP induction was able to rescue the potentiation to 
wild-type levels (Figure 4.3.7C). Data from these experiments suggest that impaired SUMOylation may be 















Figure 4.3.6.  TAT-Ubc9 transduction  
(A) Schematic diagram of the recombinant TAT-Ubc9 expression construct. 
(B) In vitro SUMOylation assay using E2-25K substrate. Representative avidin-HRP western blot. Top 
band represents SUMOylated E2-25K substrate. Lane 1: positive control, lane 2: no ATP negative 
control, lane 3: reaction with TAT-Ubc9, lane 4: reaction with TAT-Ubc9(C93S). 
(C) TAT-Ubc9 transduces neurons in the cell body layer of hippocampal area CA1 (1hr 100 nM 
incubation). Scale bar 50 µm. 
(D) TAT-Ubc9 transduces primary hippocampal neuronal cultures (1hr 100 nM incubation). Scale bar 100 
µm. 
(E) Representative Ubc9 western blot of acute hippocampal slices treated with vehicle or TAT-Ubc9 (1hr 
100 nM) and depolarized with high KCl.  
Data presented as means ± SEM. 
(Mikako Sakurai performed the molecular biology involved in constructing TAT-Ubc9. Assisted by Elena 













Figure 4.3.7.  Transducing Ubc9 rescues Aβ-induced impairments in SUMOylation and long term 
potentiation 
(A)  Hippocampal slices were treated with vehicle (PBS), TAT-Ubc9, Aβ42 oligomers or Aβ plus TAT-Ubc9 
prior to stimulation by high potassium. Representative western blots show high molecular weight 
SUMO2/3 conjugation. Vehicle n = 11 each non-stimulated and stimulated, TAT-Ubc9 n = 3 each, Aβ n = 
6 each, Aβ plus TAT-Ubc9 n = 6 each. ANOVA p = 0.005; *p < 0.05 versus all other groups. 
(B) LTP in area CA1 of hippocampal slices induced by theta burst stimulation of Schaffer collaterals. 
Perfused treatments were prior to LTP induction and include: vehicle (PBS), TAT-Ubc9 (50 nM) for 1 
hour, Aβ42 oligomers (200 nM) for 20 minutes, or combined Aβ plus TAT-Ubc9. Vehicle n = 15, TAT-Ubc9 
n = 9, Aβ n = 14, Aβ plus TAT-Ubc9 n = 9. ANOVA of the averages of the last 10 minutes p = 0.002; *p < 
0.05 versus all other groups. 
(C) LTP with hippocampal slices from Tg2576 mice. Perfused treatments were prior to LTP induction and 
include: vehicle (PBS) or TAT-Ubc9 (50 nM) for 1 hour. WT vehicle n = 10, WT TAT-Ubc9 n = 13, APP 
vehicle n = 14, APP TAT-Ubc9 n = 15. ANOVA of the averages of the last 10 minutes p = 0.001; *p < 0.05 
versus all other groups. 
Data presented as means ± SEM.  
















4.3.5 Enhancing SUMOylation rescues Aβ-induced deficits in learning and memory 
 Since enhancing SUMOylation via Ubc9 transduction restored LTP, we asked whether Aβ-
induced learning and memory deficits can also be rescued. In mice implanted with bilateral cannulas 
reaching the dorsal hippocampi (Figure 4.3.8A), the infusion of Aβ42 oligomers (200 nM) significantly 
impaired spatial learning and memory, as tested in two hippocampal-dependent behavioral tasks: 
contextual fear conditioning (FC) and the two-day radial arm water maze (RAWM). In the FC task, 
administration of Aβ42 15 minutes prior to foot shock significantly reduces freezing behavior when tested 
24 hours later. However, infusion of TAT-Ubc9 immediately after the foot shock training fully rescued the 
FC deficit (Figure 4.3.8B). TAT-Ubc9-treated mice demonstrated contextual memory similar to mice that 
did not receive Aβ. 
In the RAWM task, Aβ42 oligomers administered 15 minutes before the 1st and 6th training blocks 
significantly impaired performance in finding the hidden platform. Compared to the control group, the Aβ-
treated mice failed to reach the learning criterion (~1 error) by the end of the second day. However, 
infusion of TAT-Ubc9 immediately after the 1st and 6th blocks restored performance in this task to normal 
levels comparable to the vehicle-treated group (Figure 4.3.8C). In control experiments, TAT-Ubc9 
infusions did not affect performance on the hippocampus-independent cued conditioning (Figure 4.3.9B). 
TAT-Ubc9 also did not affect swimming speed or time to reach a visible platform, which relate to motor 















Figure 4.3.8.  Ubc9 transduction rescues Aβ-induced learning and memory deficits 
(A) Schematic diagram shows placement of cannulas reaching the dorsal hippocampi.  
(B) Contextual fear conditioning behavioral task. Cannulated mice were each infused with 2 treatments: 
1) 15 minutes prior to foot shock training and 2) immediately afterwards. Treatment groups include 
(infusion 1 + infusion 2): vehicle (PBS) + vehicle (n = 22), vehicle + TAT-Ubc9 (n = 13), Aβ42 oligomers + 
vehicle (n = 14); Aβ42 oligomers + TAT-Ubc9 (n = 13). ANOVA of % freezing behavior 24 hours after foot 
shock training p = 0.002; *p < 0.05 versus all other groups. 
(C) Radial arm water maze behavioral task. Cannulated mice were infused for training sessions 1 and 6 
with 2 treatments: 1) 15 minutes prior and 2) immediately after the session. Treatment groups include 
(infusion 1 + infusion 2): vehicle (PBS) + vehicle (n = 8), vehicle + TAT-Ubc9 (n = 8), Aβ42 oligomers + 
vehicle (n = 7); Aβ42 oligomers + TAT-Ubc9 (n = 8). ANOVA of number of errors p = 0.0002; *Aβ + vehicle 
group p < 0.05 versus all other groups. 
(D) Contextual fear conditioning behavioral task. Cannulated APP and wild-type (WT) mice were infused 
with 3 treatments: 1) 2 hours prior to foot shock training, 2) 20 minutes prior and 3) immediately 
afterwards. WT vehicle (PBS) n = 11, WT TAT-Ubc9 n = 13, APP vehicle n = 13; APP TAT-Ubc9 n = 13. 
ANOVA of % freezing behavior 24 hours after foot shock training p < 0.0001; *p < 0.05 versus all other 
groups. 
(E) Radial arm water maze behavioral task. Cannulated APP and WT mice were infused for training 
sessions 1 and 6 with 3 treatments: 1) 2 hours prior to the session, 2) 20 minutes prior and 3) 
immediately after the session. WT vehicle (PBS) n = 11, WT TAT-Ubc9 n = 14, APP vehicle n = 13; APP 
TAT-Ubc9 n = 14. ANOVA of number of errors p < 0.0001; *APP vehicle group p < 0.05 versus all other 
groups. 
Data presented as means ± SEM; n.s. = not significant.  























4.3.6 Cognitive deficits in APP transgenic mice are rescued by Ubc9 transduction 
 We have demonstrated that supplementing SUMOylation can rescue learning and memory 
impairments caused by acute Aβ exposure. However, we are also interested in the applicability of SUMO-
modifying treatments for chronic Aβ-related pathology, as occurs in AD. Therefore, we also tested TAT-
Ubc9 in 1 year-old Tg2576 APP mice, which have amyloid plaque pathology along with significant 
synaptic dysfunction. Due to the more extensive pathology compared to the acute Aβ model, we 
increased the dosing of TAT-Ubc9. In the FC task, TAT-Ubc9 was administered via cannulas 2 hours 
before, 20 minutes before and immediately after the foot shock training. When tested 24 hours later, the 
TAT-Ubc9-treated APP mice performed significantly better than non-treated APP mice (Figure 4.3.8C). In 
control experiments, TAT-Ubc9 did not affect hippocampus-independent cued conditioning or the sensory 
thresholds of the mice (Figure 4.3.9E,F). These data demonstrate the spatial specificity of the TAT-Ubc9 
infusions. Cued conditioning by a tone conditioned stimulus is dependent on the amygdala and has been 
shown to be impaired in Tg2576 mice (Barnes and Good, 2005); delivery of TAT-Ubc9 to the hippocampi 
was not able to rescue this type of learning. 
 The same TAT-Ubc9 administration protocol was applied to the RAWM task. APP mice were 
infused with TAT-Ubc9 2 hours before, 20 minutes before and immediately after the 1st and 6th training 
blocks on day 1 and day 2, respectively. Towards the end of day 2, the TAT-Ubc9-treated APP mice 
performed significantly better at finding the hidden platform compared to vehicle-treated APP mice 
(Figure 4.3.8D). In control experiments, TAT-Ubc9 did not affect swimming speed or time to reach a 
visible platform (Figure 4.3.9G,H). These experiments demonstrate that supplementation of SUMOylation 










Figure 4.3.9.  TAT-Ubc9 effects on Aβ levels and behavioral parameters  
(A) Aβ(x-40) and Aβ(x-42) ELISAs with the soluble homogenization fractions of hippocampal slices treated 
with TAT-Ubc9 (100 nM 1 hour). Aβ(x-40) n = 6 each vehicle and TAT-treated, Aβ(x-42) n = 5 each. 
(B) Cued conditioning was not significantly affected by TAT-Ubc9 infusions. Vehicle (PBS) n = 22, TAT-
Ubc9 n = 13, Aβ n = 14, Aβ + TAT-Ubc9 n = 13. 
(C) Swimming speed was not significantly affected by TAT-Ubc9 infusions. 
(D) Time to reach a visible platform was not significantly affected by TAT-Ubc9 infusions. 
(E) Cued conditioning was not significantly affected by TAT-Ubc9 infusions in Tg2576 APP mice. WT 
vehicle (PBS) n = 11, WT TAT-Ubc9 n = 13, APP vehicle n = 13; APP TAT-Ubc9 n = 13. 
(F) Sensory threshold assessments were not affected by TAT-Ubc9 infusions in APP mice. 
(C) Swimming speed was not significantly affected by TAT-Ubc9 infusions in APP mice. 
(D) Time to reach a visible platform was not significantly affected by TAT-Ubc9 infusions in APP mice. 
Data presented as means ± SEM. 




An important question that arose was whether manipulating SUMOylation affected Aβ levels. It is 
possible that the observed plasticity and memory rescue effects in the APP mice are at least partially due 
to a reduction in Aβ levels. Previous studies in cell cultures have indicated that SUMOylation may 
regulate APP processing, although the conclusions reached in those studies were in conflict regarding the 
directions of the effects (Dorval et al., 2007; Li et al., 2003; Zhang and Sarge, 2008). We investigated this 
possibility by performing ELISAs on APP hippocampal slices treated with TAT-Ubc9 (100nM, 1 hour). In 
the soluble homogenization fractions, we found no significant effect of TAT-Ubc9 on either Aβ40 or Aβ42 
levels (Figure 4.3.9A). The rescue of synaptic plasticity and cognitive function in the APP mice by TAT-
Ubc9 likely do not reflect significant reductions in the soluble Aβ pool, which constitutes the Aβ fraction 
implicated in causing synaptic pathology (Haass and Selkoe, 2007). 
 
4.3.7 Inhibiting SUMOylation is sufficient to cause long-term potentiation deficits 
 Given that activity-induced SUMOylation is impaired by Aβ and that supplementing SUMOylation 
can rescue Aβ-induced plasticity and memory deficits, we asked whether SUMOylation impairment can 
directly cause synaptic and cognitive dysfunction. To date, although multiple neuronal SUMOylation 
targets have been identified, the involvement of SUMOylation in learning and memory was unclear. To 





dominant negative (DN) point mutation in which a catalytic cysteine is changed to a serine (C93S). This 
mutation has been previously described and used for dominant negative inhibition of global SUMOylation 
(Buschmann et al., 2001; Gong et al., 1997; Xhemalce et al., 2007). When tested in hippocampal slices 
stimulated with high potassium, TAT-Ubc9(DN) was able to block the depolarization-induced increase in 
SUMOylation (Figure 4.3.10A). This dominant negative construct allowed us to specifically and acutely 
inhibit SUMOylation with high temporal and spatial control.  
 When TAT-Ubc9(DN) (100 nM) was perfused onto hippocampal slices for 1 hour prior to 
induction, LTP was significantly reduced compared to interleaved vehicle, TAT-Ubc9 or TAT-GFP controls 
(Figure 4.3.10B). Baseline transmission was not altered during the TAT protein perfusions, and input-
output curves were not affected by TAT-Ubc9 or TAT-Ubc9(DN) (Figure 4.3.10C). In addition, we checked 
with patch clamp experiments to see if SUMOylation inhibition by TAT-Ubc9(DN) affected glutamate 
receptors known to underlie LTP. However, current-voltage curves for neither AMPA receptors nor NMDA 
receptors were altered by TAT-Ubc9(DN) (Figure 4.3.11A, B). The effects of acute SUMOylation inhibition 
appear to be specific for long-term synaptic plasticity and does not impact basal synaptic transmission.   
 We also verified the effect of SUMOylation inhibition on LTP with another system. Taking an 
opposite approach to inhibit SUMOylation, we used a SUMO-specific protease, SENP1, that has broad 
SUMO deconjugating activity (Mukhopadhyay and Dasso, 2007). Since SENP1 is a relatively large 
protein (73 kD), it could not be used with the TAT transduction method. Therefore, we directly 
administered either recombinant GST-tagged SENP1 or SENP1 catalytic subunit via patch pipette to the 
intracellular environment. The recombinant SENP1 was tested in an in vitro assay and found to have full 
de-SUMOylating activity, while SENP1 with a previously-discovered inactivating mutation (C603S) did not 
(Figure S5C) (Bailey and O'Hare, 2004). When included in the patch pipette, SENP1, but not 
SENP1(C603S), fully blocked single-cell LTP in CA1 pyramidal neurons (Figure 4.3.10D). Supporting 
what we observed in the previous field potential experiments, baseline transmission was not affected by 












Figure 4.3.10.  Inhibiting SUMOylation impairs long-term potentiation 
(A)  Hippocampal slices were treated with vehicle (PBS), TAT-Ubc9 or TAT-Ubc9(DN) prior to stimulation 
by high potassium. Representative western blots show high molecular weight SUMO2/3 conjugation. 
Vehicle n = 11 each non-stimulated and stimulated, TAT-Ubc9 n = 3 each, TAT-Ubc9(DN) n = 7 each. 
ANOVA p < 0.0001; **p < 0.01 versus all other groups. 
(B) LTP in area CA1 of hippocampal slices induced by theta burst stimulation of Schaffer collaterals. 
Treatments were perfused for 1 hour prior to LTP induction. Vehicle n = 14, TAT-Ubc9 n = 9, TAT-
Ubc9(DN) n = 12, TAT-GFP n = 7. ANOVA of the averages of the last 10 minutes p = 0.0004; *TAT-
Ubc9(DN) p < 0.05 versus all other groups.  
(C) Basal synaptic transmission as measured by input-output curves were not affected by TAT-Ubc9 or 
TAT-Ubc9(DN).  
(D) Whole cell patch clamp of single-cell LTP in area CA1 induced by theta burst stimulation. Either 
vehicle, SENP1 or SENP1(C603S) inactive mutant was introduced intracellularly via the patch pipette. 
Vehicle n = 7, SENP1(C603S) n = 4, SENP1 n = 7. ANOVA of the post-tetanic time points p < 0.0001. 
Data presented as means ± SEM.  
(Assisted by Hong Zhang in some of the LTP recordings. Assisted by Hong Zhang and Elena Dale in the 
input-output measurements. Elena Dale performed the SENP1 patch clamp experiments.) 
 
 
 While long-term synaptic plasticity in the form of LTP was significantly affected by SUMOylation 
inhibition/deconjugation, we also checked a form of short-term synaptic plasticity, paired-pulse facilitation 
(PPF), that is thought to be expressed wholly presynaptically. TAT-Ubc9(DN) did not significantly affect 
PPF at any of the inter-stimulus intervals examined (Figure 4.3.11E). Together with the postsynaptic LTP 
impairment observed in the SENP1 experiments, these data indicate that SUMOylation inhibition may 













Figure 4.3.11.  Electrophysiology controls  
(A) AMPAR I-V curves. AMPA receptor currents are not affected by TAT-Ubc9(DN). Vehicle and TAT-
Ubc9(DN) n = 3 cells each. Currents normalized to -70 mV. 
(B) NMDAR I-V curves. NMDA receptor currents are not affected by TAT-Ubc9(DN). Vehicle and TAT-
Ubc9(DN) n = 3 cells each. Currents normalized to +40 mV. 
(C) Recombinant GST-SENP1 has de-SUMOylating activity. In vitro SUMOylation assay using E2-25K 
substrate; representative avidin-HRP blots. Top band represents SUMOylated substrate. Lane 1: positive 
control, lane 2: no ATP negative control, lane 3: reaction with GST-SENP1(C603S) inactive mutant, lane 
4: reaction with GST-SENP1. 
(D) Inclusion of GST-SENP1 in the patch pipette did not alter baseline synaptic transmission. Summary 
graph of EPSC recordings from CA1 pyramidal  cells  held  at  -70  mV  (n=3  cells).  Responses  in  the  
first  5  minutes  were averaged and normalized to 100%. Each point of the graph represents the average 
of six successive recordings taken every 10 seconds.  
(E) Paired-pulse facilitation (PPF) was not significantly affected by TAT-Ubc9(DN). Vehicle and TAT-
Ubc9(DN) n = 6 each. 
Data presented as means ± SEM. 
(Assisted by Ian Orozco in the AMPAR and NMDAR recordings. Assisted by Hong Zhang in the PPF 
recordings. Nsikan Akpan performed the SENP1 SUMO assay. Elena Dale performed the SENP1 



















4.3.8 SUMOylation inhibition impairs learning and memory 
 Since we found SUMOylation inhibition can impair LTP, we hypothesized that TAT-Ubc9(DN) 
would also impair learning and memory in vivo. In cannulated mice, infusions of TAT-Ubc9 or TAT-GFP 
controls did not affect memory in any of the behavioral tasks (Figure 4.3.12). However, infusions of TAT-
Ubc9(DN) 20 minutes before foot shock training significantly impaired freezing behavior 24 hours later 
(Figure 4.3.12A). Administering TAT-Ubc9(DN) immediately after the foot shock training gave similar 
results (Figure 4.3.12B), which indicate that the effect was specific to memory consolidation (Barad et al., 
1998). In control experiments, none of the treatments affected performance in the amygdala-dependent 
cued conditioning (Figure 4.3.13A). In addition, the TAT treatments did not affect sensory threshold 
(Figure 4.3.13B).  
In the Morris water maze task, which measures hippocampal-dependent reference memory, 
infusions of TAT-Ubc9(DN) after each training session significantly impaired performance starting from 
the 3rd session (Figure 4.3.12C). In the probe trial, TAT-Ubc9(DN)-treated mice spent significantly less 
time in the target quadrant compared to the other groups (Figure 4.3.12D). Control experiments indicate 
that TAT protein treatments did not affect either swimming speed or time to reach a visible platform 
(Figure 4.3.13C, D). To rule out effects on exploratory behavior or anxiety, we also performed the open 
field test and found no differences between any of the groups, including the TAT-Ubc9(DN)-treated mice 
(Figure 4.3.13E, F). Overall, these data demonstrate the novel finding of SUMO involvement in learning 





















Figure 4.3.12.  Inhibiting SUMOylation impairs learning and memory 
(A) Contextual fear conditioning behavioral task. Cannulated mice were infused 1 hour prior to foot shock 
training. Vehicle n = 16, TAT-Ubc9 n = 8, TAT-Ubc9(DN) n = 16, TAT-GFP n = 12. ANOVA of % freezing 
behavior 24 hours after foot shock training p = 0.04; *p < 0.05 versus all other groups. 
(B) Contextual fear conditioning behavioral task. Cannulated mice were infused immediately after foot 
shock training. Vehicle n = 10, TAT-Ubc9 n = 12, TAT-Ubc9(DN) n = 8, TAT-GFP n = 6. ANOVA of % 
freezing behavior 24 hours after foot shock training p = 0.0002; **p < 0.01 versus all other groups. 
(C) Morris water maze behavioral task. Cannulated mice were infused after each training session. Vehicle 
n = 11, TAT-Ubc9 n = 11, TAT-Ubc9(DN) n = 12, TAT-GFP n = 11. ANOVA of time to reach the hidden 
platform p < 0.0001; *TAT-Ubc9(DN) group p < 0.05 versus all other groups starting from the third 
session. 
(D) Water maze probe trial. Mice infused with TAT-Ubc9(DN) spent significantly less time in the target 
quadrant (TQ). Adjacent right (AR), opposite quadrant (OQ), adjacent left (AL). ANOVA of time in target 
quadrant p < 0.0001; **TAT-Ubc9(DN) group p < 0.01 versus all other groups. 
Data presented as means ± SEM.  













Figure 4.3.13.  TAT-Ubc9(DN) effects on behavioral parameters  
(A) Cued conditioning was not significantly affected by TAT-Ubc9 or TAT-Ubc9(DN) infusions. Vehicle n = 
16, TAT-Ubc9 n = 8, TAT-Ubc9(DN) n = 16, TAT-GFP n = 12. 
(B) Sensory threshold assessments were not significantly affected by TAT-Ubc9 or TAT-Ubc9(DN) 
infusions. 
(C) Time to reach a visible platform was not significantly affected by TAT-Ubc9 or TAT-Ubc9(DN) 
infusions. Vehicle n = 11, TAT-Ubc9 n = 11, TAT-Ubc9(DN) n = 12, TAT-GFP n = 11.  
(D) Swimming speed was not significantly affected by TAT-Ubc9 or TAT-Ubc9(DN) infusions.  
(E) Open field behavioral task. Percent time spent in the center was not significantly affected by TAT-
Ubc9 or TAT-Ubc9(DN) infusions. All groups n = 8 each. 
(F) Open field behavioral task. Number of entries into the center was not significantly affected by TAT-
Ubc9 or TAT-Ubc9(DN) infusions.  
Data presented as means ± SEM. 























4.4.1 SUMOylation in synaptic plasticity and cognition 
In this study, we have demonstrated for the first time that SUMOylation is involved in long-term 
synaptic plasticity and cognition. Along with other PTMs such as phosphorylation, SUMOylation likely 
plays widespread roles in the signaling networks that regulate synaptic plasticity. How analogous 
SUMOylation is to these other PTMs remains to be fully determined. Comparing with phosphorylation, 
early studies found increases in kinase activity and overall protein phosphorylation following various types 
of stimulation (Akers et al., 1986; Klann et al., 1991, 1992; Rosenblum et al., 1996; Rostas et al., 1996; 
Siciliano et al., 1994; Sweatt and Kandel, 1989). While inhibiting phosphorylation was shown to impair 
LTP as well as learning and memory (Blum et al., 1999; Lovinger et al., 1987; Malenka et al., 1989; 
Malinow et al., 1988; Schafe et al., 1999), the actual phosphorylation states of specific molecules are 
regulated by networks of kinases and phosphatases and could be either modified or de-modified upon 
plasticity induction.  
We hypothesize that the involvement of SUMOylation in synaptic plasticity is similar. In this study, 
we have determined that SUMOylation levels are globally regulated by neuronal activation and LTP-
inducing stimulation. Furthermore, such regulation appears to be necessary for learning and memory, 
since inhibiting SUMOylation causes impairments. Although we observed overall increases upon 
stimulation, the SUMOylation states of specific proteins are individually regulated and may not 
necessarily be modified in the same direction or timeframe. In our experiments, we focused on overall 
high molecular weight SUMO conjugation, which provides an assay for detecting general changes in 
regulation. Future research will elucidate the specific protein targets that undergo regulated SUMOylation 
(or de-SUMOylation) as part of the mechanisms underlying neural plasticity. There are several potential 
candidates which have been recently described to be SUMO targets in neurons. The GluR6 kainate 
receptor subunit is SUMOylated upon kainate stimulation (Martin et al., 2007a), and Arc, a well-studied 
immediate early gene involved in long-term synaptic plasticity, was recently found to be SUMOylated as 
part of a homeostatic synaptic scaling mechanism (Craig et al., 2012). These and other SUMOylated 





4.4.2 SUMOylation in Alzheimer’s disease 
Our study has also demonstrated that SUMOylation is impaired by Aβ and can be rescued by 
enhancing SUMO conjugation. Since we observed that SUMOylation inhibition on its own is sufficient to 
cause learning and memory deficits, the SUMOylation impairments by Aβ likely contribute to the synaptic 
and cognitive dysfunction of AD. It is becoming clear that, similar to other PTMs, the normal regulation of 
SUMO conjugation can become disrupted under neuropathological conditions and further contribute to 
disease processes (Sarge and Park-Sarge, 2009). Several previous studies have implicated 
SUMOylation in neurodegenerative diseases such as Huntington’s disease and spinocerebellar ataxias 
(Steffan et al., 2004; Wilkinson et al., 2010). In the AD field, a few studies have also pointed to possible 
links with SUMOylation. An analysis of genomic DNA found a single-nucleotide polymorphism in the Ubc9 
gene (UBE2I) that was associated with sporadic AD (Ahn et al., 2009). Although we did not find 
significant changes in Ubc9 protein levels in the hippocampi of AD patients or APP mice, it is possible 
that alterations in other aspects of Ubc9 regulation may affect its function under Aβ-induced pathology.   
SUMOylation may also impact AD pathology by modulating APP processing (Dorval et al., 2007; 
Li et al., 2003; Zhang and Sarge, 2008). However, the data on whether or not APP is directly 
SUMOylated and whether SUMOylation impacts Aβ levels are conflicting and unclear. We investigated 
this possibility and found that enhancing SUMOylation did not significantly affect soluble Aβ levels. 
However, altering SUMOylation may impact other aspects of APP processing, including levels of other 
cleavage products and its regulation by neuronal activity; these other factors currently cannot be ruled out 
and may play a role in the effects we observed. 
We have demonstrated that enhancement of SUMO conjugation is sufficient for countering both 
short-term and chronic Aβ-induced synaptic and cognitive deficits, which suggests that SUMO-targeted 
compounds could be relevant for AD therapeutics. Currently, SUMOylation-directed approaches are most 
active in the cancer field. Given the general role of SUMO in genomic maintenance, targeting Ubc9 and 
global SUMOylation is not a likely approach for AD drug development. However, with the continuing 
discovery of SUMOylated neuronal proteins and SUMO regulatory factors, specific ones involved in 





4.5 Additional Results 
4.5.1 Increased SUMOylation in the RIPA-insoluble fractions 
 After I discovered that SUMOylation is decreased in the soluble homogenization fraction of AD 
hippocampal tissue, I also analyzed the insoluble pellet fraction. All of the homogenizations for the 
immunoblots were performed in standard radioimmunoprecipitation assay (RIPA) buffer, which is a 
widely-used lysis buffer containing moderate amounts of ionic and nonionic detergents (0.1% SDS, 1% 
NP-40 and sodium deoxycholate). While this buffer can effectively lyse cells and solubilize cytoplasmic, 
nuclear and membrane proteins, RIPA buffer does not solubilize protein aggregates and some 
cytoskeletal elements and extracellular matrix. I analyzed the pellet fractions remaining after high-speed 
centrifugation by western blot with an anti-SUMO2/3 antibody. In contrast with the soluble fraction results, 
there appeared to be increases in SUMOylation in some of the AD tissue samples (Figure 4.5.1A). This 
trend was not statistically significant but was observable in a subset of the samples. Similarly, Ubc9 levels 
also trended towards an increase in the insoluble fractions of AD samples (Figure 4.5.1B).  
 I also performed similar analyses with the insoluble fractions from the aged Tg2576 APP 
transgenic mice. Again, although not statistically significant, there were trends towards increased levels of 
insoluble SUMO2/3 conjugates and Ubc9 in the 13-14 month-old and 24-26 month-old age groups 







Figure 4.5.1.  Levels of insoluble SUMO conjugates and Ubc9 in Alzheimer’s disease brain 
(A) SUMO2/3 western blot with the RIPA-insoluble homogenization fractions of AD hippocampal tissue 
samples. There was a trend towards increased SUMOylation in the AD samples, although this did not 
reach statistical significance. Graph displays quantification of the 50-250 kD region. Control and AD n = 6 
each. 
(B) Ubc9 western blot with the RIPA-insoluble homogenization fractions. There was a trend towards 
increased levels in the AD samples, although this did not reach statistical significant.  






Figure 4.5.2.  Levels of insoluble SUMO conjugates and Ubc9 in aged APP mice 
(A)  SUMO2/3 and Ubc9 western blots with the RIPA-insoluble homogenization fractions of aged APP 
hippocampi. There was a trend towards increased levels of SUMO conjugates and Ubc9 in the APP 
samples, although this did not reach statistical significance.  
(B)  Quantification of the SUMO2/3 blots  (50-250 kD region) in the13-14 month-old (WT and APP n = 4 
each) and 24-26 month-old (WT and APP n = 2 each) age groups.  





4.5.2 Depolarization-induced deSUMOylation in cultured neurons 
 Although the majority of the experiments I performed were with relatively in situ preparations 
(acute hippocampal slices), I also did a preliminary experiment with primary hippocampal neuron cultures 
(14 DIV). When depolarized with 50 mM KCl for 5 minutes, there was a large decrease in SUMOylation, 
particularly in high-molecular weight SUMO2/3 conjugates (Figure 4.5.3). This is in direct contrast with the 
results in hippocampal slices, which exhibited upregulated SUMOylation with both KCl depolarization as 
well as LTP-inducing theta burst stimulation. SUMO1 however appears to be minimally affected, with a 
more modest decrease in a few lower molecular weight bands.  
 
 
Figure 4.5.3.  KCl stimulation in primary hippocampal neuron cultures 
SUMO1 and SUMO2/3 western blots. High KCl (50 mM) depolarization for 5 minutes (at 37 C) in primary 








4.5.3 Morpholino-based manipulation of SUMO 
 Using TAT transduction of Ubc9, we have been able to successfully manipulate SUMOylation. 
However, this method is most useful for acute experiments since the majority of TAT proteins are not 
stable beyond a few hours inside cells. I have not yet tested the timeframe and stability of TAT-Ubc9 in 
neurons but I do not expect it to be unusually long-lived compared to other TAT proteins. In order to test 
the effects of a more chronic downregulation of SUMO, we used morpholino antisense technology. 
Morpholinos are synthetic nucleic acid oligos in which the deoxyribose rings that characterize DNA are 
replaced with morpholine rings joined by phosphorodiamidate groups (Figure 4.5.4A). Due to these major 
structural differences, morpholinos are not recognized by endogenous nucleic acid degradation 
machinery and are therefore very stable in cells, without inducing any immune responses. Morpholinos 
exert their inhibitory action via base-pair matching with the target mRNA. However, instead of RISC or 
RNase H-based degradation, as occurs with siRNA technology, morpholinos prevent translation via steric 
hindrance. Due to this mechanism, morpholinos have been reported to have much fewer off-target effects 
compared to other RNAi methods. 
 Using an antisense morpholino designed to specifically inhibit Ubc9 translation (Ubc9-AS) and a 
control morpholino with an inverted sequence (Ubc9-I), we administered the oligonucleotides to the dorsal 
hippocampi via cannulas twice daily for two weeks. Using this protocol, preliminary data indicate that 
levels of Ubc9 and basal global SUMOylation are decreased in the hippocampi (Figure 4.5.4B). Both 
SUMO1 and SUMO2/3 conjugation appear to be affected by Ubc9-AS morpholinos. In addition, I verified 
that the morpholinos can indeed transfect neurons in the hippocampus; cannula-infused FITC-labeled 
morpholinos were observed in high levels inside pyramidal neuron cell bodies and processes in area CA1 






Figure 4.5.4.  Anti-Ubc9 morpholinos transfect neurons and decrease SUMOylation  
(A)  Chemical structures of DNA and morpholino oligonucleotides 
(B)  SUMO and Ubc9 western blots of hippocampal lysates of a mouse infused with invert control (I) or 
anti-Ub9 (A) morpholinos for two weeks 
(C)  FITC-labeled morpholinos transfect pyramidal neurons in hippocampal area CA1 







4.5.4 Anti-Ubc9 morpholinos inhibit long-term potentiation and memory 
 After the two week infusion protocol, mice were sacrificed for long-term potentiation (LTP) 
experiments. Supporting my results using TAT-Ubc9, we found that downregulation of endogenous Ubc9 
protein levels significantly impaired LTP (Figure 4.5.5A). The magnitude of the impairment was similar to 
that obtained with acute TAT-Ubc9 perfusion (Figure 4.5.5B). The results are preliminary however, since 
we still need to do more experiments, including ones with the invert control morpholino.  
 
 
Figure 4.5.5.  Anti-Ubc9 morpholinos decrease hippocampal long term potentiation 
(A)  LTP is impaired in acute hippocampal slices from mice treated for two weeks with antisense Ubc9 
morpholinos (Ubc9-AS). Vehicle n = 8, Ubc9-AS n = 10. 
(B)  Quantification of the average of the last 10 minutes of LTP.  
Data presented as means ± SEM. *p < 0.05. (Assisted by Hong Zhang in the LTP recordings.) 
 
 
 We also investigated the effect of Ubc9 downregulation on learning and memory in mice. After a 
two week treatment period of twice daily morpholino infusions, mice treated with Ubc9-AS morpholinos 
performed significantly worse in the contextual fear conditioning task compared to mice treated with 
Ubc9-I control morpholinos (Figure 4.5.6A). However, interestingly, there also appeared to be a 
significant difference in cued fear conditioning, which is dependent on the amygdala (Figure 4.5.6B). No 





infused via cannulas to the dorsal hippocampi, the more intense, two week administration schedule may 
have led to diffusion and/or downstream effects in non-hippocampal regions.  
 In the Morris water maze task, a hippocampal-dependent measure of reference memory, Ubc9-
AS-treated mice again performed significantly worse than control groups, with significant deficits apparent 
starting from the 4th session (Figure 4.5.6C). These learning and memory impairments are evident in the 
probe trial, in which Ubc9-AS-treated mice spent significantly less time in the target quadrant (Figure 
4.5.6.D). There were no effects of morpholino treatment on swimming speed (Figure 4.5.6F) but there 
were significant effects on the visible platform task, a control of visual ability (Figure 4.5.6E). It is 
uncertain why Ubc9-I-treated mice reach the platform faster than vehicle control mice in two of the 







Figure 4.5.6.  Anti-Ubc9 morpholinos inhibit learning and memory 
(A)  Contextual fear conditioning task. Vehicle n = 15, Ubc9-I n = 15, Ubc9-AS n =16. Significant by 
ANOVA, ***p < 0.001 compared to control groups 
(B)  Cued conditioning task. Significant by ANOVA, *p < 0.05 compared to vehicle group 
(C)  Morris water maze task. Significant by ANOVA, **p < 0.01 compared to control groups 
(D)  Water maze probe trial. Significant by ANOVA, **p < 0.01 compared to control groups 
(E)  Visible platform task. Significant by ANOVA, *Ubc9-I group p < 0.05 compared to vehicle group 
(F)  Swimming speed. No significant differences.  





4.5.5 SUMO-CREB immunoprecipitation  
 A central issue in this and any other project on SUMOylation is the identification of the specific 
targets and pathways that are modified. While we have discovered that SUMO regulation is critically 
involved in synaptic plasticity and cognition, we do not know the key substrates that are SUMOylated in 
these processes. In our lab’s search for substrates, performed by a previous lab member, the cAMP 
response element-binding (CREB) protein came up as a candidate. CREB is a transcription factor that 
has been widely-studied and found to be crucial for learning and memory formation. In a previous study 
with mammalian cell lines, CREB was found to be SUMOylated by SUMO1 in response to hypoxia (see 
Chapter 2) (Comerford et al., 2003). The previous lab member’s data indicated that CREB may be 
SUMOylated by SUMO2/3 in vivo in mouse hippocampi. However, I was not able to replicate these 
immunoprecipitation data (Figure 4.5.7A-B). Using either CREB or SUMO2/3 antibodies to 
immunoprecipitate from hippocampal lysates, I was not able to detect SUMO1-CREB or SUMO2/3-CREB 
bands. My negative data on this topic does not necessarily mean that CREB is definitely not a SUMO 
substrate in the brain – given that in general, only a small proportion of a protein population is 






Figure 4.5.7.  Immunoprecipitation for SUMO-CREB  
(A)  Western blots with CREB immunoprecipitates, using whole hippocampal homogenates. No SUMO1-
modified or SUMO2/3-modified CREB conjugates were detected. HC = immunoprecipitation antibody 
heavy chain, LC = antibody light chain. Other bands are non-specific. 
(B)  Western blots with SUMO2/3 immunoprecipitates. No SUMO-CREB detected. Set 1: SUMO2/3 IP, 








4.5.6 Identification of SUMO-clathrin heavy chain 
 To look for potential SUMOylated substrates, I used SUMO2/3 immunoprecipitates from the 
hippocampus for liquid chromatography-tandem mass spectrometry (LC-MS/MS) analyses. There were 
multiple proteins identified in a range of molecular weights (Table 4.5.8).  However, one protein in 
particular had the highest score and the most number of peptides identified – clathrin heavy chain 1.  
 
Table 4.5.8  Mass spectrometry analysis of SUMO2/3 conjugates in the hippocampus 




 Clathrin is best known for its involvement in clathrin-mediated endocytosis (CME), the most 
widely-studied endocytotic pathway (Figure 4.5.9A). CME occurs constitutively in most mammalian cells 
and is the predominant mechanism for internalizing membrane and extracellular material (Conner and 
Schmid, 2003; Doherty and McMahon, 2009). In neurons, beyond basic cellular functions, CME is a 
critical mechanism at synapses that is involved in processes such as receptor internalization and vesicle 
retrieval. Clathrin heavy chain is a part of the clathrin triskelion, the main structural scaffold component of 
coated vesicles and pits (Figure 4.5.9B). A clathrin triskelion is composed of three light chains and three 






Figure 4.5.9.  Clathrin-mediated endocytosis 
(A)  Clathrin-mediated endocytosis (adapted from Conner and Schmid, 2003) 
(B)  Clathrin triskelion schematic (adapted from ter Haar et al., 1998) 
 
 
 To verify this mass spectrometry hit, I probed hippocampal immunoprecipitates with western blots 
(Figure 4.5.10). Immunoprecipitation with either a clathrin heavy chain (CHC) antibody or a SUMO2/3 
antibody revealed a specific band positive for both CHC and SUMO. This single band is roughly around 
the 180 kDa molecular weight of CHC, which indicates that if CHC is SUMOylated, it is likely with one 
SUMO2/3 protein. In addition, the hippocampal tissues used for the experiment were from either 1 year 
old wild-type or APP transgenic mice. There appears to be slightly less SUMO-CHC in one of the APP 





previously-discussed findings, there were decreased overall high-molecular weight SUMO2/3 
immunoprecipitates in the APP samples.  
Going back into the literature, I found that clathrin heavy chain has been previously identified as a 
potential SUMOylated substrate in four large-scale screening studies performed in cell lines (Blomster et 
al., 2009; Bruderer et al., 2011; Golebiowski et al., 2009; Schimmel et al., 2008). These studies used 
transfected tagged SUMO to pull out SUMOylated proteins under various conditions, including 
proteasome inhibition and heat shock. Confirming my findings, SUMO2-CHC was identified, with one of 
the studies reporting CHC modified by five SUMO2 proteins (Bruderer et al., 2011). Although I only 
observed a single SUMO-CHC band in my experiments, it is quite possible that poly-SUMOylated CHC 
exists in low, below-threshold amounts or is not recognized by my antibodies.  
 
 
Figure 4.5.10.  Immunoprecipitation of SUMO-clathrin heavy chain from wild-type and APP 
transgenic hippocampi 
Clathrin heavy chain and SUMO2/3 western blots of immunoprecipitates from wild-type and APP 
transgenic mice. CL = clathrin heavy chain, HC = immunoprecipitation antibody heavy chain, LC = 






4.5.7 SUMO-clathrin regulation 
 In order to investigate if and how SUMO-clathrin heavy chain levels can be regulated, and also to 
establish an assay for testing potential SUMO-CHC modifying manipulations, I used the HeLa epithelial 
cell line for faster screening. As previously discussed (see Chapter 2), certain cell stressor stimuli have 
been reported to regulate SUMOylation in cell cultures. I first tested heat shock treatment, one of the 
more commonly-used stressor stimuli. After 15 minutes at 45 C, I observed highly increased overall 
SUMOylation but no changes in SUMO-clathrin levels. I next tested serum deprivation and H2O2 oxidative 
stress (Figure 4.5.11). After an overnight (~16 hour) serum starvation, followed by 15 minutes in regular, 
serum-containing media (10% FBS), I again observed no significant changes in overall SUMOylation or 
SUMO-CHC levels, as analyzed by immunoprecipitation and western blots. However, the H2O2 oxidative 
stress stimulus (100 mM, 15 minutes at 37 C), led to a significant increase in SUMO2/3 conjugates. 
Interestingly, despite this upregulation, there was a decrease in the SUMO-CHC band. Thus, my 
preliminary data indicate that there may be an active regulation of SUMO-CHC, which is manifest in the 
decreased SUMOylation with oxidative stress.  
 
Figure 4.5.11.  SUMOylation of clathrin heavy chain may be regulatable by oxidative stress 
Clathrin western blots of SUMO2/3 immunoprecipitates from HeLa cell cultures treated with either serum 





4.5.8 SUMO-clathrin SUMOylation sites 
 Although I have observed that clathrin heavy chain is SUMOylated in vivo and in vitro by at least 
one SUMO protein, the actual conjugation site remains to be determined. Using two bioinformatics 
software packages for predicting SUMOylation, SUMOsp (Xue et al., 2006) and SUMOplot (Abgent), I 
generated a list of potential SUMO conjugation sites for CHC (Figure 4.5.12A). Although the total list of 
lysines is long for a large protein like CHC, the top three potential sites include a classic SUMO 
consensus motif, which has been found in a large proportion of SUMOylated proteins (see Chapter 2). 
This consensus site (K205) was identified as a high priority hit by both bioinformatic analyses. Lysine 205 
in CHC is located in the N-terminal domain, which has been defined as a “bladed” β-propeller structure 
(ter Haar et al., 1998). In this domain, there are seven β sheets, each with four antiparallel strands, 
arranged around a central axis (Figure 4.5.12B). K205 is located in one of the β-sheet blades, in a linker 
region between two strands.  
 In order to verify this consensus lysine, as well as the other top lysines, as actual SUMOylation 
sites, we are working on a molecular biology approach, using site-directed mutagenesis to switch lysines 
to arginines (e.g. K205R). That work is ongoing. At the same time, given that K205 is a high-probability 
site and the only SUMO consensus motif in CHC, I also took another approach to try to manipulate CHC 
SUMOylation. Again using the TAT protein transduction domain, fusion peptides containing the sequence 
around and including the K205 lysine were synthesized. The TAT-linked “decoy” peptide strategy has 
previously been used by multiple studies to interfere with protein-protein interactions (Aarts et al., 2002; 
Lustbader et al., 2004; Mao et al., 2005; Yang et al., 2004; Yao et al., 2011). The sequence for this 24 
amino acid transduction peptide that includes the CHC SUMO consensus site (TAT-CHC-D) was verified 
to be specific for CHC; a scrambled control peptide (TAT-CHC-S) was verified to not significantly 
resemble sequences in any mouse protein (NIH BLAST). Of note, human and murine CHC are nearly 
identical, with only two amino acid differences that are far from this potential SUMO site (A1146T, 
K1406R).  
 Data testing the TAT-CHC peptides are preliminary, and experiments are ongoing. In one 





in the SUMO-CHC band (Figure 4.5.12C). Future experiments will determine if regulated SUMOylation of 






Figure 4.5.12.  Preliminary test of TAT-based decoy peptide for clathrin heavy chain 
(A)  Top possible SUMOylation sites in clathrin heavy chain, as predicted by SUMOsp and SUMOplot 
bioinformatics software. 
(B)  Schematic diagrams of clathrin triskelion (light chains not depicted) and β-propeller terminal domain 
structure. K205 is located in the β-sheet labeled #5. 
(C)  Clathrin heavy chain western blot of SUMO2/3 immunoprecipitates from HeLa cells treated with TAT-
CHC-D (decoy) or TAT-CHC-S (scramble) peptides under basal conditions. 
























4.6 Additional Discussion 
4.6.1 Insoluble protein SUMOylation in AD 
 Previous studies have shown that SUMO co-localizes with protein aggregates in some 
neurodegenerative diseases (see Chapter 2). For example, phospho-tau aggregates and Lewy bodies 
containing α-synuclein aggregates have both been reported to exhibit positive SUMO1 immunostaining 
patterns in brain tissue (Pountney et al., 2005; Pountney et al., 2003; Takahashi et al., 2008). This may 
represent the aggregation of normally SUMOylated substrates, the post-hoc SUMOylation of existing 
aggregates, or a combination of both. In the examples, both tau and α-synuclein have been identified as 
SUMO substrates in cell lines. Regarding tau, there appears to be competitive antagonism between 
ubiquitin and SUMO, perhaps for the same lysine residue; in addition, tau SUMOylation appears to be 
positively regulated by phosphorylation (Dorval and Fraser, 2006). Therefore, in the case of tau, SUMO 
may be a regulatory link between the PTMs – increased pathological tau phosphorylation leads to 
enhanced SUMOylation, which antagonizes ubiquitination and ultimately contributes to a buildup of 
hyper-phosphorylated tau aggregates. Such SUMOylated aggregates may indeed constitute part of the 
increased SUMO conjugates  I observed in the insoluble fractions. However, besides tau, other 
SUMOylated proteins likely also undergo aberrant SUMO regulation in AD. As demonstrated in several 
studies, SUMOylation can directly influence a protein’s solubility and aggregation propensity (see Chapter 
2). Since I have shown that there are global changes in SUMO regulation with AD, multiple proteins may 
undergo SUMO-related aggregation in the disease.  
 It is important to note that results from analyses of global SUMOylation levels depend on the 
buffer and lysis methods, especially when those levels change in opposite directions in different fractions, 
as is the case with AD and APP transgenic tissues. In my earliest initial experiments with APP mice, I 
tried a  different homogenization method involving high SDS buffer and multiple rounds of sonication and 
centrifugation that resulted in a much more complete solubilization of the entire homogenate (e.g. almost 
no pellet fraction remaining). When those samples were analyzed by western blot, there was either no 
significant difference or even increased overall SUMOylation in the APP samples. This conflicting result 





SUMOylation. Therefore, it is important to consider the homogenization method and fractions when 
analyzing SUMOylation. 
 The observation that a SUMO enzyme, Ubc9, also tends towards an increase in the insoluble 
fraction is interesting. Since I did not observe any differences in the levels of soluble Ubc9 in AD or APP 
transgenic samples, there may be a compensatory upregulation of Ubc9 expression. This remains to be 
determined in future experiments.  
 
4.6.2 SUMOylation in cultured neurons 
 The incongruent results of depolarization-upregulated SUMO changes in acute hippocampal 
slices versus depolarization-downregulated SUMO changes in primary neuronal cultures may be due to 
multiple factors.  Besides the fundamental cellular changes induced by culturing, the cells differ from adult 
brain neurons in many ways – the two preparations are not developmentally similar , and cultured 
neurons are not 3-dimensionally supported and connected in the intricate networks that occur in the brain. 
In addition, the lack of non-neuronal regulatory components, such as glia cells and their processes, alters 
synaptic properties. Thus, a depolarizing stimulus (and any resultant synaptic activity) may cause 
disparate effects on SUMOylation, dependent on the neuronal environment, developmental stage and 
connectivity. Future experiments will determine if this is repeatable result, and if so, which specific SUMO 
regulatory differences may account for these effects.  
 Very recently, a published study described similar findings, also in cultured hippocampal neurons. 
With a 1.5 minutes KCl (60 mM) depolarization, the authors observed a significant decrease in SUMO2/3, 
but not SUMO1, conjugation 5 minutes after stimulation. Thus, changes in SUMO regulation in neurons 
appear to depend on the experimental preparation. It is in my opinion that a slice preparation with 
relatively more intact circuitry and cellular components better reflects the physiological situation in vivo. 






4.6.3 Morpholino-based Ubc9 downregulation  
 With morpholinos, we have verified the involvement of SUMOylation in LTP and learning and 
memory using a longer-term inhibition method. Reducing endogenous Ubc9 levels, which results in 
decreased SUMOylation, leads to synaptic and cognitive impairments similar to acute inhibition by TAT-
Ubc9(DN) proteins. However, there were a few interesting differences. Although not yet confirmed in 
additional samples, it appears that morpholino-mediated knockdown of Ubc9 leads to reductions in basal 
SUMOylation. This is in contrast to acute TAT-Ubc9(DN) treatment, which mainly affected stimulation-
induced SUMOylation changes. Both methods interfere with Ubc9 conjugating activity, one via decreased 
total expression and the other via dominant negative inhibition. However, the observation that TAT-
Ubc9(DN) does not decrease basal SUMOylation while morpholinos do may indicate: 1) TAT-Ubc9(DN) 
does not provide as strong of an inhibition effect, 2) distribution/localization of the inhibition effects differ,  
and/or 3) the observed SUMOylated proteins are relatively stably modified, requiring long-term Ubc9 
inhibition to induce basal changes. Further research will be necessary to investigate these possibilities.  
 
4.6.4 SUMOylated clathrin heavy chain 
 My preliminary data indicate that clathrin heavy chain is SUMOylated in vitro and in vivo in the 
brain. The finding is bolstered by the multiple previous studies which also detected SUMO2/3-modified 
CHC in cell lines. Although not yet confirmed, the potential SUMOylation site in the consensus motif 
located near the N-terminus of CHC is intriguing. The N-terminal β-propeller domains of CHC project 
inward, away from the polyhedral clathrin lattice. These terminal domains (TDs) have been found to be 
nodes for protein-protein interactions, for example, between the clathrin coat and the multitude of various 
adaptor proteins (Lemmon and Traub, 2012). These adaptor proteins are the components that dictate and 
regulate clathrin-mediated processes such as endocytosis. Adaptor protein complex 1 (AP-1) and adaptor 
protein complex 2 (AP-2) are the predominant adaptors involved in clathrin-coated vesicles from the 





which is involved in vesicle cycling and receptor trafficking, and AP180/CALM, which is involved in APP 
internalization. Both have well-characterized, direct clathrin TD interaction motifs.  
 SUMO modification of the clathrin TD can therefore have a potentially large impact on the 
regulation of clathrin-mediated processes. As a PTM, SUMOylation may disrupt and inhibit normal protein 
interactions and/or create new interaction surfaces. One can imagine that, via these mechanisms, clathrin 
SUMOylation may serve to regulate the interactions of adaptor proteins with the clathrin coat. 
SUMOylated clathrin may even introduce new functionality, via recruitment of downstream effectors with 
SUMO-interacting motifs (SIMs; see Chapter 2). Due to the tight involvement of clathrin with synaptic 
functioning, disrupting clathrin SUMOylation could potentially have large effects on synaptic transmission 
and network activity. And since clathrin-mediated endocytosis is also involved in APP processing in 
neurons (Cirrito et al., 2008), SUMO regulation could also impact Aβ physiology or Alzheimer’s pathology. 
  Future experiments will be needed to investigate these potential topics. In the immediate future, 
the specific SUMO conjugation site(s) of clathrin will be need to be confirmed and the TAT decoy 
peptides validated for inhibiting CHC SUMOylation. Should those experiments work out as hypothesized, 
the TAT decoy peptides can be tested for effects on synaptic transmission, synaptic plasticity, learning 
and memory and APP processing. It is certainly a possibility that SUMO-clathrin underlies at least part of 
the effects observed with the various Ubc9 inhibitors I have used. To support this, TAT-Ubc9(DN) and the 











Chapter 5  
 




Amyloid-β (Aβ) peptides are produced by the CNS in low picomolar amounts throughout life via 
mechanisms that can be regulated by synaptic activity. Aβ has been extensively studied as the 
pathological plaque-forming protein species in Alzheimer’s disease (AD). However, the normal 
physiological role(s) and signaling pathway(s) of Aβ peptides are currently unknown. When 
physiologically-relevant (low picomolar) amounts of Aβ are applied to acute hippocampal slices or directly 
in vivo, synaptic plasticity and memory are enhanced. Astrocytes, as crucial glial support cells with roles 
in modulating synaptic transmission, are potential cellular candidates for participating in this type of 
physiological Aβ signaling. To test this hypothesis, primary cultures of murine astrocytes were exposed to 
exogenous Aβ peptides while undergoing Fluo-4 calcium imaging. Since intracellular calcium transients 
constitute a primary mechanism of astrocyte activation, live calcium imaging was used to assay changes 
in astrocyte signaling. Upon addition of 200 pM Ab42 peptides, the percentage of astrocytes exhibiting 
spontaneous oscillatory calcium transients increased significantly by around three to fourfold. The 
periodicities of these transients were analyzed, and it was found that both the frequency and amplitude of 
the transients were enhanced after Aβ exposure. These effects were dependent on calcium influx and α7 
nicotinic acetylcholine receptors (α7-nAChRs), as the potentiation was blocked by a pharmacological α7 
inhibitor and in cultures from an α7 knockout mouse strain. In addition to spontaneous signaling, evoked 
intercellular calcium waves were also analyzed. After picomolar Aβ exposure, no significant changes 





maximum signal intensity. These results indicate that at physiological concentrations, Aβ peptides 
enhance spontaneous astrocyte calcium signaling via astrocytic α7-nAChRs. Since astrocyte-mediated 
"gliotransmission" has been found to have multiple neuromodulatory roles, Aβ peptides may have a 



























Astrocytes: Physiological Amyloid-β Signaling? 
The evidence from previous studies indicate that astrocytes can detect Aβ peptides and have 
complex regulatory signaling interactions, at least on a pathological level. However, can astrocytes also 
sense and respond to physiological amounts of Aβ peptides? 
To connect these cells to normal non-disease Aβ physiology, it is useful to examine what has 
been found for astrocytic interactions with other signaling molecules such as neurotransmitters. By 
considering these other examples, it is reasonable to hypothesize that astrocytes may sense 
physiological Aβ release at the synapse and respond with signaling that results in a feed-back modulation 
of neurotransmission. This sort of astrocyte-mediated signaling loop has indeed been demonstrated for 
glutamate, which undergoes regulated, calcium and SNARE-dependent exocytosis from vesicles in 
astrocytes (Haydon and Carmignoto, 2006). As an example, in the dentate gyrus area of the 
hippocampus, neuronal activity and synaptic glutamate release stimulate metabotropic glutamate 
receptors on nearby astrocytes, leading to activation and astrocytic glutamate release; this glutamate 
gliotransmitter then acts back on presynaptic NMDA receptors to increase the probability of release, thus 
causing an overall enhancement of the synapse (Jourdain et al., 2007). It is plausible that a similar type of 
feed-back signaling may underlie or contribute to the physiological neuromodulatory effects of Aβ 
peptides. 
 
α7 Nicotinic Acetylcholine Receptor 
This brings up additional questions – how do astrocytes detect physiological amounts of Aβ, and 
is there a specific receptor involved? Based on the background literature, one likely molecular candidate 
is the α7 nicotinic acetylcholine receptor (α7-nAChR). Nicotinic cholinergic receptors are pentameric 
assemblies that form ligand-gated cation channels and are expressed by both neurons and glia 
throughout the brain (Conejero-Goldberg et al., 2008; Gotti et al., 2007). Channel conductances vary by 





permeability to Ca2+ compared to the α4β2 subtype, the other major receptor variant in the brain. The α7 
receptor is expressed in high concentration in the hippocampus and has been well-studied for its ability to 
modify synaptic transmission (Gotti et al., 2007). In the picomolar Aβ studies from our lab, the Aβ-
mediated enhancement of synaptic transmission in hippocampal slices is specifically blocked by α7-
nAChR pharmacological antagonists and is not present in slices from α7 subunit knockout mice (Puzzo et 
al., 2008). In addition, the knockout mice also did not demonstrate memory enhancement when picomolar 
Aβ was administered in vivo. Significantly, other studies have found that Aβ peptides may either directly 
bind or indirectly affect α7-nAChRs with high picomolar affinity, consequently acting as either an agonist 
or antagonist, depending on Aβ concentration and experimental conditions (Oddo and LaFerla, 2006; 
Wang et al., 2000a; Wang et al., 2000b). With presumed physiologically-relevant picomolar 
concentrations, Aβ42 was found to bind to the receptor with very high affinity and induce sustained Ca2+ 
increases in hippocampal and neocortical nerve endings (Dougherty et al., 2003).  
With regards to astrocytes, immunohistochemical analyses have found astrocytic expression of 
α7-nAChRs in the hippocampus and cortex (Gahring et al., 2005; Graham et al., 2003), and 
electrophysiology and calcium imaging studies have demonstrated functional nicotinic receptors in 
astrocytes (Oikawa et al., 2005; Sharma and Vijayaraghavan, 2001). In cultured astrocytes and gliosome 
preparations, α7-nAChR activation leads to calcium elevation via calcium-induced-calcium-release 
(Sharma and Vijayaraghavan, 2001) and can result in glutamate release (Patti et al., 2007). These 
findings are supported by experiments with acute hippocampal slices, in which synaptic acetylcholine 
release leads to intracellular store-dependent calcium elevation in astrocytes (Araque et al., 2002). Thus, 
given that Aβ peptides are synaptically regulated and can potentially bind to α7-nAChRs with picomolar 
affinity, and given that these receptors are able to lead to astrocyte activation and gliotransmitter release, 
the α7-nAChR is well-poised to be a molecular link between physiological Aβ signaling and astrocyte-
mediated neuromodulation.  
In abnormal neurodegenerative states like Alzheimer’s Disease, such a neuromodulatory 
signaling mechanism could become dysregulated due to alterations in Aβ processing/aggregation, 





studies on human Alzheimer’s brain tissue, there is a selective increase in the expression of the α7 
subunit on astrocytes despite a general decrease in overall nicotinic receptor expression (Picciotto and 
Zoli, 2002; Teaktong et al., 2003; Teaktong et al., 2004; Yu et al., 2005). This finding was supported by 
an in vitro study which demonstrated a significant upregulation of the α7, α4 and β2 subunits in cultured 
astrocytes when exposed to Aβ42 peptides, even at low picomolar concentrations (Xiu et al., 2005). These 
findings demonstrate the impact of Aβ signaling on astrocytic nicotinic receptors; such effects could be 
based on the derailment of a normal physiological Aβ signaling pathway in astrocytes and may well 
contribute to Alzheimer’s pathology. By understanding the basic biology of Aβ peptides and the role of 





















5.3.1 Primary astrocyte cultures do not secrete Aβ42 peptides 
 For all experiments in this chapter, I used primary astrocyte cultures prepared from the forebrains 
of P0-P1 mouse pups. Almost no neurons survive the initial plating of cultures, although some microglia 
and oligodendrocytes may remain. To purify for astrocytes and remove these cells, I followed a standard 
established protocol that involves shaking the cultures overnight, which dislodges non-astrocyte cells 
(Parpura et al., 1995; Schell et al., 1995). When examined by immunocytochemistry with an antibody for 
glial fibrillary acid protein (GFAP), an astrocyte marker, the purified cultures were almost completely 
GFAP+ (Figure 5.3.1A). By light microscopy examinations, no neurons and very few microglia (phase-
dark) and oligodendrocytes (phase-bright) were present in purified cultures. The purified astrocytes plated 
on glass coverslips were readily loaded with the fluorescent Fluo-4 calcium imaging dye and consistently 
exhibited even homogenous loading distributions (Figure 5.3.1B).  
 
 
Figure 5.3.1.  Primary astrocyte cultures 
(A)  GFAP immunofluorescence of purified primary astrocyte cultures (12 DIV) prepared from P0-P1 
mouse forebrains 







 Before investigating the effects of exogenous Aβ peptides, I needed to first check if the astrocyte 
cultures endogenously secrete Aβ. Otherwise, the addition of extra amounts of Aβ may exceed what can 
be considered the range of physiologically-occurring Aβ concentrations, which has been previously 
determined to be in the low picomolar range in vivo (see Chapter 1). The issue of whether or not 
astrocytes can even express BACE and secrete Aβ peptides is also controversial, with a few studies 
reporting Aβ production by astrocytes under certain conditions (see Chapter 3). Using an ELISA for Aβ(x-
42) peptides with culture supernatants, I found that astrocyte cultures, either before or after purification, do 
not secrete significantly detectable amounts of Aβ42 (Figure 5.3.2A). This is in contrast to mixed neuron-
astrocyte co-cultures, which did have significant amounts of Aβ42 in the supernatants (~50-60 pM). I also 
examined the time course of Aβ production in the cultures, in case I were to do experiments with neuron-
astrocyte co-cultures. Prior to the start of an imaging session, the co-cultures had the expected ~60 pM 
Aβ42 concentration in the supernatant, and astrocyte cultures had negligible amounts (Figure 5.3.2B). 
Immediately after the culture media was replaced by imaging buffer wash-in, the Aβ42 concentration 
dipped to near zero, as expected. For an hour afterwards, which is approximately the length of a typical 
imaging experiment, the Aβ42 concentrations did not significantly increase for either culture type. 
Therefore, the addition of picomolar Aβ to these cultures does not exceed what can be considered 






Figure 5.3.2.  Primary astrocyte cultures do not secrete significant amounts of Aβ42 peptides 
(A)  Aβ(x-42) ELISA with culture supernatants from purified astrocyte cultures (14 DIV; n = 4), initial pre-
purification astrocyte cultures (7 DIV; n = 2), and mixed neuron-astrocyte co-cultures (14 DIV; n = 4).  
(B)  Aβ(x-42) ELISA with a time-course of supernatants collected: before the start of an imaging experiment 
(baseline), immediately after media removal and imaging buffer wash-in (time-point 0), 30 minutes into an 
imaging experiment, or 60 minutes into an imaging experiment. 
Data presented as means ± SEM. 
 
 
5.3.2 Calcium transient analysis  
 Spontaneous calcium transients and oscillations have been observed in astrocytes in vitro and in 
vivo and are likely involved in modulating neuronal activity (see Chapter 3). To study this type of calcium 
signaling, I used the Fluo-4 calcium indicator dye, which fluoresces when bound to calcium and is an 
improved version of the widely-used Fluo-3 dye. Compared to other common calcium dyes, Fluo-4 
exhibits increased intensity and dynamic range, which allows for lower concentrations in experiments thus 
minimizing potential interferences in calcium signaling (Gee et al., 2000).  
 Fluo-4-loaded astrocyte culture coverslips were imaged by confocal microscopy at a rate of 0.33 
Hz. Initially, I analyzed the movie files using ImageJ software (NIH) by manually selecting regions of 





included a relatively small subset of the total cell population in the imaging field (e.g. bigger cells, brighter 
cells, etc.). Therefore, I switched to MetaMorph analysis software (Molecular Devices), which has much 
more sophisticated thresholding and segmentation abilities. I created a script that parsed the entire image 
field and which was quite successful in automatically delineating cell ROIs (Figure 5.3.3A). Although a 
handful of cells were missed, and the segmentation was not perfect at defining every cell, I believe this 
method is superior to manual ROI selection – the entire image field and most cells are included in 
analyses, and there is no manual selection bias. I used this analysis method for all of the spontaneous 
calcium transient analyses in this chapter. 
 Since I did not find any commercial software packages suitable for analyzing large amounts of 
calcium transient data, I teamed up with a collaborator to program custom analysis software in Igor Pro 
(Wavemetrics). Using a defined set of parameters, the program automatically detected calcium transients 
above a certain threshold. I found that a threshold of a 40% (1.4 fold) increase was suitable for detecting 
most events. However, all analyses and automatic detections in the calcium traces were manually 
inspected and confirmed as well.  
 I observed a large variation in the types of calcium transients in the astrocyte cultures (Figure 
5.3.3B). While some cells had a single calcium transient event during the imaging session (usually 10 
minutes each), many others exhibited a distinct oscillatory-type calcium signaling. In general, the 
transients varied widely in amplitude and frequency. On average, in baseline control conditions, 
approximately 38% of the total cell population (out of an average 288 cells) had ~3 spontaneous calcium 
transients per 10 minute session, with an average amplitude of ~2.3 fold increase over the baseline 
signal.  
 It should be noted, however, that I sometimes observed significant decay in the signal amplitude 
over time, especially in the high-frequency oscillating astrocytes (Figure 5.3.3C). This may be due to 
photo-bleaching effects. Therefore, in the analyses and graphs of amplitude in this chapter, there is a 
noticeable decrease of the measure over the time-course of a imaging experiment; this is an experimental 










Figure 5.3.3.  Analysis of whole-cell spontaneous calcium transients in astrocyte cultures 
(A)  Example of a MetaMorph script outcome, for automatic segmentation and delineation of cell ROIs in 
a confocal movie file input. 
(B)  Example Fluo-4 calcium imaging traces from individual cell ROIs.  
Normalized intensity measure = ∆F / Fo  
(C)  Examples of decay of signal amplitude over time in some cells 
(Assisted by Pallav Kosuri in the programming of the analysis software.) 
 
 
5.3.3 Aβ42 effects on spontaneous astrocyte calcium transients 
 After establishing the analysis procedure, I investigated the effects of picomolar Aβ42 peptides on 
spontaneous calcium transient properties. The basic experimental protocol involved imaging Fluo-4-
loaded astrocyte cultures in 10 minute blocks for a total of 60 minutes. The initial block served as the 
baseline control against which later measurements were normalized. Prior to the next block, Aβ42 peptides 
(or the other treatments described in this chapter) were washed in. Data from the image analyses were 
averaged per each block (0.33 Hz imaging over 10 minutes). The measures I analyzed included: 
proportion of cells (out of the total imaged field) exhibiting spontaneous calcium transients, frequency of 
transients, and amplitude of transients. 
 For this first set of experiments, I used 200 pM synthetic human Aβ42 peptides, which has been 
previously demonstrated to enhance LTP and cognition in our lab (Puzzo et al., 2008). I tested both 
freshly prepared Aβ (DMSO solution of new peptide film) as well as oligomerized Aβ (aged overnight) and 
found that the fresh Aβ had significant potentiating effects on all three of the analyzed transient 
parameters (Figure 5.3.4). 200 pM fresh Aβ42 peptides induced increases in the proportion of actively 
signaling astrocytes as well as the frequency and amplitude of those calcium transients. However, aged 
oligomerized Aβ42 peptides did not have these effects. Since the fresh Aβ42 peptides were immediately 
diluted down to the pM range after re-suspension of the peptide film in DMSO, the majority of the 
peptides are likely in monomeric form (Stine et al., 2003). These results indicate that Aβ42 peptides, likely 







Figure 5.3.4.  Picomolar Aβ42 peptides enhance spontaneous astrocyte calcium transients 
(A)  Proportion of astrocytes exhibiting spontaneous calcium transients. Vehicle n = 19 (5411 cells), Aβ42 
monomeric 200 pM n = 20 (5845 cells), Aβ42 oligomeric 200 pM n = 17 (4798 cells) 
(B)  Frequency of spontaneous calcium transients.  
(C)  Amplitude of spontaneous calcium transients. 
Arrow indicates imaging block before which Aβ was added. Data presented as means ± SEM, all 
normalized to the baseline control block (first point on the graphs). 
 
 
5.3.4 Enhancement effects are specific for Aβ peptides 
 In order to verify that Aβ peptides are the molecules responsible for the enhancement of 
astrocyte calcium signaling (and not some other peptides or chemicals in the preparations), I tested an 
anti-Aβ monoclonal antibody, 6E10, in neutralization experiments. 6E10 is a widely-used Aβ antibody that 
recognizes the N-terminus of human Aβ peptides (a.a. 1-17). The antibody has been demonstrated to 
bind to monomeric and fibrillar Aβ (Dahlgren et al., 2002; Kayed et al., 2007). The antibody by itself did 
not significantly affect astrocyte calcium signaling (Figure 5.3.5). However, including 6E10 together with 
200 pM Aβ42 peptides (fresh monomeric preparation) inhibited the potentiation effects on all three 
parameters. Thus, Aβ peptides are the specific molecules responsible for the enhancement effects on 






Figure 5.3.5.  Enhancement of calcium transients is specific for Aβ peptides 
(A)  Proportion of astrocytes exhibiting spontaneous calcium transients. Vehicle n = 19 (5411 cells), Aβ42 
200 pM n = 20 (5845 cells), 6E10 n = 4 (1209 cells), Aβ42 200 pM + 6E10 n = 8 (2395 cells) 
(B)  Frequency of spontaneous calcium transients.  
(C)  Amplitude of spontaneous calcium transients. 
Arrow indicates imaging block before which Aβ/6E10 was added. Data presented as means ± SEM, all 
normalized to the baseline control block (first point on the graphs). 
 
 
5.3.5 Aβ40 peptides do not enhance calcium transients 
 In the brain, Aβ42 is a relatively minor Aβ species – Aβ40 is the common predominant form and is 
present at roughly ten times higher concentrations in vivo. Therefore, it is possible and even probable that 
Aβ40 peptides also have normal physiological signaling functions. I investigated their potential role in 
modulating astrocyte calcium signaling and found that, in contrast to Aβ42 peptides, Aβ40 peptides do not 
have the same enhancement effects on spontaneous calcium transients (Figure 5.3.6). There may be a 
potentiation of transient frequency by Aβ40 at the 20 and 30 minute blocks; however, these effects did not 
end up being statistically significant versus vehicle by ANOVA (Figure 5.3.11). In these experiments, Aβ42 






Figure 5.3.6.  Aβ40 peptides do not significantly affect astrocyte whole-cell calcium transients 
(A)  Proportion of astrocytes exhibiting spontaneous calcium transients. Vehicle n = 19 (5411 cells), Aβ42 
200 pM n = 20 (5845 cells), Aβ40 200 pM n = 6 (1723 cells). 
(B)  Frequency of spontaneous calcium transients.  
(C)  Amplitude of spontaneous calcium transients. 
Arrow indicates imaging block before which Aβ was added. Data presented as means ± SEM, all 
normalized to the baseline control block (first point on the graphs). 
 
 
5.3.6 Spontaneous astrocyte calcium transients require calcium influx 
 Astrocyte calcium signaling can involve different mechanisms and calcium sources, including IP3-
regulated intracellular calcium stores and calcium-induced calcium release (CICR) that stimulates 
ryanodine receptor-gated stores (see Chapter 3). In order to determine if calcium influx is involved in the 
Aβ-mediated potentiation of astrocyte calcium signaling, I tested imaging buffer that did not have calcium. 
Wash-in of this Ca2+-free buffer eventually eliminated calcium transient signaling and prevented the 






Figure 5.3.7.  Enhancement of spontaneous transients depends on calcium influx 
(A)  Proportion of astrocytes exhibiting spontaneous calcium transients. Vehicle n = 19 (5411 cells), Aβ42 
200 pM n = 20 (5845 cells), Ca2+-free n = 3 (891 cells), Aβ42 200 pM + Ca2+-free n = 4 (1179 cells) 
(B)  Frequency of spontaneous calcium transients.  
(C)  Amplitude of spontaneous calcium transients. 
Arrow indicates imaging block before which Aβ/Ca2+-free buffer was added. Data presented as means ± 
SEM, all normalized to the baseline control block (first point on the graphs). 
 
 
5.3.7 Primary astrocyte cultures express the α7 nAChR subunit 
 As previously discussed, the α7 nicotinic acetylcholine receptor (α7-nAChR) has been found to 
be involved in picomolar Aβ signaling and can lead to CICR-mediated calcium elevations in astrocytes. 
To verify that my primary astrocyte cultures do express the α7 nAChR subunit, I used a polyclonal anti-α7 
antibody in immunofluorescence and western blot analyses of the cultured astrocytes. In the 
immunofluorescence study, I observed positive labeling of astrocytes in a punctate distribution (Figure 
5.3.8A). Similarly, the western blots also demonstrated strong positive bands at the right molecular weight 
of the α7 subunit (Figure 5.3.9B). Curiously, the astrocyte cultures had a doublet band pattern while adult 
brain tissues had a single band; it is unclear why there are two bands but a similar doublet α7 pattern has 
been previously observed in mammalian cell cultures (Williams et al., 2005).  
 However, a big caveat to these observations is the possible non-specificity of the α7 antibody. A 





even in α7 knockout mice (Herber et al., 2004). Although the specific antibody I used was not tested in 
that study, preliminary data from our lab indicates that this antibody also appears to have non-specific 
binding in α7 knockout mice. To get around this problem, I used α-bungarotoxin, a known specific 
antagonist of α7-nAChRs instead. Live cell-surface labeling of cultures with fluorophore-conjugated 
(Alexa Fluor 594; Invitrogen) α-bungarotoxin revealed strong punctate staining of cultured hippocampal 
neurons, as expected (Figure 5.3.8C). And in my purified astrocyte cultures, I also observed significant 
labeling in a punctate pattern. Along with the previous studies which demonstrated functional α7-nAChRs 
on astrocytes, I concluded that my astrocyte cultures do express cell-surface α7-nAChRs, which may 
therefore be a potential source for calcium influx involved Aβ signaling. 
 
 
Figure 5.3.8.  Primary astrocyte cultures express the α7 nAChR subunit 
(A)  Immunocytochemistry with an α7 nAChR subunit antibody (Chemicon/Millipore). Fluorescence 
microscopy picture (left) and confocal microscopy picture (right) of labeled astrocytes. 
(B)  Western blot of astrocyte cultures and adult brain tissues with an α7 nAChR subunit antibody. Lane 
1: astrocyte culture, non-reducing sample buffer, lane 2: astrocyte culture, reducing sample buffer, lane 3: 
adult cortical tissue, lane 4: adult hippocampal tissue. 
(C)  Live cell-surface labeling of neuron (left) and astrocyte (right) cultures with Alexa Fluor 594-





5.3.8 Aβ-mediated enhancement is dependent on α7-nAChR7s 
 I investigated the possible involvement of α7-nAChRs in astrocyte Aβ signaling with both a 
pharmacological agent and an α7 knockout mouse line. Methyllycaconitine (MLA) is a potent α7-nAChR 
antagonist which has stronger affinity and higher-specificity binding compared to α-bungarotoxin (Davies 
et al., 1999). When I washed in 200 pM Aβ42 peptides with MLA, most of the enhancement effects on 
calcium transients were abolished (Figure 5.3.9). Only the potentiation of amplitude in the 60 minute block 
was not reversed by MLA (Figure 5.3.12E).  
 Using astrocyte cultures obtained from an α7 knockout mouse line, I also obtained similar results. 
This α7 knockout has a targeted deletion of the last three exons of the α7 subunit gene; brains from these 
mice lack α-bungarotoxin and nicotine binding sites, and neurons do not have nicotine-induced currents 
(Orr-Urtreger et al., 1997). This same mouse line was previously used in our lab to demonstrate that the 
picomolar Aβ-mediated enhancement of LTP and memory is dependent on α7-nAChRs (Puzzo et al., 
2008). However, the cellular location of the necessary α7-nAChRs has not been determined. My 
hypothesis is that astrocytic α7-nAChRs are involved in the Aβ signaling that underlies its nootropic 
effects. Indeed, supporting this hypothesis, 200 pM Aβ42 peptides no longer had enhancing effects on 







Figure 5.3.9.  Enhancement of calcium transients by Aβ42 peptides depends on α7-nAChRs 
(A)  Proportion of astrocytes exhibiting spontaneous calcium transients. Vehicle n = 19 (5411 cells), Aβ42 
200 pM n = 20 (5845 cells), Aβ42 200 pM + MLA n = 13 (3929 cells), α7 knockout (KO) n = 5 (1505 cells), 
α7 knockout + Aβ42 200 pM n = 9 (2801 cells). 
(B)  Frequency of spontaneous calcium transients.  
(C)  Amplitude of spontaneous calcium transients. 
Arrow indicates imaging block before which Aβ/MLA was added. Data presented as means ± SEM, all 

















5.4.9 Summaries of Aβ42-mediated enhancement of astrocyte calcium transients 
 In summary, 200 pM Aβ42 peptides can potentiate multiple parameters of spontaneous astrocyte 
calcium transients. The proportion of active cells that exhibit these transients was significantly increased 
by Aβ42 starting from the 30 minute imaging block and lasting until the end of the experiment (Figure 
5.3.10). This effect was prevented by the 6E10 Aβ antibody, Ca2+-free buffer, MLA α7-nAChR antagonist 
and in α7 subunit knockout astrocytes.  
 Similarly, the frequency of the calcium transients and oscillations was significantly increased by 
Aβ42 starting from the 40 minute imaging block (Figure 5.3.11). Interestingly, the MLA + Aβ42 group had a 
significantly decreased number of transients during the 20 minute block so inhibiting astrocytic α7-
nAChRs may have an independent effect on calcium transients (but this issue has not yet been further 
explored).  
 The amplitude of calcium transients was also significantly potentiated by Aβ42 starting from the 30 
minute imaging block (Figure 5.3.12). The only other statistically significant comparison in the ANOVA 
was the Aβ + MLA group; the concurrent MLA treatment did not prevent the amplitude enhancement 
during the 60 minute block (Figure 5.3.12E). Overall, these data support the existence of α7-nAChR-
dependent astrocyte calcium signaling pathways that are responsive to Aβ peptides at physiologically-










Figure 5.3.10.  Summary of 200 pM Aβ42 effects on the proportion of active astrocytes 
(A)  Effects on proportion of astrocytes exhibiting calcium transients during the 20 minute imaging block 
(immediately after Aβ/treatment wash-in). 
(B)  Effects on proportion during the 30 minute imaging block. 
(C)  Effects on proportion during the 40 minute imaging block. 
(D)  Effects on proportion during the 50 minute imaging block. 
(E)  Effects on proportion during the 60 minute imaging block. 
Data presented as means ± SEM, all normalized to the 10 minute baseline control block. 




















Figure 5.3.11.  Summary of 200 pM Aβ42 effects on the frequency of calcium transients in active 
astrocytes 
(A)  Effects on calcium transient/oscillation frequency during the 20 minute imaging block (immediately 
after Aβ/treatment wash-in). 
(B)  Effects on frequency during the 30 minute imaging block. 
(C)  Effects on frequency during the 40 minute imaging block. 
(D)  Effects on frequency during the 50 minute imaging block. 
(E)  Effects on frequency during the 60 minute imaging block. 
Data presented as means ± SEM, all normalized to the 10 minute baseline control block. 






















Figure 5.3.12.  Summary of 200 pM Aβ42 effects on the amplitude of calcium transients of active 
astrocytes 
(A)  Effects on calcium transient/oscillation amplitude during the 20 minute imaging block (immediately 
after Aβ/treatment wash-in). 
(B)  Effects on amplitude during the 30 minute imaging block. 
(C)  Effects on amplitude during the 40 minute imaging block. 
(D)  Effects on amplitude during the 50 minute imaging block. 
(E)  Effects on amplitude during the 60 minute imaging block. 
Data presented as means ± SEM, all normalized to the 10 minute baseline control block. 
















5.3.9 Preliminary data: glutamate gliotransmitter 
 Activated astrocytes can impact neuronal functioning and synaptic transmission through the 
release of gliotransmitters, which include glutamate, ATP and D-serine (see Chapter 3). To investigate 
the possibility that calcium transient potentiation by picomolar Aβ42 peptides may result in gliotransmitter 
release, I conducted a preliminary experiment to measure glutamate concentrations in culture 
supernatants. I collected samples of the supernatant at various time-points before and after exposure to 
200 pM Aβ42 peptides. While there seemed to be a general decrease in glutamate concentration with time 
(in imaging buffer), possibly due to glutamate transporter activity, there were no significant differences 
between vehicle and Aβ groups (Figure 5.3.13). However, these are preliminary pilot experiment data. It 
is possible that the glutamate assay (Invitrogen Amplex) is not sensitive enough to pick up small changes 
in concentration; I tried to use the minimal buffer volume possible but the bulk supernatant sampling 
method may not be appropriate for this type of experiment. Future research should involve testing 




Figure 5.3.13.  Glutamate concentration assay 
Culture media/imaging buffer supernatant of astrocyte cultures collected before or at various time-points 
after exposure to 200 pM Aβ42 peptides. Pre = basal culture media, 0 = immediately after switch to 





5.3.10 Evoked intercellular calcium waves 
 Besides spontaneous calcium transients and oscillations, intercellular calcium waves have also 
been observed in astrocyte cultures and brain slices (see Chapter 3). One method of evoking calcium 
waves is by deformation of the cell membrane via a light mechanical stimulus using a glass micropipette 
electrode (Charles et al., 1991; Innocenti et al., 2000; Scemes and Giaume, 2006). A large increase in 
cytosolic calcium levels spreads radially from the contacted astrocyte to neighboring astrocytes, 
eventually encompassing most of the cells in the imaging field, with calcium elevations that can last 
several minutes (Figure 5.3.14). Although this is not a physiological stimulus, the method allows for the 
temporally and spatially-controlled induction of an intercellular calcium signaling event.  
In order to analyze the calcium waves, my collaborator assisted me in creating another custom 
analysis program in Igor Pro (Wavemetrics). I generated distance-time histogram maps of the calcium 
waves which allowed visualization of the intensity as well as the spatial and temporal spread (Figure 
5.3.15). In general, as with the spontaneous transients, there was significant variation in the evoked wave 











Figure 5.3.14.  Evoked intercellular calcium wave in cultured astrocytes 
Example time-lapse series of a mechanically-evoked intercellular calcium wave in an astrocyte culture. 











Figure 5.3.15.  Distance-time maps of astrocyte calcium waves 
Example distance-time histogram analysis maps of evoked calcium waves in astrocyte cultures. Time is 
plotted on the y-axis, and distance from the wave initiation point is plotted on the x-axis. Fluo-4 calcium 
dye fluorescence intensity (normalized) is represented by the heat map colors. 






5.3.11 Intercellular calcium waves are not affected by Aβ42 peptides 
 To investigate how Aβ42 peptides may impact astrocyte calcium waves, I applied Aβ for 20 
minutes to the culture prior to inducing waves with a light mechanical stimulus (contact with a patch 
micropipette). I tested both the 200 pM concentration as well as a much higher 200 nM concentration of 
oligomerized Aβ42. The 200 nM concentration is well-documented by our lab and others to cause 
pathological effects on synaptic function and cognitive performance. Since the only observed instances of 
astrocyte calcium waves in vivo were in aged APP/PS1 transgenic mice (see Chapter 3), it is possible 
that waves represent a pathological signaling event and thus are more likely to be affected by high Aβ 
levels than low picomolar amounts. However, in my analyses, I did not detect any significant differences 
between the Aβ and vehicle groups in several calcium wave parameters: distance travelled, time span, 
velocity and maximal calcium signal intensity (Figure 5.3.16). Thus, at least on this first-pass analysis, 
Aβ42 peptides at either physiological or pathological concentrations do not significantly affect evoked 






Figure 5.3.16.  Calcium wave parameters are not significantly affected by Aβ42 peptides 
(A)  The distance travelled by calcium waves is not significantly affected by Aβ42 peptides at either 200 pM 
or 200 nM concentrations. Vehicle n = 11, 200 pM n = 12, 200 nM n = 6. 
(B)  The time span of calcium waves is not significantly affected by Aβ42 peptides. 
(C)  The velocity of calcium waves is not significantly affected by Aβ42 peptides. 
(D)  The maximum Fluo-4 intensity of calcium waves (normalized to baseline) is not significantly affected 
by Aβ42 peptides. 










5.4.1 Astrocyte calcium signaling in Aβ pathology 
 In this study, I have demonstrated that picomolar amounts of Aβ, such as occurs in vivo in the 
healthy brain, can be detected by astrocytes which then respond with enhanced calcium transient 
signaling. Since it has previously been demonstrated that very high, pathological concentrations of Aβ 
can lead to aberrant astrocyte calcium signals (see Chapter 3), it is likely that such pathology-related 
events represent dysfunction of underlying physiological pathways. As an example illustrating this point, 
after I had started this project, another study was published using in vivo calcium imaging of astrocytes in 
APP/PS1 transgenic mice (Kuchibhotla et al., 2009). In that study, spontaneous astrocyte calcium 
transients were analyzed in young pre-plaque mice and older mice with amyloid plaques. In the relatively 
aged mice (6-8 months old), it was observed that: 1) global calcium levels were elevated in astrocytes, 2) 
proportion of actively-signaling astrocytes was increased, 3) amplitudes of the transients were increased, 
and 4) synchrony of the transients (and rare intercellular calcium waves) were enhanced. Two of those 
findings (increased proportion and amplitudes) are in line with what I observed in my experiments, in 
terms of direction and magnitude of the effects. These similarities could be interpreted to mean that Aβ-
related pathology in astrocytes represents a hijacking of normal Aβ signaling pathways. The chronically 
high concentrations of Aβ peptides in the transgenic mice could lead to continous activation of astrocytes, 
an abnormal process that could contribute to the disease state. Since the astrocyte effects were not 
observed in younger APP/PS1 mice that had not yet developed plaques (3 months old), there may be a 
degree of resistance in the astrocytes early on to high Aβ levels.  
Regarding the two other main results from that study,  I was not able to directly assess absolute 
intracellular calcium concentrations in my experiments with Fluo-4 since it is not a ratiometric dye and 
also undergoes significant photobleaching. However, increased spatiotemporal synchrony is a parameter 
that can be investigated in future second-pass analyses with my data set. In addition, the rarity of in vivo 
intercellular calcium waves in the APP/PS1 study, which were observed to occur only in older transgenic 





therefore, Aβ in low physiologically-relevant amounts is not likely to impact this type of pathological 
signaling, as evidenced by my calcium wave results.  
 
5.4.2 Potential future experiments  
 In addition to spatiotemporal synchrony, other parameters of calcium transient signaling could 
also be investigated in future analyses of the data set. For example, analogous to spontaneous activity in 
neurons, the parameters of rise time, decay time and duration could be analyzed for effects by 200 pM Aβ 
peptides.  
 There are also many possibilities for additional future experiments based on my findings. For 
example, the specific molecular mechanisms underlying the Aβ effects on spontaneous calcium 
transients can be elucidated with various pharmacological treatments. Astrocyte calcium transients have 
been previously determined to involve intracellular calcium store release, via either the IP3 or ryanodine 
pathways. In particular, α7-nAChRs on astrocytes have been shown to lead to calcium elevations via 
calcium-induced calcium release (CICR) from ryanodine-sensitive stores (Sharma and Vijayaraghavan, 
2001). It would therefore be interesting to investigate if the α7-nAChR involvement I observed does 
indeed lead to release from intracellular calcium stores via ryanodine receptors and CICR; if verified, that 
would indicate that picomolar Aβ modulates astrocyte signaling by known physiological signaling 
pathways.  
 I would also be interested in further examining the issue of Aβ40 and astrocyte signaling. As the 
predominant Aβ isoform in vivo, I have not abandoned my hypothesis that this peptide can be detected by 
astrocytes and affect calcium signaling. The concentration of Aβ40 that I tested in my earlier experiments 
was the same 200 pM used for the Aβ42 peptides. However, in the brain, Aβ40 is normally present at ~10x 
the concentration of Aβ42 so it is possible that the 200 pM concentration is too low to impact astrocyte 
signaling. It would therefore be interesting to test additional concentrations of Aβ40 peptides.  
 Another area that requires additional research is the gliotransmission issue. My preliminary data 





discussed, the bulk-supernatant assay format may not be sensitive enough to detect small changes in 
glutamate release. There are multiple other possible techniques for glutamate detection which offer 
higher-resolution sensitivity. For example, glutamate release can be directly imaged with a NAD+ 
reduction assay (by L-glutamic dehydrogenase) that results in a UV-fluorescent NADH product. This 
method has been previously used to image glutamate release patterns in astrocyte cultures (Innocenti et 
al., 2000). Another possible technique that offers both high temporal and spatial resolution involves 
biosensor glutamate “sniffer” cells; these are HEK293 cells that have been transfected with an AMPAR 
subunit, GluR1, containing a point mutation (L497Y) that prevents receptor desensitization. By plating 
these cells on top of astrocyte cultures, these sniffer cells offer access points for patch-clamp recordings 
which reflect local glutamate release. This method has also been previously used to measure glutamate 
release in astrocyte cultures (Lee et al., 2007a). Alternatively, it may be that glutamate is not the 
gliotransmitter that is released by Aβ signaling in astrocytes. Other possibilities include ATP, D-serine, 
cytokines (e.g. TNFα) and neurotrophins (e.g. BDNF) (see Chapter 3).  
 Ultimately, the goal of these experiments and the project in general is to examine if astrocytes are 
involved in the enhancement of synaptic plasticity and memory by picomolar Aβ. With the culture system, 
this could be accomplished by investigating the potentiating effects of Aβ peptides on patch-clamped 
single-neuron LTP. Then by producing co-cultures of neurons and astrocytes of mixed wild-type and α7 
knockout genotypes, the specific involvement of astrocytes and astrocytic α7-nAChRs in any Aβ 
neuromodulatory effects could be determined (e.g. wild-type neurons on α7 knockout astrocytes). The 
relative ease of making mixed co-cultures is an advantage of the in vitro culture system. In vivo, this could 
potentially be accomplished with an astrocyte-targeted Cre/Lox-mediated α7 knockout; such a mouse 
would enable experiments to test the involvement of astrocyte α7-nAChRs in the picomolar Aβ-mediated 






5.4.3 Note on limitations  
As a side note, there are certain limitations to this study that I would like to mention. For one 
thing, astrocyte cultures do not represent a physiological context and are lacking other components, such 
as neurons and microglia, which may influence physiological Aβ signaling effects. Cultured astrocytes 
also lose important morphological characteristics such as the fine 3D branching processes which contact 
synapses in situ. However, while it’s certainly possible that such limitations may affect the results (a 
situation that would apply to most culture models), purified astrocyte cultures have been successfully 
used to discover many astrocytic signaling mechanisms that have later been confirmed in slices and in 
vivo. I view my study as an initial first step towards the investigation of physiological Aβ signaling 
pathways in astrocytes – I have demonstrated that astrocytes can detect and respond to picomolar 
amounts of Aβ, and future studies will determine if the specific effects I observed (e.g. in the parameters 
of proportion, frequency, amplitude) are manifested with in situ preparations as well. A second factor to 
consider is the use of the Fluo-4 indicator dye, which necessarily involves some amount of calcium 
buffering. In a previous study, the use of a high concentration (20 µM) of Fluo-4 reduced the number of 
astrocytes with spontaneous calcium signaling (Parri and Crunelli, 2003). Although I used a much lower 
dye concentration (4 µM), certain aspects such as the magnitude of the calcium effects I observed may 
not reflect actual physiological values. However, the use of calcium-binding indicators is unavoidable in 
these types of studies; based on previous validated findings from calcium imaging studies, it is likely that 













Chapter 6  
 
Conclusion and Future Directions 
 
 
6.1 Aβ Physiology and Pathology in Alzheimer’s Disease 
 Almost three decades after its discovery, and over a hundred years after the initial 
characterization of Alzheimer’s disease (AD), the amyloid-β (Aβ) peptide has retained a large part of its 
enigma. Although much has been discovered about the pathological processes caused by Aβ, especially 
with high concentrations and aggregated forms, a great deal remains unknown. As a primary molecular 
culprit underlying AD, Aβ has remained in the spotlight of both basic research and drug discovery efforts. 
However, despite many successful preclinical animal model findings and multiple not-so-successful 
clinical trials testing Aβ-targeted therapeutics, the “amyloid cascade hypothesis” has yet to be truly 
validated. Multiple large-scale clinical trial failures later, there are still no effective treatments for slowing 
the progression of AD. Is this due to a lack of full understanding of Aβ biology and pathology?  
That does seem to be the case, since there are multiple key questions that remain unanswered 
despite a great deal of research effort. What initiates pathological Aβ processes in AD, including its 
aggregation into neurotoxic oligomer forms? Can targeting Aβ, whether in its soluble or insoluble states, 
stop or even reverse disease processes? If so, when should the intervention be administered? Those are 
the major preoccupying questions in the field although another is equally important, with significant 
clinical implications, but is not often addressed: What are the normal physiological functions of Aβ 
peptides, and could loss-of-function partially account for AD pathology in addition to toxic gain-of-
function? Importantly, given the predominance of anti-Aβ strategies in AD drug development, how should 





physiology of Aβ is as important as its pathology, in part because the latter is likely dependent to some 
degree on the former. We need to understand both how Aβ peptides, as aggregates or otherwise, lead to 
neurotoxicity as well participate in normal signaling processes. Aβ pathology has been the focus of a 
much larger body of research, but it is important to keep in mind that dysfunction of normal physiology 
may at least partially underlie Aβ-mediated pathological processes.  
For my thesis, I have addressed both sides of this issue by investigating the impact of 
pathological high concentrations of Aβ oligomers as well as physiologically-relevant picomolar amounts of 
Aβ on cellular signaling pathways. Although I have performed these studies using different model 
systems and cell/tissue types, both provide findings that enlighten understanding of Aβ involvement in 
AD. Ultimately, I believe fuller knowledge from both ends of the spectrum, physiology to pathology, will be 
required to enable truly successful therapeutics for Alzheimer’s disease.  
 
6.2 Picomolar Aβ effects on astrocyte calcium signaling 
 For physiological Aβ signaling, I chose to investigate astrocytes since I hypothesized that these 
cells can respond to synaptically-released Aβ in a similar manner as with neurotransmitters. The latter 
has been well-documented, with initial characterizations in primary astrocyte cultures treated with 
exogenous neurotransmitter (glutamate) application. Therefore, I sought to use those experiments as a 
template for this project in investigating the effects of exogenous Aβ. From a large body of research, there 
is solid evidence that astrocytes can detect and respond to Aβ at high concentrations and aggregated 
forms. I have now demonstrated in my study that astrocytes can also detect Aβ at a physiologically-
relevant picomolar concentration and respond with enhanced spontaneous calcium signaling.  
This type of spontaneous signaling has been found in acute hippocampal slices as well as in vivo; 
it has been estimated that up to ~50-65% of astrocytes in situ exhibit spontaneous calcium signaling 
events or oscillations that are independent of neuronal activity (Hirase et al., 2004; Nett et al., 2002). 
Such intracellular calcium elevations in astrocytes have been previously found to cause multiple 
neuromodulatory effects in nearby neurons, including increased frequency of miniature postsynaptic 





particular, SICs in hippocampal CA1 neurons were found to be synchronized by glutamate released 
during spontaneous astrocyte calcium elevations (Angulo et al., 2004; Fellin et al., 2004). Thus, any 
alterations of spontaneous calcium signaling in astrocytes could have significant effects on the excitability 
of a large number of neurons. With 200 pM Aβ peptides, I observed increased proportion, frequency and 
amplitude of spontaneous calcium signals. Although these culture findings likely cannot be directly 
extrapolated to the brain, they do indicate that Aβ can enhance calcium signaling at concentrations that 
an astrocyte in vivo would encounter. This enhanced calcium signaling could increase gliotransmission, 
for example in mediating synchronized SICs, which could then have modulatory effects on synaptic 
plasticity and higher-order network functions within the local circuit. 
 It would eventually be very interesting to examine picomolar Aβ signaling effects on a much more 
localized scale as well, within individual astrocytic processes in situ. With advanced imaging methods, 
astrocytes have recently been demonstrated to have rapid miniature calcium transients that can be highly 
confined to functional microdomains within a process (Di Castro et al., 2011; Panatier et al., 2011). These 
mini calcium events likely reflect local single-synapse activity and support the involvement of tripartite 
astrocytes in modulating elementary synaptic transmission. In my study, I have analyzed whole-cell 
spontaneous calcium transients, which is just one type of astrocyte calcium signaling. Aβ may also exert 
modulatory effects on microdomain calcium signaling and highly-localized gliotransmission. This seems 
like a probable hypothesis, since Aβ peptides can undergo synaptic activity-regulated release, likely at or 
near synaptic terminals (Cirrito et al., 2008). Thus, astrocytic processes, which are intimately associated 
with synapses, are perfectly positioned to sense the synaptically-released Aβ peptides, which in the 
synaptic cleft may reach even higher concentrations than has been measured by interstitial fluid 
microdialysis. It seems probable and even likely that this localized Aβ release may regulate mini 
astrocytic calcium transients, potentially via α7-nAChRs as well.  
My finding that picomolar Aβ enhancement of calcium transients depends on astrocytic α7 
nicotinic acetylcholine receptors (α7-nAChRs) also raises interesting questions. The α7-nAChR has been 
previously identified as a potential Aβ binding partner, with a high affinity in the picomolar range (Wang et 





that the Aβ peptides bind to the α7-nAChRs on the astrocytes and modulate calcium signaling via calcium 
induced calcium release. In the AD brain, despite marked reductions in acetylcholine receptors and loss 
of cholinergic neurons, α7-nAChRs have been observed to be selectively upregulated in astrocytes in the 
hippocampus and entorhinal cortex (Teaktong et al., 2003; Teaktong et al., 2004). Interestingly, this was 
not observed in another common neurodegenerative disease, dementia with Lewy bodies, that is also 
characterized by cholinergic deficits; thus, the astrocytic α7-nAChR upregulation is not just a general 
homeostatic compensation. If the signaling model that I posited is correct, then the increased astrocytic 
α7-nAChR expression in AD would result in aberrantly increased calcium signaling events. The 
downstream effects are difficult to predict, but they may include abnormal gliotransmission and 
dysregulated synaptic transmission. AD, after all, is primarily a disease of synaptic failure and involves 
marked deficits in plasticity; given what is known about astrocyte modulation of synaptic function, it is 
highly plausible that abnormal astrocyte activity, manifested in altered calcium signaling, is involved in the 
synaptic impairments. As previously discussed (see Chapter 5), a live calcium imaging study in APP/PS1 
mice supports this model (Kuchibhotla et al., 2009). I propose that their findings of pathologically-
increased astrocyte calcium signaling in the transgenic mice represent dysfunction of a normal 
physiological Aβ signaling pathway in astrocytes, as evidenced by my data.  
My study illustrates how knowledge of a potentially physiological Aβ function can be used to 
better understand a pathological Aβ-related process. Eventually, astrocytes could be a potential cellular 
target for AD drug development. These cells are involved in many facets of AD pathology, from 
inflammation and oxidative stress to potentially dysfunctional gliotransmission. Further elucidating the 
pathways of both physiological and pathological Aβ signaling in astrocytes is important for understanding 
AD and finding ways to successfully and fully treat the disease.  
 
6.3 SUMOylation in synaptic plasticity and memory 
 I have also investigated pathological Aβ signaling effects on another cell signaling pathway – the 





SUMOylation in normal synaptic plasticity and memory, since almost nothing was known about this topic. 
I will start with my thoughts on the normal physiology of SUMO in neurons before discussing the impact of 
Aβ on those processes. 
As a relatively new post-translational modification (PTM), SUMO has been gaining increasing 
traction beyond the nuclear and genomic fields in which it was initially characterized. In neuroscience, 
SUMO has recently gained recognition as a potentially important regulator of neuronal and synaptic 
function; multiple neuronal proteins have now been identified as SUMOylated substrates. Thus far, 
SUMO appears to have similar roles as other PTMs such as phosphorylation and ubiquitination – by 
altering a protein’s topology and downstream interactions with other proteins, SUMOylation can regulate 
function, localization and stability. With such diverse potential roles in a large variety of proteins, SUMO is 
positioned to be a key regulator of synaptic transmission and plasticity. 
 In my study, I have discovered that SUMOylation is indeed critically involved in long-term synaptic 
plasticity and memory formation in the hippocampus. The overall global increase in SUMOylation upon 
stimulation is reminiscent of similar changes observed in protein phosphorylation with plasticity induction 
(see Chapter 4.4). The regulation of the two PTMs in this situation may actually be causally-linked since 
SUMOylation and phosphorylation can directly and indirectly interact. For example, with phosphorylation-
dependent SUMO modification (PDSM; see Chapter 2), initial changes in phosphorylation can directly 
regulate SUMO conjugation of the same protein. In my KCl stimulation experiments, I observed a 
maximal increase in SUMOylation around the 5 minute post-stimulation time point, with no detected 
changes at earlier time points. However, plasticity-induced phosphorylation is a much earlier event, with 
significant increases detectable in the first minute after stimulation (including by high KCl) (Siciliano et al., 
1994). Therefore, it is interesting to speculate that early changes in phosphorylation may dictate, at least 
partially, the subsequent modification(s) by SUMO via PDSM. And since SUMOylation has been found to 
regulate multiple kinases and phosphatases, there is the potential for high-complexity cross-talk 
regulation between the PTMs in synaptic plasticity processes. 
 In addition, it has also recently been discovered that Ubc9 can be phosphorylated by a 





Phosphorylation of Ubc9 enhanced its SUMO conjugation activity by increasing the formation of the 
Ubc9-SUMO thioester complex. Cdk1 is a kinase that is predominantly involved in mitosis; however, it is 
not a far stretch to imagine that Ubc9 may also undergo phosphorylation by other kinases that are active 
at the synapse. In my experiments, I did not observe any changes in Ubc9 protein levels with stimulation. 
While that does not rule out changes in localized Ubc9 levels in synaptic microdomains (e.g. altered Ubc9 
distribution), net changes in Ubc9 levels do not account for the SUMOylation effects I observed. However, 
it is entirely possible that phosphorylation of Ubc9 may partially underlie activity-dependent SUMOylation. 
Future experiments will be necessary to investigate these possibilities.  
 Another interesting point to note is that the SUMOylation effects I observed mostly involved 
SUMO2/3. The global SUMO changes after KCl and theta-burst stimulation occurred predominantly with 
high-molecular weight SUMO2/3 conjugates; in contrast, I observed minimal changes in SUMO1 
conjugation levels. In the SUMO field, a majority of previous studies, including those in neurons, 
investigated SUMO1 conjugates. In large part, however, this was due to a seeming lack of attention to 
SUMO2/3, which were the relative latecomers in the field. SUMO1 (and the yeast homolog Smt3) was the 
first-discovered SUMO paralog and has retained the focus in most SUMOylation studies. However, it is 
interesting to note that in mammalian cells, the free pool of unconjugated SUMO2/3 is much larger than 
that of SUMO1 (Saitoh and Hinchey, 2000); in an early estimate, using the COS-7 cell line, there was ~50 
times more free SUMO2/3 than SUMO1. In my own experiments with mouse brain tissues, I have 
confirmed this paralog asymmetry. Thus, it appears that conjugation by SUMO2/3 likely has a larger 
dynamic capacity compared to SUMO1, which may make SUMO2/3 a more appropriate candidate for 
rapidly-regulated processes such as synaptic plasticity. In addition, a previous study found that SUMO1 
conjugation dynamics are much slower compared to SUMO2/3 (Ayaydin and Dasso, 2004). Supporting 
this observation, SUMO1 deconjugation is mediated by mostly by SENP1 and, with lower efficiency, 
SENP2. In contrast, all of the known SENP proteases (SENPs 1, 2, 3, 5, 6, 7) have activity for SUMO2/3 
(Mukhopadhyay and Dasso, 2007; Shen et al., 2009). These results indicate that modification by 





In addition, SUMO2/3 can conjugate to itself via a SUMO consensus site that is not present in 
SUMO1. Although the exact function(s) of these polymeric SUMO2/3 chains versus monomeric 
conjugation remain unclear, there is evidence to suggest that poly-SUMO chains may dictate downstream 
specificity via effector proteins containing multiple SUMO interaction motifs (Tatham et al., 2008). In my 
study, the changes I observed in the high molecular weight region likely include various poly-SUMOylated 
proteins, which may be especially labile to changes in SUMO regulation. Recently, the lack of effect in 
SUMO1 conjugation after high-KCl stimulation was confirmed in another study using cultured neurons 
(see also Chapter 4) (Loriol et al., 2012a). Therefore, I propose that SUMO2/3 are the predominant 
paralogs involved in synaptic plasticity, a viewpoint that is supported by the enhanced dynamic nature of 
SUMO2/3 modification.  
The primary future goal that requires additional research is the identification and validation of the 
target substrate(s) that undergo activity-dependent SUMOylation. My preliminary data indicate that 
CREB, our previous top candidate, is not SUMOylated in the hippocampus (at least not in detectable 
quantities). Clathrin heavy chain does appear to be SUMOylated in vivo, although the functional 
consequences and whether or not the modification is activity-regulated have not been determined. SUMO 
target validation can be particularly challenging due to multiple reasons. For most proteins capable of 
being SUMOylated, generally only a small proportion is modified at any given time. SUMOylation is also a 
highly dynamic modification, with many deconjugating proteases, so SUMO conjugates are particularly 
vulnerable in biochemical analyses. In addition, studying the functional consequences of SUMOylation 
can be tricky; there appears to be significant redundancy in some SUMO-regulated protein complexes, 
with multiple SUMO interacting motifs, so that the removal of a SUMO modification may not significantly 
impact the overall functional process.  
Additional experiments will determine the validity of the SUMO-clathrin and the functionality of the 
modification. Clathrin heavy chain does present a tempting target, since clathrin-mediated endocytosis 
(CME) is such a ubiquitous process that is tightly involved in neuron-specific processes such as synaptic 
vesicle retrieval and receptor endocytosis. SUMOylation of clathrin could also impact both Aβ physiology 





Should SUMOylation be found to regulate the binding of clathrin adapter proteins, as I previously 
speculated, it would have significant consequences for basic neuronal physiology as well as AD 
pathology. 
 
6.4 SUMOylation in Alzheimer’s disease 
 In brain tissue from Alzheimer’s disease (AD) patients and Tg2576 APP transgenic mice, I 
observed overall decreases in SUMOylation compared to controls. Due to the complex and numerous 
regulatory networks involved in SUMOylation, there are a large number of potential causes. One 
speculation is that chronic oxidative stress, which is known to occur in AD, may impair SUMOylation. 
While very high concentrations of a strong oxidative stressor, H2O2, has been shown to induce increases 
in SUMOylation, lower and likely more physiologically relevant H2O2 amounts have been shown to greatly 
decrease overall SUMOylation; this effect was found to be due to direct oxidation of the SUMO 
conjugating enzymes, Uba2 and Ubc9 (Bossis and Melchior, 2006). Significantly, endogenous production 
of reactive oxygen species, and not just exogenously applied H2O2, was found to result in this type of 
oxidative regulation in a macrophage cell line. Although not yet demonstrated for the brain, the increased 
levels of reactive oxygen species and oxidative stress that occurs with AD could potentially induce this 
type of SUMOylation inhibition, which would produce the pattern of overall downregulation that I 
observed. Intriguingly, although very preliminary, I did observe a decrease in SUMOylated clathrin heavy 
chain with H2O2 stress in HeLa cells and possibly in APP transgenic hippocampi as well. Future 
experiments are necessary to further investigate this avenue of research. 
 Another potential factor that could lead to downregulated SUMOylation in AD involves cross-talk 
interactions with other PTMs such as ubiquitin. As previously discussed (see Chapter 2), SUMO can 
directly and indirectly interact with other PTMs both in the same protein and across target subsets. Tying 
in with a previous study from our lab, alterations in protein ubiquitination may affect SUMO conjugation. 
Multiple previous studies have demonstrated that ubiquitin and SUMO can either compete for the same 





ubiquitinated proteins; furthermore, as previously demonstrated by our lab, activity of Uch-L1, a de-
ubiquitinating enzyme, is decreased in APP/PS1 transgenic mice (Gong et al., 2006). Therefore, it is 
possible that abnormal regulation of the ubiquitin-proteasome system may negatively impact 
SUMOylation under chronic Aβ pathology. Such effects may be due to competitive antagonism or more 
indirect effects on the SUMO regulatory system, many components of which can be regulated by 
ubiquitination.  
 It is interesting to note that I did not observe any effects on basal SUMOylation levels with an 
acute (20 minutes) 200 nM Aβ42 treatment in acute slices. Since this treatment did impair the activity-
dependent increase in SUMOylation, this may imply that the SUMO conjugation states of the detected 
proteins are relatively stable within that time frame. In addition, the acute Aβ treatment does not seem to 
induce an immediate effect on the de-SUMOylation of these substrates. These results lead me to 
hypothesize that Aβ oligomers primarily affect SUMOylation via regulation of the conjugation pathways, at 
least early on in the pathology. With longer term, chronic Aβ pathology, however, there may be additional 
effects on SUMO deconjugation as well. These possibilities will need to be addressed in future 
experiments. For example, the levels and distribution of the multiple SENP SUMO proteases should be 
analyzed and compared between controls and AD or APP transgenic tissues. As with phosphorylation, 
the balance of modification is crucial and dependent on both conjugating kinases and deconjugating 
phosphatases. This is likely to apply to SUMOylation in AD as well, so the topic of SENP regulation is an 
important one to investigate in future studies.  
 Ultimately, the question this project hopes to answer is: could targeting SUMOylation be a 
potential therapeutic strategy for AD? My results with mouse models suggest that this may eventually be 
plausible. In both the acute Aβ infusion/perfusion model and 1 year old APP transgenic mice, we were 
able to rescue the deficits in LTP as well as spatial learning and memory. This implies that there is a 
SUMO inhibition bottleneck that impairs synapses under Aβ-induced pathology. However, whether this 
bottleneck is a global phenomenon (e.g. oxidative inhibition of Ubc9) or is due to impaired SUMOylation 
of specific key target(s) remains to be determined. Importantly, both for understanding the normal 





undergo synaptic activity-dependent regulation and determine whether this process is affected by Aβ. If 
such substrate(s) are found, they can potentially be specifically targeted in drug development efforts. 
However, if the impairment is due to upstream changes in SUMOylation, for example with Ubc9 (function, 
levels, localization), then therapeutic development would be much trickier due to the tight involvement of 
SUMO in nuclear and genomic functions. The primary challenge there would be in correctly targeting 
Ubc9 manipulations to the right compartments (e.g. synapses).  
 
Conclusion 
 Aβ peptides are a ubiquitous presence in the healthy brain throughout life. It is with the currently-
unknown triggers (in sporadic AD) that Aβ acquires pathogenic functions through increased 
concentrations and aggregated assemblies. When that occurs, neurotoxic effects may be caused by gain-
of-function, especially by abnormal Aβ oligomers. However, loss-of-function may also account for part of 
the pathology. In both cases, the normal physiological roles of Aβ likely underlie some of the toxic effects, 
which motivates my proposition that a more complete understanding of Aβ from both the physiological 
and pathological standpoints is necessary to truly address Alzheimer’s disease. We have begun the initial 
characterizations of physiological Aβ signaling in astrocytes and pathological Aβ regulation of SUMO. 
Continuing research on both topics will be important both for basic knowledge of Aβ signaling pathways 
















7.1 Chapter 4 Experimental Procedures 
 
Animals 
Breeding colonies for wild-type C57BL/6J and Tg2576 APP transgenic mice (Hsiao et al., 1996) were 
housed in animal facilities at Columbia University and maintained on a 12-hour light/dark cycle. Unless 
otherwise specified, 12-14 month old males were used for the Tg2576 experiments. For electrophysiology 
and behavior experiments with only wild-type mice, 4-6 month old males were used. For whole cell patch 
clamp recordings, 3-4 week old males were used. Mice were sacrificed by cervical dislocation followed by 
decapitation. For biochemical studies, hippocampi were dissected out and snap frozen in liquid nitrogen. 
 
Post-mortem human brain tissue 
Frozen post-mortem hippocampal tissues were obtained from the New York Brain Bank at Columbia 
University Medical Center, in accordance with institutional review board guidelines. Alzheimer’s disease 
samples were obtained from patients with autopsy-confirmed AD. Controls did not have any major 
neuropathology and did not meet National Institutes of Health-Reagan Institute criteria for AD. Samples 








Amyloid-β peptide preparation 
Aβ42 peptides (American Peptide Company) were prepared as previously described (Dahlgren et al., 
2002; Puzzo et al., 2008; Stine et al., 2003). Frozen lyophilized peptides were warmed to room 
temperature, dissolved to 1 mM in hexafluoroisopropanol, and dried by evaporation and SpeedVac to 
produce peptide films. Prior to use, films were dissolved in anhydrous dimethylsulfoxide (DMSO) to 5 mM 
and bath sonicated at room temperature. To prepare oligomers, the DMSO solution was diluted to 100 
µM in PBS and incubated overnight at 4°C.  
 
Recombinant protein expression plasmids 
TAT-Ubc9 and TAT-Ubc9(DN) constructs were made by subcloning murine Ubc9 or Ubc9(C93S) (gifts 
from Dr. Olli Jänne, U. of Helsinki, Finland) into a TAT-HA-6xHis vector (gift from Dr. Steven Dowdy, U. of 
California, San Diego). The TAT-GFP construct was made by excising the GFP fragment from the 
pEGFP-1 plasmid (Clontech) and subcloning it into the TAT vector. GST-SENP1 and GST-
SENP1(C603S) constructs were gifts from Dr. Steve Goldstein, U. of Chicago. Protein expression in E. 
coli and purification via the 6xHis tag/GST tag were performed according to standard procedures. 
 
Purification of recombinant proteins 
Recombinant TAT transduction proteins were expressed in BL21-CodonPlus (DE3)-RIPL E. coli 
(Stratagene), with induction by 0.5 M IPTG at 37 C. The bacteria were collected by centrifugation, and the 
pellet was frozen at -80 C until purification. TAT proteins were purified by standard 6x His tag affinity 
chromatography, as previously described (Becker-Hapak et al., 2001). Briefly, bacterial pellets were lysed 
in HEPES-buffered 8 M urea buffer, sonicated, shaken at room temperature for an hour, and 
subsequently clarified by high-speed centrifugation. The supernatant fraction was purified using affinity 
chromatography with Ni-NTA agarose resin (Qiagen). After extensive washes, the TAT proteins were 
eluted using imidazole (500 mM). The fractions were subsequently desalted with PD-10 columns (GE 
Healthcare) into PBS + 15% glycerol. Aliquots were snap frozen and stored at -80C until use. Purified 





HA tag (Covance). Recombinant GST-SENP1 proteins were expressed and purified as previously 
described (Rajan et al., 2005). Briefly, proteins were expressed in E-coli BL21(DE3)pLysS E. coli 
(Novagen). Bacterial pellets were lysed in a buffer containing 300 mM NaCl, 50 mM Tris pH 8.0, 5 mM 
EDTA, 1× complete protease inhibitor (Roche), sonicated and clarified by centrifugation. The supernatant 
fraction was applied to glutathione sepharose beads for 2 hours at 4° C on a rotating shaker. The bead s 
were extensively washed with a buffer containing 50 mM Tris, pH 7.4, 300 mM NaCl and eluted with 15 
mM glutathione. Protein identity was confirmed by western blot with antibodies against SENP1 
(Invitrogen) and GST (Sigma Aldrich).   
 
SUMO conjugation assay 
In vitro SUMO1 and SUMO2 conjugation assays were purchased from Boston Biochem (catalog # K-710, 
K-715) and performed according to the manufacturer’s protocols. Reaction components included 
biotinylated E2-25K SUMOylation substrate, E1 conjugating enzyme (SAE1/SAE2), SUMO, Mg-ATP and 
Ubc9 (or TAT-Ubc9). Assays were processed with avidin-HRP western blotting. 
 
Acute hippocampal slices and high-potassium stimulation 
Following decapitation, hippocampi were rapidly removed and transverse slices (400 µm) were cut with a 
tissue chopper. Slices were allowed to recover for at least 90 minutes prior to use. Extracellular field 
potential and whole cell patch clamp recordings were performed with the CA3-CA1 Schaffer collateral 
pathway according to standard procedures (see below). For high-potassium stimulation studies, the 
depolarization buffer included 50 mM KCl in regular ACSF buffer, with decreased NaCl concentration (74 
mM) to maintain osmolarity. A stimulation time of 2 minutes was used for all high-KCl experiments. After 









Extracellular field potential recordings 
Transverse hippocampal slices (400 µm) were cut with a tissue chopper and maintained in an interface 
chamber at 29 C for at least 90 minutes prior to recording, as previously described (Puzzo et al., 2008). 
The artificial cerebrospinal fluid (ACSF) bath buffer consisted of (in mM): 124 NaCl, 4.4 KCl, 1 Na2HPO4, 
25 NaHCO3 , 2 CaCl2 , 2 MgCl2, 10 glucose. The buffer was continuously aerated with 95% O2 / 5% 
CO2 to a final pH of 7.4. Field extracellular postsynaptic potentials (fEPSPs) were recorded using a 
stimulating electrode (bipolar tungsten) at the CA3-CA1 Schaffer collateral fibers and a recording 
electrode (ACSF-filled glass pipette) at the CA1 stratum radiatum. Basal synaptic transmission was 
assessed by plotting stimulus voltages (V) against the corresponding fEPSP slopes. Stimulus intensity 
was set so that baseline responses were approximately 1/3 of the maximum evoked response. LTP was 
induced using theta-burst stimulation (4 pulses at 100 Hz, with the bursts repeated at 5 Hz and each 
tetanus including three ten-burst trains separated by 15 sec). Responses were measured as fEPSP 
slopes expressed as percentages of the baseline average. Paired pulse facilitation (PPF) was elicited 
through two successive stimuli, separated by an inter-stimulus interval, and measured as a ratio of the 
two fEPSP slopes. All experiments were performed with interleaved controls. 
 
Whole cell patch clamp recordings 
LTP recordings: P17-P28 male mice were used. Coronal hippocampal slices were cut using a Leica VT 
1000S vibratome (Leica Microsystems) and maintained in a submerged chamber perfused with ACSF 
containing (in mM): 125 NaCl, 2.5 KCl, 1.25 Na2HPO4 , 25 NaHCO3 , 2 CaCl2 , 1.3 MgCl2 , 25 glucose, 
pH=7.4 (95% O2 , 5% CO2 ). Slices were permitted to recover for at least 90 min before use. Whole cell 
recordings were obtained from CA1 pyramidal cells that were voltage-clamped at -70 mV. The bath 
solution contained ACSF with 50 µM picrotoxin. The internal electrode solution contained (in mM): 130 K-
gluconate, 10 KCl, 4 NaCl, 10 HEPES, 1 MgCl2  0.06 CaCl2, 0.1 EGTA, 4 Mg-ATP, 0.3 Na2GTP, 10 
Phosphocreatine-Tris; pH was adjusted to 7.3 with KOH, and osmolarity was adjusted to 290 mOsm with 
sucrose. Synaptic responses were evoked by stimulating the Schaffer collateral pathway at a frequency 





tetanus and then returned to the voltage clamp mode. To eliminate artifacts due to variation of the seal 
properties, the access resistance was monitored for constancy throughout all experiments. If changes of 
more than 10% were detected, the recordings were discarded. Responses were measured as EPSC 
amplitudes and expressed as percentage of baseline. Each point of the LTP graph represents the 
average of six consecutive recordings.  
AMPAR / NMDAR current recordings only: The internal electrode solution contained (in mM): 117.5 
Cs2MeSO4, 17.5 CsCl, 10 Hepes, 4 NaCl, 1 EGTA, 4 MgATP, 0.3 Na2GTP, 10 phosphocreatine-Tris, 
and 10 QX-314-Cl, pH 7.3, 285mOsm. AMPAR currents were measured with 10 µM bicuculline and 40 
µM D-APV in the bath solution.  NMDAR currents were measured with 10 µM bicuculline and 10 µM 
CNQX in the bath solution. 
 
Tissue homogenization for SDS-PAGE and immunoprecipitation 
Tissues were homogenized in ice-cold standard radioimmunoprecipitation assay (RIPA) buffer containing 
protease and phosphatase inhibitors (Pierce), as well as 20 mM N-ethylmaleimide (NEM), an 
isopeptidase inhibitor, to prevent SUMO deconjugation. After centrifugation at 15,000 rpm for 20 minutes 
at 4 C, the RIPA-soluble supernatant fraction was removed, and the protein concentrations were 
quantified. For SDS-PAGE, the lysate was mixed with standard SDS-PAGE Laemmli sample buffer and 
briefly boiled for 2 minutes. The RIPA-insoluble pellet fraction was washed twice in lysis buffer and 
solubilized in 3x Laemmli sample buffer. 
 
Western blot 
Western blot analyses of the SDS-PAGE samples were carried out according to standard procedures. 
Generally, 30-40 µg of proteins were loaded per lane in tris-glycine polyacrylamide gels (Pierce, 
Invitrogen Novex). Proteins were blotted onto 0.2 µm nitrocellulose membranes using a standard 
submerged transfer protocol. For high molecular weight SUMO conjugates, a 10% methanol, 0.03% SDS 
transfer buffer was used. After transfer, blots were blocked in 5% bovine serum albumin in tris-buffered 





overnight, diluted in blocking solution. The antibodies used include: SUMO2/3 (Invitrogen), SUMO1 (Cell 
Signaling), Ubc9 (BD), CREB (Cell Signaling, Santa Cruz Biotechnology), β-actin (Abcam), TUJ1 
(Promega), HA tag (Covance). The secondary antibodies were either horseradish peroxidase (HRP) 
conjugates or DyLight fluorophore conjugates (Pierce), depending on the detection system. Blots were 
developed with SuperSignal West Dura enhanced chemiluminescence (ECL) substrate for HRP, or 
scanned using the Odyssey system (Licor) for infrared labeling detection. Digitized blot images were 
analyzed using ImageJ (NIH) software. For quantification, data were always normalized to an internal 
loading control (β-actin, GAPDH, or tubulin). 
 
Immunoprecipitation 
Sheep anti-mouse and sheep anti-rabbit Dynabeads (Invitrogen) were used for immunoprecipitations. 
Capture antibodies or IgG control antibodies were incubated with the appropriate Dynabeads overnight at 
4 C. Prepared RIPA buffer homogenates (see above) were quantified and equalized in concentration (to 
the lowest in the experimental set). Homogenates were then added to washed Dynabeads and rotated for 
2 hours at 4 C. After extensive washes in tris-buffered saline (TBS) containing protease and phosphatase 
inhibitors plus 20 mM N-ethylmaleimide, proteins were eluted from the beads with 2x Laemmli sample 
buffer and subjected to SDS-PAGE western blotting. 
 
Aβ ELISAs 
Aβ(x-40) and Aβ(x-42) ELISAs were purchased from Covance and performed according to manufacturer’s 
protocols. Tissues were homogenized in tris-buffered saline containing protease inhibitors (Pierce), and 
the soluble fractions were used for the ELISAs.  
 
 
Primary hippocampal neuron cultures  
Primary hippocampal neuron cultures were prepared as previously described (Ninan and Arancio, 2004). 
Hippocampi were dissected from P0-P1 mouse brains in cold Hank’s balanced salt solution (HBSS) and 





with a flame-polished Pasteur pipette.  Cells were plated in dishes/coverslips coated with poly-D-lysine 
and laminin. For the first 24 hours, hippocampal cells were grown in media containing 84% Eagle’s 
minimum essential medium (MEM), supplemented with 10% heat-inactivated fetal calf serum, 45 mM 
glucose, 1% MEM vitamin solution, and 2 mM glutamine. After 24 hours, the media was replaced with 
96.5% Neurobasal A, 2% B27-nutrient, 1% heat-inactivated fetal calf serum, 0.4mM glutamine, 6.6 ng/ml 
5-flurodioxyuridine in 16.4 ng/ml uridine, and 0.5 mM kynurenic acid. All cultures were maintained at 37 C 
in a 95% air, 5% CO2 humidified incubator. 
 
Cell line cultures  
Mammalian cell line cultures (HeLa, 3T3, Neuro-2a) were maintained according to standard protocols. To 
passage cells, 80-90% confluent cultures were washed in warm HBSS, detached with 0.25% trypsin-
EDTA, and centrifuged to pellet cells. Cultures were grown on culture-treated dishes and plates. Glass 
coverslips were coated with poly-D-lysine first. The media used was Dulbecco's Modified Eagle Medium 
(DMEM) plus GlutaMax (3.97 mM; Invitrogen), supplemented with 10% heat-inactivated fetal calf serum 
plus penicillin (100 U/ml) and streptomycin (100 µg/ml). All cultures were maintained at 37 C in a 95% air, 
5% CO2 humidified incubator. 
 
Immunofluorescence 
Immunostaining was performed according to standard protocols. Briefly, cultured cells/hippocampal 
sections were fixed in 4% paraformaldehyde and permeabilized with Triton X-100. Blocking was done in 
1% BSA plus 5% normal goat serum. Primary antibodies were diluted in blocking solution and incubated 
for 2 hours at room temperature or overnight at 4 C. Antibodies used include: MAP-2 (Cell Signaling), HA 
tag (Covance), CREB (Cell Signaling, Santa Cruz Biotechnology), phospho-CREB (Cell Signaling, 
Thermo Scientific, Millipore). Secondary antibodies were Alexa Fluor conjugates (Invitrogen) and were 
applied for 1 hour, diluted in PBS. After PBS washes and DAPI counterstain where appropriate, samples 





microscopy with a Spot CCD camera or by confocal microscopy with a Nikon D-Eclipse C1 microscope. 
Analyses were performed with ImageJ (NIH) software.  
 
Cannula implantation and infusion protocols 
Cannulas were implanted as previously described (Puzzo et al., 2008). Briefly, mice were anesthetized, 
and bilateral cannulas were implanted to reach the dorsal hippocampi. The mice were allowed to recover 
for 6-8 days following implantation. Infusions were done with 1 µL of vehicle/treatment over 1 minute (per 
side). For FC studies, Aβ infusions were performed 15 minutes prior to the foot shock training. For RAWM 
studies, Aβ infusions were performed 15 minutes prior to the 1st and 6th sessions. TAT-Ubc9 infusions 
were performed at time points described in the text.  
 
Behavioral studies 
Fear conditioning (FC). FC was performed as previously described (Puzzo et al., 2008). Briefly, mice 
were placed in a conditioning chamber for 2 minutes. Subsequently, a 30 second tone sound was played 
and a 2 second foot shock was administered at the end of the tone. The mice were left in the chamber for 
an additional 30 seconds. After 24 hours, the mice were placed back in the same chamber, and freezing 
behavior was scored using Freezeview software; freezing behavior was defined as the absence of 
movement except for breathing. Contextual fear memory was assessed over 5 minutes in the chamber. 
Cued fear learning was assessed 24 hours after the contextual assessment by placing the mice in a novel 
context for 2 minutes (pre-tone) and then playing the training tone sound for 3 minutes (post-tone). 
Sensory thresholds were assessed by measuring the minimal foot shock intensities at which a mouse 
manifested a behavioral response in three categories: visible response to shock (flinching), extreme 
motor response (jumping) and vocalized distress (screaming).  
Radial arm water maze (RAWM). The two-day RAWM was performed as previously described (Alamed 
et al., 2006). Briefly, mice were trained to find an escape platform located in one of the six maze arms. On 
day 1, five blocks of 3 trials each are performed with alternation between visible and hidden platform. On 





by the number of entries into incorrect maze arms (errors). Swimming ability and vision are assessed by 
measuring swim speed and the time it takes to reach a visible platform in an open pool.  
Morris water maze (MWM). The MWM was performed as previously described (Puzzo et al., 2008). 
Briefly, mice were trained to find a hidden platform in an open pool, with two sessions of three trials each 
repeated for three days. Scoring was by the time required to reach the platform. A probe trial was 
performed after training to test memory retention; the platform was removed and the percent time spent in 
each quadrant of the pool was recorded with a video tracking system (HVS Image).  
 
Statistical analyses 
All data are presented as means ± SEM. Data were analyzed by two-tailed Student’s t-test or ANOVA 
plus post-hoc Tukey’s multiple comparisons test using Prism (GraphPad) software. The threshold for 































6.2 Chapter 5 Experimental Procedures 
 
Animals 
Breeding colonies for wild-type C57BL/6J and α7 nAChR subunit knockout mice (Orr-Urtreger et al., 
1997) were housed in animal facilities at Columbia University and maintained on a 12-hour light/dark 
cycle. For preparation of primary cultures, P0-P1 mice were used.  
 
Primary astrocyte cultures 
Astrocyte cultures were prepared from P0-P1 mouse pups as previously described (Parpura et al., 1995; 
Schell et al., 1995). Forebrains (including cortices and hippocampi) were dissected in cold HBSS, with 
careful complete removal of meninges to prevent fibroblast contamination. The tissues were dissociated 
with 0.25% trypsin, followed by trituration and plating in culture-treated flasks. The media was high-
glucose Dulbecco's Modified Eagle Medium (DMEM) plus GlutaMax (3.97 mM; Invitrogen), supplemented 
with 10% heat-inactivated fetal calf serum plus penicillin (100 U/ml) and streptomycin (100 µg/ml). After 
the cells reached confluence (after about one week), the flasks were sealed and shaken for 2-3 hours on 
an orbital shaker (37 C, 200 r.p.m.). The media was then replaced, and the sealed flasks were shaken 
again overnight (~16 hours). The following day, the cultures were extensively washed and then passaged 
with cell detachment by 0.25% trypsin-EDTA. For calcium imaging experiments, passaged cells were 
plated on glass coverslips coated with poly-D-lysine. In all experiments, ~12-16 DIV confluent cultures 
that underwent the one passage were used (no cultures were passaged more than once). Culture 
composition was regularly assessed by light microscopy to determine presence of non-astrocyte cells 
(e.g. phase-bright oligodendrocytes, phase-dark microglia). 
 
Amyloid-β peptide preparation 
Aβ peptides (American Peptide Company) were prepared as previously described (Dahlgren et al., 2002; 
Puzzo et al., 2008; Stine et al., 2003). Frozen lyophilized peptides were warmed to room temperature, 





films. Prior to use, films were dissolved in anhydrous dimethylsulfoxide (DMSO) to 5 mM and bath 
sonicated at room temperature. For fresh, mostly monomeric preparations, the DMSO solution was then 
immediately diluted down to the picomolar concentration range in imaging buffer. For an oligomeric 
preparation, the DMSO solution was diluted to 100 µM in PBS and incubated overnight at 4°C.  
 
Fluo-4 calcium imaging 
Confluent astrocyte cultures on glass coverslips were removed into imaging buffer. Buffer composition (in 
mM): NaCl (140), KCl (5), MgCl2 (2), CaCl2 (2), glucose (5), HEPES (10), pH 7.4. Cells were loaded with 
Fluo-4 in its cell-permeant acetoxymethyl (AM) ester form, diluted to 4 µM in imaging buffer plus 0.08% 
Pluronic F-127 to aid dye loading (Invitrogen). Coverslips were incubated with this Fluo-4 solution for 30 
minutes at room temperature, washed, and then incubated in regular imaging buffer for another 30 
minutes allow de-esterification of the dye. Coverslips were then transferred to the imaging stage on the 
microscope. A Nikon D-Eclipse C1 confocal microscope was used for all experiments, with excitation of 
Fluo-4 by the 488 nm argon laser. Time-lapse movies were acquired at 0.33 Hz, generally for 10 minutes 
at a time.  
 
Calcium wave stimulation 
Glass micropipette electrodes were pulled from thick-walled borosilicate glass tubing, filled with imaging 
buffer, and mounted on a piezoelectric micromanipulator normally used for electrophysiology 
experiments. With constant monitoring of the resistance (with 10 mV square pulses), the electrode was 
slowly lowered into the bath solution and towards the cell layer; the resistance significantly increased 
when near a cell (e.g. from ~5 MΩ to ~6-7 MΩ). Immediately upon contact with the cell surface, the 
resistance jumps (e.g. to ~20 MΩ), and the micropipette is immediately withdrawn. This mechanical 








Spontaneous calcium transient analysis 
Movies were recorded at 0.33 Hz in the Nikon Eclipse confocal software and were subsequently imported 
into MetaMorph software (Molecular Devices) for automated segmentation and quantification of regions of 
interest (ROIs). The quantified data traces were then analyzed with in Igor Pro (Wavemetrics) using a 
custom-programmed script. All fluorescent data values were normalized to the global minimum value. 
Traces were plotted with these normalized data as fold changes. The basic threshold used for the 
identification of calcium transients was a minimum 40% rise in normalized fluorescent signal intensity. 
This threshold reliably detected all distinct calcium peaks with minimal contamination by noise. 
Amplitudes were calculated as (peak maxima) – (base minimum). The frequency measure reflects the 
absolute number of calcium transients (e.g. per 10 minute imaging session).  
 
Evoked calcium wave analysis 
Movies were directly imported into Igor Pro software (Wavemetrics) and analyzed with a custom-
programmed script. All fluorescent data values were normalized to the global maximum value and plotted 
as a percentage of this. The center wave initiation point was manually set, from which the radial 
distribution of intensities was calculated. In the 2D space-time maps, each horizontal line represents a 
histogram at a particular time frame, based on 1 pixel binning. Distance and time measures were based 
on a threshold intensity of 50%.  
 
Immunofluorescence 
Immunostaining was performed according to standard protocols. Briefly, cultured cells were washed and 
fixed in 4% paraformaldehyde followed by permeabilization with Triton X-100. Blocking was done in 1% 
BSA plus 5% normal goat serum. Primary antibodies were diluted in blocking solution and incubated for 2 
hours at room temperature. Antibodies used include multiple for α7 nAChR subunit (Chemicon/Millipore, 
Santa Cruz Biotechnology). Secondary antibodies were Alexa Fluor conjugates (Invitrogen) and were 
applied for 1 hour, diluted in PBS. After PBS washes and DAPI counterstain, samples were mounted in 





CCD camera or by confocal microscopy with a Nikon D-Eclipse C1 microscope. Analyses were performed 
with ImageJ (NIH) software.  
 
α-bungarotoxin surface labeling  
Alexa Fluor 594-conjugated α-bungarotoxin (1 mg/ml stock in water; Invitrogen) was diluted in cell culture 
media to 0.1 µM and applied to cultures for 15 minutes at 37 C. After multiple washes, the cells were fixed 
in 4% paraformaldehyde, mounted with Vectashield (Vector Labs) and examined by confocal microscopy. 
 
Western blot 
SDS-PAGE and western blot analyses were carried out according to standard procedures. Generally, 
cells were washed and directly lysed in 2x Laemmli sample buffer. Equal volumes of lysates were loaded 
per lane in tris-glycine polyacrylamide gels (Pierce). Proteins were blotted onto 0.2 µm nitrocellulose 
membranes using a standard submerged transfer protocol. After transfer, blots were blocked in 5% 
bovine serum albumin in tris-buffered saline (TBS) plus 0.05% Tween-20, or fish serum SeaBlock 
(Pierce). Primary antibodies were incubated overnight, diluted in blocking solution. The antibodies used 
include: multiple for α7 nAChR subunit (Chemicon/Millipore, Santa Cruz Biotechnology), β-actin (Abcam). 
The secondary antibodies were either horseradish peroxidase (HRP) conjugates or DyLight fluorophore 
conjugates (Pierce), depending on the detection system. Blots were developed with SuperSignal West 
Dura enhanced chemiluminescence (ECL) substrate for HRP, or scanned using the Odyssey system 
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